BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1926] [Article Influence: 707.3] [Reference Citation Analysis]
Number Citing Articles
1 Wu CC, Tseng CW, Tseng KC, Chen YC, Wu TW, Chang SY, Chang YJ, Chao YC, Hsu CS. Radiofrequency ablation versus surgical resection for the treatment of solitary hepatocellular carcinoma 2 cm or smaller: A cohort study in Taiwan. J Formos Med Assoc 2021;120:1249-58. [PMID: 33288401 DOI: 10.1016/j.jfma.2020.11.010] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Barone M, Viggiani MT, Losurdo G, Principi M, Leo AD. Systematic review: Renin-angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma. World J Gastroenterol 2019; 25(20): 2524-2538 [PMID: 31171895 DOI: 10.3748/wjg.v25.i20.2524] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
3 Reizine E, Chalaye J, Mule S, Regnault H, Perrin C, Calderaro J, Laurent A, Amaddeo G, Kobeiter H, Tacher V, Itti E, Luciani A. Utility of Early Posttreatment PET/CT Evaluation Using FDG or 18F-FCH to Predict Response to 90Y Radioembolization in Patients With Hepatocellular Carcinoma. AJR Am J Roentgenol 2021. [PMID: 34494448 DOI: 10.2214/AJR.21.26485] [Reference Citation Analysis]
4 Schotten C, Ostertag B, Sowa JP, Manka P, Bechmann LP, Hilgard G, Marquardt C, Wichert M, Toyoda H, Lange CM, Canbay A, Johnson P, Wedemeyer H, Best J. GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients. Pharmaceuticals (Basel) 2021;14:735. [PMID: 34451832 DOI: 10.3390/ph14080735] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Fan PL, Ding H, Mao F, Chen LL, Dong Y, Wang WP. Enhancement patterns of small hepatocellular carcinoma (≤ 30 mm) on contrast-enhanced ultrasound: Correlation with clinicopathologic characteristics. Eur J Radiol 2020;132:109341. [PMID: 33069987 DOI: 10.1016/j.ejrad.2020.109341] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
6 Chan MV, McDonald SJ, Ong YY, Mastrocostas K, Ho E, Huo YR, Santhakumar C, Lee AU, Yang J. HCC screening: assessment of an abbreviated non-contrast MRI protocol. Eur Radiol Exp 2019;3:49. [PMID: 31853685 DOI: 10.1186/s41747-019-0126-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
7 Sharma R, Motedayen Aval L. Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma. Front Immunol 2021;12:652007. [PMID: 33790915 DOI: 10.3389/fimmu.2021.652007] [Reference Citation Analysis]
8 Zenlander R, Havervall S, Magnusson M, Engstrand J, Ågren A, Thålin C, Stål P. Neutrophil extracellular traps in patients with liver cirrhosis and hepatocellular carcinoma. Sci Rep 2021;11:18025. [PMID: 34504150 DOI: 10.1038/s41598-021-97233-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Huh YJ, Kim DH, Kim B, Choi JI, Rha SE. Per-Feature Accuracy of Liver Imaging Reporting and Data System Locoregional Treatment Response Algorithm: A Systematic Review and Meta-Analysis. Cancers (Basel) 2021;13:4432. [PMID: 34503241 DOI: 10.3390/cancers13174432] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhang YF, Lu LH, Zhong C, Chen MS, Guo RP, Wang L. Prognostic Value of the Preoperative Lymphocyte-C-Reactive Protein Ratio in Hepatocellular Carcinoma Patients Treated with Curative Intent: A Large-Scale Multicentre Study. J Inflamm Res 2021;14:2483-95. [PMID: 34140796 DOI: 10.2147/JIR.S311994] [Reference Citation Analysis]
11 Qi C, Li S, Zhang L. Development and Validation of a Clinicopathological-Based Nomogram to Predict the Survival Outcome of Patients with Recurrent Hepatocellular Carcinoma After Hepatectomy Who Underwent Microwave Ablation. Cancer Manag Res. 2020;12:7589-7600. [PMID: 32904581 DOI: 10.2147/cmar.s266052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Endo K, Kuroda H, Kanazawa J, Sato T, Fujiwara Y, Abe T, Sato H, Kooka Y, Oikawa T, Sawara K, Takikawa Y. Impact of Grip Strength in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib. Cancers (Basel) 2020;12:E2146. [PMID: 32756366 DOI: 10.3390/cancers12082146] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
13 Ji F, Yeo YH, He C, Li J, Gao X, Li Z, Henry L, Nguyen MH. Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment. J Hepatol 2019;70:209-11. [PMID: 30337127 DOI: 10.1016/j.jhep.2018.09.016] [Reference Citation Analysis]
14 Radosa CG, Radosa JC, Grosche-Schlee S, Zöphel K, Plodeck V, Kühn JP, Kotzerke J, Hoffmann RT. Holmium-166 Radioembolization in Hepatocellular Carcinoma: Feasibility and Safety of a New Treatment Option in Clinical Practice. Cardiovasc Intervent Radiol 2019;42:405-12. [PMID: 30603976 DOI: 10.1007/s00270-018-2133-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
15 Lee S, Kim SS, Chang DR, Kim H, Kim MJ. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging. Clin Mol Hepatol 2020;26:340-51. [PMID: 32492765 DOI: 10.3350/cmh.2020.0004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 14.0] [Reference Citation Analysis]
16 Lin XN, Lin QX, Li SM, Xie KP, Hou J, Chen R. Hepatitis E virus re-infection accelerates hepatocellular carcinoma development and relapse in a patient with liver cirrhosis: A case report and review of literature. World J Hepatol 2020; 12(12): 1358-1366 [PMID: 33442461 DOI: 10.4254/wjh.v12.i12.1358] [Reference Citation Analysis]
17 Shi F, Lian S, Mai Q, Mo Z, Zhuang W, Cui W, Shen L, Chen M, Wu P, Chen X. Microwave ablation after downstaging of hepatocellular carcinoma: outcome was similar to tumor within Milan criteria. Eur Radiol. 2020;30:2454-2462. [PMID: 32002636 DOI: 10.1007/s00330-019-06604-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 Zhou Y, Yang Y, Zhou B, Wang Z, Zhu R, Chen X, Ouyang J, Li Q, Zhou J. Challenges Facing Percutaneous Ablation in the Treatment of Hepatocellular Carcinoma: Extension of Ablation Criteria. J Hepatocell Carcinoma 2021;8:625-44. [PMID: 34189133 DOI: 10.2147/JHC.S298709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Catalano M, Casadei-Gardini A, Vannini G, Campani C, Marra F, Mini E, Roviello G. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma. Expert Rev Clin Pharmacol 2021;:1-13. [PMID: 34289756 DOI: 10.1080/17512433.2021.1958674] [Reference Citation Analysis]
20 Banzato T, Rubini G, Orlandi R, Bargellini P, Bonsembiante F, Zotti A. Contrast-enhanced ultrasound features of hepatocellular carcinoma in dogs. Vet Rec 2020;186:187. [PMID: 31662577 DOI: 10.1136/vr.105282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Zhang S, He L, Bo C, Yang S, An Y, Li N, Zhao Y, Zhao L, Ma W, Zheng Z. Comparison of stereotactic body radiation therapy versus fractionated radiation therapy for primary liver cancer with portal vein tumor thrombus. Radiat Oncol 2021;16:149. [PMID: 34391452 DOI: 10.1186/s13014-021-01874-7] [Reference Citation Analysis]
22 Choi JM, Yu JS, Cho ES, Kim JH, Chung JJ. Texture Analysis of Hepatocellular Carcinoma on Magnetic Resonance Imaging: Assessment for Performance in Predicting Histopathologic Grade. J Comput Assist Tomogr 2020;44:901-10. [PMID: 32976263 DOI: 10.1097/RCT.0000000000001087] [Reference Citation Analysis]
23 Suzuki H, Iwamoto H, Nakano M, Nakamura T, Masuda A, Sakaue T, Tanaka T, Nakano D, Kuromatsu R, Niizeki T, Okamura S, Shimose S, Shirono T, Noda Y, Kamachi N, Yano H, Kawaguchi A, Koga H, Torimura T. Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments. Transl Oncol 2021;14:101201. [PMID: 34388691 DOI: 10.1016/j.tranon.2021.101201] [Reference Citation Analysis]
24 Coral GP, Branco F, Meurer R, Marcon PDS, Fontes PRO, Mattos AA. RESULTS OF IMMUNOHISTOCHEMISTRY IN THE DIFFERENTIAL DIAGNOSIS OF EARLY HEPATOCELLULAR CARCINOMA AND NODULES WITH HIGH-GRADE DYSPLASIA IN PATIENTS WITH CIRRHOSIS. Arq Gastroenterol 2021;58:82-6. [PMID: 33909802 DOI: 10.1590/S0004-2803.202100000-14] [Reference Citation Analysis]
25 Eso Y, Nakano S, Mishima M, Arasawa S, Iguchi E, Takeda H, Takai A, Takahashi K, Seno H. Branched‐chain amino acid to tyrosine ratio is an essential pre‐treatment factor for maintaining sufficient treatment intensity of lenvatinib in patients with hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2020;27:913-21. [DOI: 10.1002/jhbp.821] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Brozzetti S, Tancredi M, Bini S, De Lucia C, Antimi J, D'Alterio C, De Sanctis GM, Furlan C, Malpassuti VC, Lucatelli P, Di Martino M, Bezzi M, Ciardi A, Pascale RM. HCC in the Era of Direct-Acting Antiviral Agents (DAAs): Surgical and Other Curative or Palliative Strategies in the Elderly. Cancers (Basel) 2021;13:3025. [PMID: 34204186 DOI: 10.3390/cancers13123025] [Reference Citation Analysis]
27 Swierz MJ, Storman D, Riemsma RP, Wolff R, Mitus JW, Pedziwiatr M, Kleijnen J, Bala MM. Percutaneous ethanol injection for liver metastases. Cochrane Database Syst Rev 2020;2:CD008717. [PMID: 32017845 DOI: 10.1002/14651858.CD008717.pub3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Cong M, Ou X, Huang J, Long J, Li T, Liu X, Wang Y, Wu X, Zhou J, Sun Y, Shang Q, Chen G, Ma H, Xie W, Piao H, Yang Y, Gao Z, Xu X, Tan Z, Chen C, Zeng N, Wu S, Kong Y, Liu T, Wang P, You H, Jia J, Zhuang H. A Predictive Model Using N-Glycan Biosignatures for Clinical Diagnosis of Early Hepatocellular Carcinoma Related to Hepatitis B Virus. OMICS 2020;24:415-23. [PMID: 32522092 DOI: 10.1089/omi.2020.0055] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Colli A, Nadarevic T, Miletic D, Giljaca V, Fraquelli M, Štimac D, Casazza G. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;4:CD013346. [PMID: 33855699 DOI: 10.1002/14651858.CD013346.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Komatsu H, Inui A, Yoshio S, Fujisawa T. Pharmacotherapy options for managing hepatitis B in children. Expert Opin Pharmacother 2021;22:449-67. [PMID: 33090882 DOI: 10.1080/14656566.2020.1841165] [Reference Citation Analysis]
31 Eldafashi N, Darlay R, Shukla R, McCain MV, Watson R, Liu YL, McStraw N, Fathy M, Fawzy MA, Zaki MYW, Daly AK, Maurício JP, Burt AD, Haugk B, Cordell HJ, Bianco C, Dufour JF, Valenti L, Anstee QM, Reeves HL. A PDCD1 Role in the Genetic Predisposition to NAFLD-HCC? Cancers (Basel) 2021;13:1412. [PMID: 33808740 DOI: 10.3390/cancers13061412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 Wang R, Zang W, Hu B, Deng D, Ling X, Zhou H, Su M, Jiang J. Serum ESPL1 Can Be Used as a Biomarker for Patients With Hepatitis B Virus-Related Liver Cancer: A Chinese Case-Control Study. Technol Cancer Res Treat 2020;19:1533033820980785. [PMID: 33308056 DOI: 10.1177/1533033820980785] [Reference Citation Analysis]
33 Lang S, Martin A, Kasper P, Schramm C, Kütting F, Goeser T, Steffen HM, Demir M. Hepatocellular carcinoma surveillance with liver imaging is not associated with improved survival. Scand J Gastroenterol 2020;55:222-7. [PMID: 31990240 DOI: 10.1080/00365521.2020.1718747] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
34 Wang J, Feng L, Zhang L. Combining cellular immunotherapy was an optional choice for unresectable advanced HCC: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2021;45:101440. [PMID: 32709504 DOI: 10.1016/j.clinre.2020.04.010] [Reference Citation Analysis]
35 Viganò L, Costa G, Di Tommaso L. Liver resection for multifocal hepatocellular carcinoma: is it an option? Hepatobiliary Surg Nutr 2019;8:530-3. [PMID: 31673548 DOI: 10.21037/hbsn.2019.05.12] [Reference Citation Analysis]
36 Han X, Dong J, Liu Z, Wu B, Tian Y, Tan H, Cheng W. Quantitative dynamic contrast-enhanced ultrasound to predict intrahepatic recurrence of hepatocellular carcinoma after radiofrequency ablation: a cohort study. International Journal of Hyperthermia 2020;37:1066-73. [DOI: 10.1080/02656736.2020.1817576] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Kim JH, Yoon JH, Joo I, Lee JM. Evaluation of Primary Liver Cancers Using Hepatocyte-Specific Contrast-Enhanced MRI: Pitfalls and Potential Tips. J Magn Reson Imaging 2021;53:655-75. [PMID: 32700807 DOI: 10.1002/jmri.27213] [Reference Citation Analysis]
38 von Hessen L, Roumet M, Maurer MH, Lange N, Reeves H, Dufour JF, Radu P. High subcutaneous adipose tissue density correlates negatively with survival in patients with hepatocellular carcinoma. Liver Int 2021;41:828-36. [PMID: 33280219 DOI: 10.1111/liv.14755] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
39 Kotoh Y, Suehiro Y, Saeki I, Hoshida T, Maeda M, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Higaki S, Fujii I, Suzuki C, Shindo Y, Tokumitsu Y, Nagano H, Sakaida I, Yamasaki T. Novel Liquid Biopsy Test Based on a Sensitive Methylated SEPT9 Assay for Diagnosing Hepatocellular Carcinoma. Hepatol Commun 2020;4:461-70. [PMID: 32140662 DOI: 10.1002/hep4.1469] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
40 Anastasopoulos NT, Lianos GD, Tatsi V, Karampa A, Goussia A, Glantzounis GK. Clinical heterogeneity in patients with non-alcoholic fatty liver disease-associated hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2020;14:1025-33. [PMID: 32746645 DOI: 10.1080/17474124.2020.1802244] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
41 Iuamoto LR, Meyer A. Commentary on "The risk factors for long-term survival outcome in solitary hepatocellular carcinoma up to 2 cm: Propensity score matching analysis in a population cohort with a high rate of HBV infection". Int J Surg 2019;72:144-5. [PMID: 31707012 DOI: 10.1016/j.ijsu.2019.10.045] [Reference Citation Analysis]
42 Muszbek N, Remak E, Evans R, Brennan VK, Colaone F, Shergill S, Mullan D, Ross PJ. Cost-utility analysis of selective internal radiation therapy with Y-90 resin microspheres in hepatocellular carcinoma. Future Oncol 2021;17:1055-68. [PMID: 33222542 DOI: 10.2217/fon-2020-1004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Morshid A, Elsayes KM, Khalaf AM, Elmohr MM, Yu J, Kaseb AO, Hassan M, Mahvash A, Wang Z, Hazle JD, Fuentes D. A machine learning model to predict hepatocellular carcinoma response to transcatheter arterial chemoembolization. Radiol Artif Intell. 2019;1. [PMID: 31858078 DOI: 10.1148/ryai.2019180021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
44 da Fonseca LG, Marta GN, Braghiroli MIFM, Chagas AL, Carrilho FJ, Hoff PM, Sabbaga J. Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib. BMC Cancer 2018;18:1250. [PMID: 30545331 DOI: 10.1186/s12885-018-5173-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
45 Ji D, Chen GF, Niu XX, Zhang M, Wang C, Shao Q, Wu V, Wang Y, Cheng G, Hurwitz SJ, Schinazi RF, Lau G. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study. Metabol Open 2021;10:100090. [PMID: 33889834 DOI: 10.1016/j.metop.2021.100090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Iavarone M, Sangiovanni A, Carrafiello G, Rossi G, Lampertico P. Management of hepatocellular carcinoma in the time of COVID-19. Ann Oncol. 2020;31:1084-1085. [PMID: 32330540 DOI: 10.1016/j.annonc.2020.04.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
47 Mahboobnia K, Pirro M, Marini E, Grignani F, Bezsonov EE, Jamialahmadi T, Sahebkar A. PCSK9 and cancer: Rethinking the link. Biomed Pharmacother 2021;140:111758. [PMID: 34058443 DOI: 10.1016/j.biopha.2021.111758] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Kwee SA, Wong LL, Sato MM, Acoba JD, Rho YS, Srivastava A, Landsittel DP. Transarterial Radioembolization for Hepatocellular Carcinoma with Major Vascular Invasion: A Nationwide Propensity Score-Matched Analysis with Target Trial Emulation. J Vasc Interv Radiol 2021;32:1258-1266.e6. [PMID: 34242775 DOI: 10.1016/j.jvir.2021.07.001] [Reference Citation Analysis]
49 Possner M, Gordon-Walker T, Egbe AC, Poterucha JT, Warnes CA, Connolly HM, Ginde S, Clift P, Kogon B, Book WM, Walker N, Wagenaar LJ, Moe T, Oechslin E, Kay WA, Norris M, Dillman JR, Trout AT, Anwar N, Hoskoppal A, Broering DC, Bzeizi K, Veldtman G. Hepatocellular carcinoma and the Fontan circulation: Clinical presentation and outcomes. Int J Cardiol 2021;322:142-8. [PMID: 32828959 DOI: 10.1016/j.ijcard.2020.08.057] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
50 Bae SH, Park HC. Local modalities for inoperable hepatocellular carcinoma: radiofrequency ablation versus stereotactic body radiotherapy. Ann Transl Med 2018;6:S3. [PMID: 30613579 DOI: 10.21037/atm.2018.08.28] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
51 Son JH, Choi SH, Kim SY, Jang HY, Byun JH, Won HJ, Lee SJ, Lim YS. Validation of US Liver Imaging Reporting and Data System Version 2017 in Patients at High Risk for Hepatocellular Carcinoma. Radiology 2019;292:390-7. [PMID: 31210614 DOI: 10.1148/radiol.2019190035] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
52 Kierans AS, Najjar M, Dutruel SP, Gavlin A, Chen C, Lee MJ, Askin G, Halazun KJ. Evaluation of the LI-RADS treatment response algorithm in hepatocellular carcinoma after trans-arterial chemoembolization. Clin Imaging 2021;80:117-22. [PMID: 34303189 DOI: 10.1016/j.clinimag.2021.06.009] [Reference Citation Analysis]
53 Villani R, Cavallone F, Sangineto M, Fioravanti G, Romano AD, Serviddio G. Management of intermediate-stage hepatocellular carcinoma in the elderly with transcatheter arterial chemoembolization failure: Retreatment or switching to systemic therapy? Int J Clin Pract 2021;75:e13733. [PMID: 32981175 DOI: 10.1111/ijcp.13733] [Reference Citation Analysis]
54 Conticchio M, Inchingolo R, Delvecchio A, Laera L, Ratti F, Gelli M, Anelli F, Laurent A, Vitali G, Magistri P, Assirati G, Felli E, Wakabayashi T, Pessaux P, Piardi T, di Benedetto F, de'Angelis N, Briceño J, Rampoldi A, Adam R, Cherqui D, Aldrighetti LA, Memeo R. Radiofrequency ablation vs surgical resection in elderly patients with hepatocellular carcinoma in Milan criteria. World J Gastroenterol 2021; 27(18): 2205-2218 [PMID: 34025074 DOI: 10.3748/wjg.v27.i18.2205] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Labeur TA, Berhane S, Edeline J, Blanc JF, Bettinger D, Meyer T, Van Vugt JLA, Ten Cate DWG, De Man RA, Eskens FALM, Cucchetti A, Bonnett LJ, Van Delden OM, Klümpen HJ, Takkenberg RB, Johnson PJ. Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib. Liver Int 2020;40:215-28. [PMID: 31579990 DOI: 10.1111/liv.14270] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
56 Lim C, Goumard C, Salloum C, Tudisco A, Napoli N, Boggi U, Azoulay D, Scatton O. Outcomes after 3D laparoscopic and robotic liver resection for hepatocellular carcinoma: a multicenter comparative study. Surg Endosc 2021;35:3258-66. [DOI: 10.1007/s00464-020-07762-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
57 Mei J, Li SH, Wang QX, Zhong XP, Lu LH, Kan A, Wei W, Guo RP. A novel treatment strategy using indocyanine green for transarterial chemoembolization in BCLC stage C hepatocellular carcinoma. Cancer Med 2020;9:62-76. [PMID: 31701652 DOI: 10.1002/cam4.2671] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
58 Wang J, Fan Z, Li J, Yang J, Liu X, Cheng J. Transcription factor specificity protein 1-mediated Serine/threonine kinase 39 upregulation promotes the proliferation, migration, invasion and epithelial-mesenchymal transition of hepatocellular carcinoma cells by activating the transforming growth factor-β1 /Smad2/3 pathway. Bioengineered 2021;12:3566-77. [PMID: 34281492 DOI: 10.1080/21655979.2021.1947939] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
59 Kudo M. A new era of systemic therapy for intermediate and advanced stage hepatocellular carcinoma. Hepatobiliary Surg Nutr 2020;9:530-3. [PMID: 32832511 DOI: 10.21037/hbsn-20-420] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Ahn YH, Lee H, Kim DY, Lee HW, Yu SJ, Cho YY, Jang JW, Jang BK, Kim CW, Kim HY, Park H, Cho HJ, Park B, Kim SS, Cheong JY. Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C. Gut Liver 2021;15:410-9. [PMID: 32893194 DOI: 10.5009/gnl20151] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
61 Mahalingam D, Chelis L, Nizamuddin I, Lee SS, Kakolyris S, Halff G, Washburn K, Attwood K, Fahad I, Grigorieva J, Asmellash S, Meyer K, Oliveira C, Roder H, Roder J, Iyer R. Detection of Hepatocellular Carcinoma in a High-Risk Population by a Mass Spectrometry-Based Test. Cancers (Basel) 2021;13:3109. [PMID: 34206321 DOI: 10.3390/cancers13133109] [Reference Citation Analysis]
62 Ye Z, Jiang H, Chen J, Liu X, Wei Y, Xia C, Duan T, Cao L, Zhang Z, Song B. Texture analysis on gadoxetic acid enhanced-MRI for predicting Ki-67 status in hepatocellular carcinoma: A prospective study. Chin J Cancer Res. 2019;31:806-817. [PMID: 31814684 DOI: 10.21147/j.issn.1000-9604.2019.05.10] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
63 Zhang J, Chen G, Zhang P, Zhang J, Li X, Gan D, Cao X, Han M, Du H, Ye Y. The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. PLoS One. 2020;15:e0228857. [PMID: 32053643 DOI: 10.1371/journal.pone.0228857] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 21.0] [Reference Citation Analysis]
64 Ben Ammar M, Nouri-Neuville M, Cornelis FH. Percutaneous image-guided therapies of primary liver tumors: Techniques and outcomes. Presse Med 2019;48:e245-50. [PMID: 31445698 DOI: 10.1016/j.lpm.2019.07.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Wakabayashi T, Ouhmich F, Gonzalez-Cabrera C, Felli E, Saviano A, Agnus V, Savadjiev P, Baumert TF, Pessaux P, Marescaux J, Gallix B. Radiomics in hepatocellular carcinoma: a quantitative review. Hepatol Int. 2019;13:546-559. [PMID: 31473947 DOI: 10.1007/s12072-019-09973-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 17.0] [Reference Citation Analysis]
66 Huang JF, Huang CF, Yeh ML, Dai CY, Yu ML, Chuang WL. Updates in the management and treatment of HCV genotype 3, what are the remaining challenges? Expert Rev Anti Infect Ther. 2018;16:907-912. [PMID: 30396303 DOI: 10.1080/14787210.2018.1544492] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
67 Désert R, Nieto N, Musso O. Dimensions of hepatocellular carcinoma phenotypic diversity. World J Gastroenterol 2018; 24(40): 4536-4547 [PMID: 30386103 DOI: 10.3748/wjg.v24.i40.4536] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
68 Han G, Berhane S, Toyoda H, Bettinger D, Elshaarawy O, Chan AWH, Kirstein M, Mosconi C, Hucke F, Palmer D, Pinato DJ, Sharma R, Ottaviani D, Jang JW, Labeur TA, van Delden OM, Pirisi M, Stern N, Sangro B, Meyer T, Fateen W, García-Fiñana M, Gomaa A, Waked I, Rewisha E, Aithal GP, Travis S, Kudo M, Cucchetti A, Peck-Radosavljevic M, Takkenberg RB, Chan SL, Vogel A, Johnson PJ. Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. Hepatology 2020;72:198-212. [PMID: 31698504 DOI: 10.1002/hep.31022] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 27.0] [Reference Citation Analysis]
69 Yoh K, Nishikawa H, Enomoto H, Iwata Y, Ikeda N, Aizawa N, Nishimura T, Iijima H, Nishiguchi S. Grip Strength: A Useful Marker for Composite Hepatic Events in Patients with Chronic Liver Diseases. Diagnostics (Basel) 2020;10:E238. [PMID: 32325995 DOI: 10.3390/diagnostics10040238] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
70 Liang LY, Wong VW, Toyoda H, Tse YK, Yip TC, Yuen BW, Tada T, Kumada T, Lee HW, Lui GC, Chan HL, Wong GL. Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients. J Gastroenterol 2020;55:899-908. [PMID: 32556643 DOI: 10.1007/s00535-020-01700-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
71 Patel K, Lamm R, Altshuler P, Dang H, Shah AP. Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy. Int J Mol Sci 2020;21:E6757. [PMID: 32942580 DOI: 10.3390/ijms21186757] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
72 Huang Y, Huang X, Zeng J, Lin J. Knockdown of MUC16 (CA125) Enhances the Migration and Invasion of Hepatocellular Carcinoma Cells. Front Oncol 2021;11:667669. [PMID: 34150633 DOI: 10.3389/fonc.2021.667669] [Reference Citation Analysis]
73 Qu C, Jiao Y, Wang Y. A liquid biopsy assay for identifying early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals. Mol Cell Oncol 2019;6:e1614419. [PMID: 31528693 DOI: 10.1080/23723556.2019.1614419] [Reference Citation Analysis]
74 Yang X, Yuan C, Zhang Y, Wang Z. Magnetic resonance radiomics signatures for predicting poorly differentiated hepatocellular carcinoma: A SQUIRE-compliant study. Medicine (Baltimore) 2021;100:e25838. [PMID: 34106622 DOI: 10.1097/MD.0000000000025838] [Reference Citation Analysis]
75 Reuken PA, Lutz P, Casper M, Al-Herwi E, Stengel S, Spengler U, Stallmach A, Lammert F, Nischalke HD, Bruns T. The ATG16L1 gene variant rs2241880 (p.T300A) is associated with susceptibility to HCC in patients with cirrhosis. Liver Int 2019;39:2360-7. [PMID: 31484215 DOI: 10.1111/liv.14239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
76 Serenari M, Han K, Ravaioli F, Kim S, Cucchetti A, Han D, Odaldi F, Ravaioli M, Festi D, Pinna AD, Cescon M. A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma. Journal of Hepatology 2020;73:855-62. [DOI: 10.1016/j.jhep.2020.04.032] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 22.0] [Reference Citation Analysis]
77 Yoon JH, Lee JM, Lee DH, Joo I, Jeon JH, Ahn SJ, Kim ST, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH. A Comparison of Biannual Two-Phase Low-Dose Liver CT and US for HCC Surveillance in a Group at High Risk of HCC Development. Liver Cancer 2020;9:503-17. [PMID: 33083277 DOI: 10.1159/000506834] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
78 Campos Carrascosa L, van Beek AA, de Ruiter V, Doukas M, Wei J, Fisher TS, Ching K, Yang W, van Loon K, Boor PPC, Rakké YS, Noordam L, Doornebosch P, Grünhagen D, Verhoef K, Polak WG, IJzermans JNM, Ni I, Yeung YA, Salek-Ardakani S, Sprengers D, Kwekkeboom J. FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells. J Immunother Cancer 2020;8:e000816. [PMID: 32900860 DOI: 10.1136/jitc-2020-000816] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
79 Pomej K, Scheiner B, Park D, Bauer D, Balcar L, Meischl T, Mandorfer M, Reiberger T, Müller C, Trauner M, Pinter M. Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib. Cancers (Basel) 2020;12:E2961. [PMID: 33066190 DOI: 10.3390/cancers12102961] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
80 Sano S, Nakata S, Wada S, Kuroiwa M, Sakai H, Kusama K, Machida T, Nishio A, Ito I, Sodeyama H. Pathological complete response by advanced hepatocellular carcinoma with massive macrovascular invasion to hepatic arterial infusion chemotherapy: a case report. World J Surg Oncol 2019;17:229. [PMID: 31878937 DOI: 10.1186/s12957-019-1772-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
81 Jin Z, Chen L, Zhong B, Zhou H, Zhu H, Song J, Guo J, Zhu X, Ji J, Ni C, Teng G. Machine-learning analysis of contrast-enhanced computed tomography radiomics predicts patients with hepatocellular carcinoma who are unsuitable for initial transarterial chemoembolization monotherapy: A multicenter study. Transl Oncol. 2021;14:101034. [PMID: 33567388 DOI: 10.1016/j.tranon.2021.101034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
82 Meyers N, Jadoul A, Bernard C, Delwaide J, Lamproye A, Detry O, Honoré P, Gerard L, Hustinx R. Inter-observer variability of 90Y PET/CT dosimetry in hepatocellular carcinoma after glass microspheres transarterial radioembolization. EJNMMI Phys 2020;7:29. [PMID: 32399636 DOI: 10.1186/s40658-020-00302-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Cerrito L, Ponziani FR, Garcovich M, Tortora A, Annicchiarico BE, Pompili M, Siciliano M, Gasbarrini A. Regorafenib: a promising treatment for hepatocellular carcinoma. Expert Opin Pharmacother. 2018;19:1941-1948. [PMID: 30345837 DOI: 10.1080/14656566.2018.1534956] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
84 Lemieux S, Buies A, F Turgeon A, Hallet J, Daigle G, Côté F, Provencher S. Effect of Yttrium-90 transarterial radioembolization in patients with non-surgical hepatocellular carcinoma: A systematic review and meta-analysis. PLoS One 2021;16:e0247958. [PMID: 33662011 DOI: 10.1371/journal.pone.0247958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Liang J, Zhi Y, Deng W, Zhou W, Li X, Cai Z, Zhu Z, Zeng J, Wu W, Dong Y, Huang J, Zhang Y, Xu S, Feng Y, Ding F, Zhang J. Development and validation of ferroptosis-related lncRNAs signature for hepatocellular carcinoma. PeerJ 2021;9:e11627. [PMID: 34178478 DOI: 10.7717/peerj.11627] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
86 Nishikawa H, Yoh K, Enomoto H, Nishimura T, Nishiguchi S, Iijima H. Combined grip strength and calf circumference as a useful prognostic system in patients with liver diseases: a large cohort study. Ann Transl Med 2021;9:624. [PMID: 33987322 DOI: 10.21037/atm-20-6901] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Campani C, Bensi C, Milani S, Galli A, Tarocchi M. Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes. J Hepatocell Carcinoma 2020;7:107-16. [PMID: 32802809 DOI: 10.2147/JHC.S252506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
88 Fujiwara N, Hoshida Y. Hepatocellular Carcinoma Risk Stratification by Genetic Profiling in Patients with Cirrhosis. Semin Liver Dis 2019;39:153-62. [PMID: 30912093 DOI: 10.1055/s-0039-1681031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
89 Bartolotta TV, Terranova MC, Gagliardo C, Taibbi A. CEUS LI-RADS: a pictorial review. Insights Imaging. 2020;11:9. [PMID: 32020352 DOI: 10.1186/s13244-019-0819-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
90 Fernandez-Placencia R, Berrospi-Espinoza F, Uribe-Rivera K, Medina-Cana J, Chavez-Passiuri I, Sanchez-Bartra N, Paredes-Galvez K, Luque-Vasquez Vasquez C, Celis-Zapata J, Ruiz-Figueroa E. Preoperative Predictors for 90-Day Mortality after Pancreaticoduodenectomy in Patients with Adenocarcinoma of the Ampulla of Vater: A Single-Centre Retrospective Cohort Study. Surg Res Pract 2021;2021:6682935. [PMID: 33728373 DOI: 10.1155/2021/6682935] [Reference Citation Analysis]
91 Cucchetti A, Serenari M, Sposito C, Di Sandro S, Mosconi C, Vicentin I, Garanzini E, Mazzaferro V, De Carlis L, Golfieri R, Spreafico C, Vanzulli A, Buscemi V, Ravaioli M, Ercolani G, Pinna AD, Cescon M. Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant. Journal of Hepatology 2020;73:342-8. [DOI: 10.1016/j.jhep.2020.03.018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
92 van Beek AA, Zhou G, Doukas M, Boor PPC, Noordam L, Mancham S, Campos Carrascosa L, van der Heide-Mulder M, Polak WG, Ijzermans JNM, Pan Q, Heirman C, Mahne A, Bucktrout SL, Bruno MJ, Sprengers D, Kwekkeboom J. GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma. Int J Cancer 2019;145:1111-24. [PMID: 30719701 DOI: 10.1002/ijc.32181] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
93 Feng Y, Wang L, Lv H, Shi T, Xu C, Zheng H, Qi J, Zhao X, Li J, Gao Y, Qin C, Zhu Q. Microwave ablation versus radiofrequency ablation for perivascular hepatocellular carcinoma: a propensity score analysis. HPB (Oxford) 2021;23:512-9. [PMID: 32839089 DOI: 10.1016/j.hpb.2020.08.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
94 Ito K, Takemura N, Inagaki F, Mihara F, Kokudo N. Difference in treatment algorithms for hepatocellular carcinoma between world's principal guidelines. Glob Health Med. 2020;2:282-291. [PMID: 33330822 DOI: 10.35772/ghm.2020.01066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
95 Chu HH, Kim JH, Shim JH, Yoon SM, Kim PH, Alrashidi I. Chemoembolization Plus Radiotherapy Versus Chemoembolization Plus Sorafenib for the Treatment of Hepatocellular Carcinoma Invading the Portal Vein: A Propensity Score Matching Analysis. Cancers (Basel) 2020;12:E1116. [PMID: 32365655 DOI: 10.3390/cancers12051116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
96 Depauw L, De Weerdt G, Gys B, Demeulenaere S, Mebis W, Ysebaert D. Pediatric fibrolamellar hepatocellular carcinoma: case report and review of the literature. Acta Chir Belg 2021;121:204-10. [PMID: 34082642 DOI: 10.1080/00015458.2019.1660060] [Reference Citation Analysis]
97 Li P, Erten O, Akbulut S, Gokceimam M, Berber E. An Analysis of Free-hand Targeting in Laparoscopic Liver Microwave Ablation. Surg Laparosc Endosc Percutan Tech 2020;31:215-9. [PMID: 33048898 DOI: 10.1097/SLE.0000000000000868] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Mai R, Lu H, Bai T, Liang R, Lin Y, Ma L, Xiang B, Wu G, Li L, Ye J. Artificial neural network model for preoperative prediction of severe liver failure after hemihepatectomy in patients with hepatocellular carcinoma. Surgery 2020;168:643-52. [DOI: 10.1016/j.surg.2020.06.031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
99 Pandyarajan V, Govalan R, Yang JD. Risk Factors and Biomarkers for Chronic Hepatitis B Associated Hepatocellular Carcinoma. Int J Mol Sci 2021;22:E479. [PMID: 33418899 DOI: 10.3390/ijms22020479] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
100 Li S, Lyu N, Han X, Li J, Lai J, He M, Deng H, Shi M, Wang H, Zhao M. Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis. J Vasc Interv Radiol 2021;32:1267-1276.e1. [PMID: 34166806 DOI: 10.1016/j.jvir.2021.06.008] [Reference Citation Analysis]
101 Ebadi M, Moctezuma-Velazquez C, Meza-Junco J, Baracos VE, DunichandHoedl AR, Ghosh S, Sarlieve P, Owen RJ, Kneteman N, Montano-Loza AJ. Visceral Adipose Tissue Radiodensity Is Linked to Prognosis in Hepatocellular Carcinoma Patients Treated with Selective Internal Radiation Therapy. Cancers (Basel) 2020;12:E356. [PMID: 32033166 DOI: 10.3390/cancers12020356] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
102 Sapisochin G, Hibi T, Toso C, Man K, Berenguer M, Heimbach J, Greten TF, Pugh TJ, Dawson LA, Mazzaferro V. Transplant Oncology in Primary and Metastatic Liver Tumors: Principles, Evidence, and Opportunities. Ann Surg 2021;273:483-93. [PMID: 33065633 DOI: 10.1097/SLA.0000000000004071] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
103 Miguet M, Adam JP, Blanc JF, Lapuyade B, Bernard P, Buscail E, Neau-Cransac M, Vendrely V, Laurent C, Chiche L. Multidisciplinary meetings specific to hepatocellular carcinoma: How to proceed? J Visc Surg 2019;156:217-27. [PMID: 31203872 DOI: 10.1016/j.jviscsurg.2018.09.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
104 Lim J, Kim HI, Kim E, Kim J, An J, Chang S, Kim SO, Lee HC, Lee YS, Shim JH. Variceal bleeding is aggravated by portal venous invasion of hepatocellular carcinoma: a matched nested case-control study. BMC Cancer 2021;21:11. [PMID: 33402105 DOI: 10.1186/s12885-020-07708-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Schulte N, Li M, Zhan T, Dreikhausen L, Sollors J, Antoni C, Diehl S, Schoenberg SO, Rahbari N, Reissfelder C, Giordano FA, Ebert MP, Teufel A. Response of advanced HCC to pembrolizumab and lenvatinib combination therapy despite monotherapy failure. Z Gastroenterol 2020;58:773-7. [PMID: 32785913 DOI: 10.1055/a-1190-5681] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
106 Wang Q, Huang J, Zhang H, Liu H, Yu M. Identification and analysis of immune-related subtypes of hepatocellular carcinoma. Exp Biol Med (Maywood) 2021;246:667-77. [PMID: 33231514 DOI: 10.1177/1535370220970130] [Reference Citation Analysis]
107 Pang Q, Liu S, Wang L, Pan H, Wang C, Zhou L, Lu Y, Liu H. The Significance of Platelet-Albumin-Bilirubin (PALBI) Grade in Hepatocellular Carcinoma Patients Stratified According to Platelet Count. Cancer Manag Res 2020;12:12811-22. [PMID: 33364830 DOI: 10.2147/CMAR.S277013] [Reference Citation Analysis]
108 Zhong BY, Yan ZP, Sun JH, Zhang L, Hou ZH, Zhu XL, Wen L, Ni CF. Random Survival Forests to Predict Disease Control for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib. Front Mol Biosci 2021;8:618050. [PMID: 34095216 DOI: 10.3389/fmolb.2021.618050] [Reference Citation Analysis]
109 Duvoux C, Belli LS, Fung J, Angelico M, Buti M, Coilly A, Cortesi P, Durand F, Féray C, Fondevila C, Lebray P, Martini S, Nevens F, Polak WG, Rizzetto M, Volpes R, Zoulim F, Samuel D, Berenguer M. 2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation. Aliment Pharmacol Ther 2021;54:583-605. [PMID: 34287994 DOI: 10.1111/apt.16374] [Reference Citation Analysis]
110 Wang C, He W, Yuan Y, Zhang Y, Li K, Zou R, Liao Y, Liu W, Yang Z, Zuo D, Qiu J, Zheng Y, Li B, Yuan Y. Comparison of the prognostic value of inflammation-based scores in early recurrent hepatocellular carcinoma after hepatectomy. Liver Int 2020;40:229-39. [PMID: 31652394 DOI: 10.1111/liv.14281] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
111 Xu G, Jin B, Xian X, Yang H, Zhao H, Du S, Makuuchi M, Pawlik TM, Mao Y. Evolutions in the Management of Hepatocellular Carcinoma over Last 4 Decades: An Analysis from the 100 Most Influential Articles in the Field. Liver Cancer 2021;10:137-50. [PMID: 33977090 DOI: 10.1159/000513412] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
112 Poynard T, Peta V, Deckmyn O, Munteanu M, Moussalli J, Ngo Y, Rudler M, Lebray P, Pais R, Bonyhay L, Charlotte F, Thibault V, Fartoux L, Lucidarme O, Eyraud D, Scatton O, Savier E, Valantin MA, Ngo A, Drane F, Rosmorduc O, Imbert-Bismut F, Housset C, Thabut D, Ratziu V; HECAM-FibroFrance Group. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Aliment Pharmacol Ther 2019;49:308-20. [PMID: 30569507 DOI: 10.1111/apt.15082] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
113 Kuo TM, Chang KM, Kao KJ. Why Cannot BCLC 0- or A-Stage Patients Receive Curative Treatment? Gastrointest Tumors 2020;7:125-33. [PMID: 33173776 DOI: 10.1159/000509824] [Reference Citation Analysis]
114 Mei J, Tang YH, Wei W, Shi M, Zheng L, Li SH, Guo RP. Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma. Front Oncol 2021;11:618206. [PMID: 33718175 DOI: 10.3389/fonc.2021.618206] [Reference Citation Analysis]
115 Yoo GS, Yu JI, Park HC, Hyun D, Jeong WK, Lim HY, Choi MS, Ha SY. Do Biliary Complications after Proton Beam Therapy for Perihilar Hepatocellular Carcinoma Matter? Cancers (Basel) 2020;12:E2395. [PMID: 32847035 DOI: 10.3390/cancers12092395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
116 Petroni ML, Brodosi L, Bugianesi E, Marchesini G. Management of non-alcoholic fatty liver disease.BMJ. 2021;372:m4747. [PMID: 33461969 DOI: 10.1136/bmj.m4747] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
117 Beumer BR, de Wilde RF, Metselaar HJ, de Man RA, Polak WG, Ijzermans JNM. The Treatment Effect of Liver Transplantation versus Liver Resection for HCC: A Review and Future Perspectives. Cancers (Basel) 2021;13:3730. [PMID: 34359629 DOI: 10.3390/cancers13153730] [Reference Citation Analysis]
118 Gupta S, Khan S, Kawka M, Gujjuri R, Chau I, Starling N, Cunningham D, Jiao LR, Gall T. Clinical utility of clonal origin determination in managing recurrent hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2021;:1-9. [PMID: 34402366 DOI: 10.1080/17474124.2021.1967144] [Reference Citation Analysis]
119 Papatheodoridis GV, Sypsa V, Dalekos GN, Yurdaydin C, Van Boemmel F, Buti M, Calleja JL, Chi H, Goulis J, Manolakopoulos S, Loglio A, Voulgaris T, Gatselis N, Keskin O, Veelken R, Lopez-gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Idilman R, Esteban R, Janssen HL, Berg T, Lampertico P. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. Journal of Hepatology 2020;72:1088-96. [DOI: 10.1016/j.jhep.2020.01.007] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 34.0] [Reference Citation Analysis]
120 Long HY, Huang TY, Xie XY, Long JT, Liu BX. Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis. World J Clin Cases 2021; 9(21): 5754-5768 [PMID: 34368295 DOI: 10.12998/wjcc.v9.i21.5754] [Reference Citation Analysis]
121 Hsiao P, Hsieh KC, Chen YS, Hsu CC, Lo GH, Li YC, Hsieh PM, Lin HY, Wu TC, Yeh JH, Lin CW. Sorafenib with concurrent multiple-line therapies improves overall survival in advanced stage hepatocellular carcinoma. Medicine (Baltimore) 2019;98:e16074. [PMID: 31232945 DOI: 10.1097/MD.0000000000016074] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
122 Wei J, Jiang H, Gu D, Niu M, Fu F, Han Y, Song B, Tian J. Radiomics in liver diseases: Current progress and future opportunities. Liver Int 2020;40:2050-63. [PMID: 32515148 DOI: 10.1111/liv.14555] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
123 Borgheresi A, Covey A, Yarmohammadi H, Boas FE, Ziv E, Getrajdman G, Erinjeri J, Jarnagin W, Harding JJ, D'Angelica M, Gonen M, Brown KT. Embolization with microspheres alone for hepatocellular carcinoma with portal vein tumor: analysis of outcome and liver function at disease progression. HPB (Oxford) 2020;22:588-94. [PMID: 31474455 DOI: 10.1016/j.hpb.2019.08.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
124 Li TT, Sun J, Wang Q, Li WG, He WP, Yang RC, Duan XZ. The effects of stereotactic body radiotherapy on peripheral natural killer and CD3+CD56+ NKT-like cells in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2021;20:240-50. [PMID: 33454220 DOI: 10.1016/j.hbpd.2020.12.015] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Fan CT, Lin WW, Chen MJ, Shiu SI. Isolated Right Ventricular Metastasis in a Woman with Advanced Hepatocellular Carcinoma after Palliative Therapy. Case Rep Gastroenterol 2019;13:487-97. [PMID: 31911761 DOI: 10.1159/000504566] [Reference Citation Analysis]
126 Wang HW, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Chuang PH, Wang JH, Lee MH, Chen CH, Peng CY. On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1177. [PMID: 32392752 DOI: 10.3390/cancers12051177] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
127 Pirisi M, Leutner M, Romito R, Gaia S. Novel Calculators for Risk Stratification in Hepatocellular Carcinoma: A Concise Review. J Clin Gastroenterol 2020;54:789-94. [PMID: 32773489 DOI: 10.1097/MCG.0000000000001406] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Kovac JD, Ivanovic A, Milovanovic T, Micev M, Alessandrino F, Gore RM. An overview of hepatocellular carcinoma with atypical enhancement pattern: spectrum of magnetic resonance imaging findings with pathologic correlation. Radiol Oncol 2021;55:130-43. [PMID: 33544992 DOI: 10.2478/raon-2021-0004] [Reference Citation Analysis]
129 Tsai YF, Liu FC, Chen CY, Lin JR, Yu HP. Effect of Mycophenolate Mofetil Therapy on Recurrence of Hepatocellular Carcinoma after Liver Transplantation: A Population-Based Cohort Study. J Clin Med 2021;10:1558. [PMID: 33917215 DOI: 10.3390/jcm10081558] [Reference Citation Analysis]
130 Shawon MA, Yousuf MAK, Raheem E, Ahmed S, Dipti TT, Hoque MR, Taniguchi H, Karim MR. Epidemiology, clinical features, and impact of food habits on the risk of hepatocellular carcinoma: A case-control study in Bangladesh. PLoS One 2020;15:e0232121. [PMID: 32339207 DOI: 10.1371/journal.pone.0232121] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
131 Yoh T, Seo S, Ogiso S, Morino K, Fukumitsu K, Ishii T, Nakamoto Y, Taura K. Quantitative assessment of microvascular invasion in hepatocellular carcinoma using preoperative serological and imaging markers. HPB (Oxford) 2021;23:1039-45. [PMID: 33262049 DOI: 10.1016/j.hpb.2020.10.024] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
132 Sachar Y, Brahmania M, Dhanasekaran R, Congly SE. Screening for Hepatocellular Carcinoma in Patients with Hepatitis B. Viruses 2021;13:1318. [PMID: 34372524 DOI: 10.3390/v13071318] [Reference Citation Analysis]
133 Lacin S, Yalcin S, Karakas Y, Hassan MM, Amin H, Mohamed YI, Rashid A, Morris JS, Xiao L, Qayyum A, Kaseb AO. Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study. J Hepatocell Carcinoma 2020;7:143-53. [PMID: 32984091 DOI: 10.2147/JHC.S258930] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
134 Labeur TA, Hofsink Q, Takkenberg RB, van Delden OM, Mathôt RAA, Schinner R, Malfertheiner P, Amthauer H, Schütte K, Basu B, Kuhl C, Mayerle J, Ricke J, Klümpen HJ. The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma - a substudy of the SORAMIC trial. Acta Oncol 2020;59:1028-35. [PMID: 32366155 DOI: 10.1080/0284186X.2020.1759826] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
135 Lal LS, Aly A, Le LB, Peckous S, Seal B, Teitelbaum A. Healthcare costs related to adverse events in hepatocellular carcinoma treatment: A retrospective observational claims study. Cancer Rep (Hoboken) 2021;:e1504. [PMID: 34494389 DOI: 10.1002/cnr2.1504] [Reference Citation Analysis]
136 Hilmi M, Neuzillet C, Calderaro J, Lafdil F, Pawlotsky JM, Rousseau B. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. J Immunother Cancer 2019;7:333. [PMID: 31783782 DOI: 10.1186/s40425-019-0824-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 19.5] [Reference Citation Analysis]
137 Li Z, Wang C, Si G, Zhou X, Li Y, Li J, Jiao D, Han X. Image-guided microwave ablation of hepatocellular carcinoma (≤5.0 cm): is MR guidance more effective than CT guidance? BMC Cancer 2021;21:366. [PMID: 33827464 DOI: 10.1186/s12885-021-08099-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Deng M, Li S, Mei J, Lin W, Zou J, Wei W, Guo R. High SGO2 Expression Predicts Poor Overall Survival: A Potential Therapeutic Target for Hepatocellular Carcinoma. Genes (Basel) 2021;12:876. [PMID: 34200261 DOI: 10.3390/genes12060876] [Reference Citation Analysis]
139 Christou CD, Tooulias A, Tsolakidis A, Papayiannis V, Pianetcki-Tsiantzi B, Tsoulfas G, Papadopoulos VN. Management of Hepatocellular Carcinoma in the Era of Individualized Therapy: The Experience of a Greek Tertiary Center.Ochsner J. 2020;20:272-278. [PMID: 33071659 DOI: 10.31486/toj.19.0092] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
140 Calvaruso V, Petta S, Cacciola I, Cabibbo G, Cartabellotta F, Distefano M, Scifo G, Di Rosolini MA, Russello M, Prestileo T, Madonia S, Malizia G, Montineri A, Digiacomo A, Licata A, Benanti F, Bertino G, Enea M, Battaglia S, Squadrito G, Raimondo G, Cammà C, Craxì A, Di Marco V; Rete Sicilia Selezione Terapia - HCV (RESIST-HCV). Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort. J Viral Hepat 2021;28:1190-9. [PMID: 33896097 DOI: 10.1111/jvh.13523] [Reference Citation Analysis]
141 Moctezuma-Velázquez C, Lewis S, Lee K, Amodeo S, Llovet JM, Schwartz M, Abraldes JG, Villanueva A. Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B. JHEP Rep 2021;3:100364. [PMID: 34712933 DOI: 10.1016/j.jhepr.2021.100364] [Reference Citation Analysis]
142 Pinato DJ, Fessas P, Sapisochin G, Marron TU. Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma. Hepatology. 2021;74:483-490. [PMID: 33369758 DOI: 10.1002/hep.31697] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
143 Laimer G, Schullian P, Putzer D, Eberle G, Goldberg SN, Bale R. Can accurate evaluation of the treatment success after radiofrequency ablation of liver tumors be achieved by visual inspection alone? Results of a blinded assessment with 38 interventional oncologists. Int J Hyperthermia 2020;37:1362-7. [PMID: 33302747 DOI: 10.1080/02656736.2020.1857445] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
144 Uhlig J, Sellers CM, Stein SM, Kim HS. Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database. Eur Radiol. 2019;29:2679-2689. [PMID: 30560364 DOI: 10.1007/s00330-018-5902-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
145 Kim JM, Cho SY, Rhu J, Jung M, Her JH, Lim O, Choi GS, Shin EC, Hwang YK, Joh JW. Adjuvant therapy using ex vivo-expanded allogenic natural killer cells in hepatectomy patients with hepatitis B virus related solitary hepatocellular carcinoma: MG4101 study. Ann Hepatobiliary Pancreat Surg 2021;25:206-14. [PMID: 34053923 DOI: 10.14701/ahbps.2021.25.2.206] [Reference Citation Analysis]
146 Choi GH, Jang ES, Kim JW, Jeong SH. Prognostic role of plasma level of angiopoietin-1, angiopoietin-2, and vascular endothelial growth factor in hepatocellular carcinoma. World J Gastroenterol 2021; 27(27): 4453-4467 [PMID: 34366616 DOI: 10.3748/wjg.v27.i27.4453] [Reference Citation Analysis]
147 Rim CH, Yim HJ, Park S, Seong J. Recent clinical applications of external beam radiotherapy for hepatocellular carcinoma according to guidelines, major trials and meta-analyses. J Med Imaging Radiat Oncol. 2019;63:812-821. [PMID: 31482683 DOI: 10.1111/1754-9485.12948] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
148 Mei J, Li SH, Wang QX, Lu LH, Ling YH, Zou JW, Lin WP, Wen YH, Wei W, Guo RP. Resection vs. Sorafenib for Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Real World, Propensity Score Matched Analytic Study. Front Oncol 2020;10:573. [PMID: 32432036 DOI: 10.3389/fonc.2020.00573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
149 Turkes F, Chau I. Ramucirumab and its use in the treatment of hepatocellular carcinoma. Future Oncol. 2019;. [PMID: 30644314 DOI: 10.2217/fon-2018-0822] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
150 Reig M, Cabibbo G. Antiviral therapy in the palliative setting of HCC (BCLC-B and -C). J Hepatol 2021;74:1225-33. [PMID: 33582128 DOI: 10.1016/j.jhep.2021.01.046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
151 Zhang HL, Zhu JE, Li JX, Li XL, Sun LP, Xu HX, Yu SY. US-guided percutaneous microwave ablation (MWA) of submandibular gland: A new minimal invasive and effective treatment for refractory sialorrhea and treatment response evaluation with contrast-enhanced imaging techniques. Clin Hemorheol Microcirc 2021;78:215-26. [PMID: 33682703 DOI: 10.3233/CH-211115] [Reference Citation Analysis]
152 Yuan G, Li R, Li Q, Hu X, Ruan J, Fan W, Wang J, Huang W, Zang M, Chen J. Interaction between hepatitis B virus infection and the efficacy of camrelizumab in combination with apatinib therapy in patients with hepatocellular carcinoma: a multicenter retrospective cohort study. Ann Transl Med 2021;9:1412. [PMID: 34733964 DOI: 10.21037/atm-21-3020] [Reference Citation Analysis]
153 Gregory J, Dioguardi Burgio M, Corrias G, Vilgrain V, Ronot M. Evaluation of liver tumour response by imaging. JHEP Rep 2020;2:100100. [PMID: 32514496 DOI: 10.1016/j.jhepr.2020.100100] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
154 Ahn JC, Teng PC, Chen PJ, Posadas E, Tseng HR, Lu SC, Yang JD. Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma. Hepatology 2021;73:422-36. [PMID: 32017145 DOI: 10.1002/hep.31165] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 27.0] [Reference Citation Analysis]
155 Cagnin M, Biasiolo A, Martini A, Ruvoletto M, Quarta S, Fasolato S, Angeli P, Fassina G, Pontisso P. Serum Squamous Cell Carcinoma Antigen-Immunoglobulin M complex levels predict survival in patients with cirrhosis. Sci Rep 2019;9:20126. [PMID: 31882893 DOI: 10.1038/s41598-019-56633-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
156 Song J, Liu Y, Lin L, Zhao Y, Wang X, Zhong M, Xie T, Luo Y, Li S, Yang R, Li H. Glycyrrhetinic acid modified and pH-sensitive mixed micelles improve the anticancer effect of curcumin in hepatoma carcinoma cells. RSC Adv 2019;9:40131-45. [DOI: 10.1039/c9ra07250k] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
157 Lee IC, Hung YW, Liu CA, Lee RC, Su CW, Huo TI, Li CP, Chao Y, Lin HC, Hou MC, Huang YH. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma. Liver Int. 2019;39:1704-1712. [PMID: 31319016 DOI: 10.1111/liv.14194] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
158 Ou HY, Cheng YF, Chuang YH, Hsu HW, Chen CL, Lazo MZ, Weng CC, Yu CY, Tsang LL, Huang TL, Tong YS. Quantification of Functional MR Predicts Early Response in Post-doxorubicin Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma. Dig Dis Sci. 2019;. [PMID: 31732907 DOI: 10.1007/s10620-019-05951-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
159 Liu ZL, Zhu LL, Liu JH, Pu ZY, Ruan ZP, Chen J. Vascular endothelial growth factor receptor-2 and its association with tumor immune regulatory gene expression in hepatocellular carcinoma. Aging (Albany NY) 2020;12:25172-88. [PMID: 33223512 DOI: 10.18632/aging.104119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 Kuo FY, Liu YW, Lin CC, Yong CC, Wang CC, Chen CL, Cheng YF, Wang JH, Yen YH. Microscopic portal vein invasion is a powerful predictor of prognosis in patients with hepatocellular carcinoma who have undergone liver resection. J Surg Oncol 2021;123:222-35. [PMID: 33084068 DOI: 10.1002/jso.26260] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 An J, Kim HI, Oh B, Oh YJ, Oh JH, Kim W, Sung CO, Shim JH. Integrated prognostic and histogenomic justification of stage-directed therapy for single large hepatocellular carcinoma: a Korean nationwide registry study. Gut 2021:gutjnl-2021-325844. [PMID: 34493591 DOI: 10.1136/gutjnl-2021-325844] [Reference Citation Analysis]
162 Sigurdsson B, Sigurdardottir R, Arnardottir MB, Lund SH, Jonasson JG, Björnsson ES. A nationwide study on hepatocellular carcinoma. Cancer Epidemiology 2020;69:101835. [DOI: 10.1016/j.canep.2020.101835] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
163 Wallace MC, Samuelson S, Khoo T, Ooi J, Tibballs J, Ferguson J, Preen DB, Knuiman M, Garas G, MacQuillan G, Adams LA, Jeffrey GP. The MAAPE score in intermediate and advanced hepatocellular carcinoma treated with Yttrium-90 resin microsphere radioembolization. J Gastroenterol Hepatol 2020;35:1945-52. [PMID: 32036614 DOI: 10.1111/jgh.15008] [Reference Citation Analysis]
164 Foerster F, Galle PR. Ultrasound for Hepatocellular Carcinoma Surveillance: Still Looking for the Fortune Teller. Liver Transpl 2018;24:1167-8. [PMID: 30021053 DOI: 10.1002/lt.25309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
165 Kudo M, Lim HY, Cheng AL, Chao Y, Yau T, Ogasawara S, Kurosaki M, Morimoto N, Ohkawa K, Yamashita T, Lee KH, Chen E, Siegel AB, Ryoo BY. Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial. Liver Cancer 2021;10:275-84. [PMID: 34239813 DOI: 10.1159/000515553] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
166 Byrd K, Alqahtani S, Yopp AC, Singal AG. Role of Multidisciplinary Care in the Management of Hepatocellular Carcinoma. Semin Liver Dis 2021;41:1-8. [PMID: 33764480 DOI: 10.1055/s-0040-1719178] [Reference Citation Analysis]
167 Campion D, Tucci A, Ponzo P, Caviglia GP. Non-invasive biomarkers for the detection of hepatocellular carcinoma. Minerva Biotecnol 2019;31. [DOI: 10.23736/s1120-4826.18.02488-6] [Cited by in Crossref: 13] [Article Influence: 6.5] [Reference Citation Analysis]
168 Weng S, Xu X, Li Y, Yan C, Chen J, Ye R, Zhu Y, Wen L, Hong J. Quantitative analysis of multiphase magnetic resonance images may assist prediction of histopathological grade of small hepatocellular carcinoma. Ann Transl Med 2020;8:1023. [PMID: 32953823 DOI: 10.21037/atm-20-2874] [Reference Citation Analysis]
169 Liu Y, Wang X, Xiao J, Sun J, Zhang Y. Prognostic value of postoperative change in liver stiffness in patients with HBV-related hepatocellular carcinoma. J Int Med Res 2020;48:300060520908763. [PMID: 32290747 DOI: 10.1177/0300060520908763] [Reference Citation Analysis]
170 Nishida T, Kataoka H. Glypican 3-Targeted Therapy in Hepatocellular Carcinoma. Cancers (Basel). 2019;11. [PMID: 31510063 DOI: 10.3390/cancers11091339] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
171 Lin CW, Chen YS, Lo GH, Wu TC, Yeh JH, Yeh ML, Dai CY, Huang JF, Chuang WL, Roberts L, Jun DW, Toyoda H, Yasuda S, Nguyen MH, Yu ML. Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma. Hepatol Int 2021;15:946-56. [PMID: 34008091 DOI: 10.1007/s12072-021-10169-8] [Reference Citation Analysis]
172 Lee J, Shin IS, Yoon WS, Koom WS, Rim CH. Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: Meta-analyses and a systematic review. Radiother Oncol 2020;145:63-70. [PMID: 31923711 DOI: 10.1016/j.radonc.2019.12.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 28.0] [Reference Citation Analysis]
173 Jeong Y, Lee KJ, Lee SJ, Shin YM, Kim MJ, Lim YS, Lee HC, Jung J, Park JH, Kim JH, Kim SY, Yoon SM. Radiofrequency ablation versus stereotactic body radiation therapy for small (≤ 3 cm) hepatocellular carcinoma: A retrospective comparison analysis. J Gastroenterol Hepatol 2021;36:1962-70. [PMID: 33594690 DOI: 10.1111/jgh.15442] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Kimura T, Takeda A, Tsurugai Y, Kawano R, Doi Y, Oku Y, Hioki K, Miura H, Nagata Y. A Multi-Institutional Retrospective Study of Repeated Stereotactic Body Radiation Therapy for Intrahepatic Recurrent Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2020;108:1265-1275. [PMID: 32712256 DOI: 10.1016/j.ijrobp.2020.07.034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
175 Weiss J, Winkelmann MT, Gohla G, Kübler J, Clasen S, Nikolaou K, Hoffmann R. MR-guided microwave ablation in hepatic malignancies: clinical experiences from 50 procedures. Int J Hyperthermia 2020;37:349-55. [PMID: 32286087 DOI: 10.1080/02656736.2020.1750713] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
176 Long X, Zhang L, Cheng Q, Chen Q, Chen XP. Solitary hepatic lymphangioma mimicking liver malignancy: A case report and literature review. World J Clin Cases 2020; 8(19): 4633-4643 [PMID: 33083428 DOI: 10.12998/wjcc.v8.i19.4633] [Reference Citation Analysis]
177 Chi C, Chau G, Lee R, Chen Y, Lei H, Hou M, Chao Y, Huang Y. Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection. Journal of the Formosan Medical Association 2020;119:125-33. [DOI: 10.1016/j.jfma.2019.02.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
178 Tian MX, Luo LP, Liu WR, Deng W, Yin JC, Jin L, Jiang XF, Zhou YF, Qu WF, Tang Z, Wang H, Tao CY, Fang Y, Qiu SJ, Zhou J, Liu JF, Fan J, Shi YH. Development and validation of a prognostic score predicting recurrence in resected combined hepatocellular cholangiocarcinoma. Cancer Manag Res 2019;11:5187-95. [PMID: 31239773 DOI: 10.2147/CMAR.S195964] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
179 Sun Q, Shi J, Ren C, Du Z, Shu G, Wang Y. Survival analysis following microwave ablation or surgical resection in patients with hepatocellular carcinoma conforming to the Milan criteria. Oncol Lett 2020;19:4066-76. [PMID: 32391107 DOI: 10.3892/ol.2020.11529] [Reference Citation Analysis]
180 Hao W, Binbin J, Wei Y, Kun Y. Can Radiofrequency Ablation Replace Liver Resection for Solitary Colorectal Liver Metastasis? A Systemic Review and Meta-Analysis. Front Oncol 2020;10:561669. [PMID: 33312946 DOI: 10.3389/fonc.2020.561669] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
181 Hu X, Bao M, Huang J, Zhou L, Zheng S. Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma. Front Oncol 2020;10:541479. [PMID: 33102213 DOI: 10.3389/fonc.2020.541479] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
182 Mo Z, Cheong JYA, Xiang L, Le MTN, Grimson A, Zhang DX. Extracellular vesicle-associated organotropic metastasis. Cell Prolif 2021;54:e12948. [PMID: 33145869 DOI: 10.1111/cpr.12948] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
183 Kim MP, Yang JK, Jun BG, Kim YD, Cheon GJ, Jung HJ, Yoo JJ, Kim SG, Kim YS, Jeong SW, Jang JY, Kim HS, Lee SH. Effect of antiviral therapy in patients with low HBV DNA level on transarterial chemoembolization for hepatocellular carcinoma. J Viral Hepat 2021;28:1011-8. [PMID: 33759295 DOI: 10.1111/jvh.13508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
184 Hiraoka A, Kumada T, Hatanaka T, Tada T, Kariyama K, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Chikara O, Tamai T, Kakizaki S, Tojima H, Nagashima T, Ueno T, Takizawa D, Naganuma A, Ohama H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Michitaka K, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan), and GLSG (Gunma Liver Study Group). Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. Hepatol Res 2021;51:880-9. [PMID: 33837620 DOI: 10.1111/hepr.13644] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
185 Swierz MJ, Storman D, Riemsma RP, Wolff R, Mitus JW, Pedziwiatr M, Kleijnen J, Bala MM. Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases. Cochrane Database Syst Rev 2020;3:CD009498. [PMID: 32163181 DOI: 10.1002/14651858.CD009498.pub4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
186 Reicher J, Mafeld S, Priona G, Reeves HL, Manas DM, Jackson R, Littler P. Early Experience of Trans-arterial Chemo-Embolisation for Hepatocellular Carcinoma with a Novel Radiopaque Bead. Cardiovasc Intervent Radiol 2019;42:1563-70. [PMID: 31455987 DOI: 10.1007/s00270-019-02317-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
187 Kim TH, Park JW, Kim BH, Kim H, Moon SH, Kim SS, Woo SM, Koh YH, Lee WJ, Kim DY, Kim CM. Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma? Cancers (Basel). 2019;11. [PMID: 30781391 DOI: 10.3390/cancers11020230] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
188 Rodriguez De Santiago E, Téllez L, Guerrero A, Albillos A. Hepatocellular carcinoma after Fontan surgery: A systematic review. Hepatol Res 2021;51:116-34. [DOI: 10.1111/hepr.13582] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
189 Sevic I, Spinelli FM, Cantero MJ, Reszegi A, Kovalszky I, García MG, Alaniz L; Laboratorio de Microambiente Tumoral, Centro de Investigaciones Básicas y Aplicadas (CIBA), Universidad Nacional de la Pcia. de Bs. As. Centro de Investigaciones y Transferencia del Noroeste de la Pcia. de Bs. As. (CIT NOBA, UNNOBA-CONICET), Junín, Bs. As., Argentina, Laboratorio de Microambiente Tumoral, Centro de Investigaciones Básicas y Aplicadas (CIBA), Universidad Nacional de la Pcia. de Bs. As. Centro de Investigaciones y Transferencia del Noroeste de la Pcia. de Bs. As. (CIT NOBA, UNNOBA-CONICET), Junín, Bs. As., Argentina, Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, CONICET, Universidad Austral, Derqui-Pilar, Argentina, 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary, 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary, Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, CONICET, Universidad Austral, Derqui-Pilar, Argentina, Laboratorio de Microambiente Tumoral, Centro de Investigaciones Básicas y Aplicadas (CIBA), Universidad Nacional de la Pcia. de Bs. As. Centro de Investigaciones y Transferencia del Noroeste de la Pcia. de Bs. As. (CIT NOBA, UNNOBA-CONICET), Junín, Bs. As., Argentina. The Role of the Tumor Microenvironment in the Development and Progression of Hepatocellular Carcinoma. In: Tirnitz-parker JE, editor. Hepatocellular Carcinoma. Codon Publications; 2019. pp. 29-45. [DOI: 10.15586/hepatocellularcarcinoma.2019.ch2] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
190 Arora SP, Liposits G, Caird S, Dunne RF, Moffat GT, Okonji D, Rodriquenz MG, Dua D, Dotan E. Hepatocellular carcinoma in older adults: A comprehensive review by Young International Society of Geriatric Oncology. J Geriatr Oncol 2020;11:557-65. [PMID: 31704038 DOI: 10.1016/j.jgo.2019.10.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
191 Tan YW, Ye Y, Sun L. Argon-helium cryoablation for thoracic vertebrae with metastasis of hepatocellular carcinoma-related hepatitis B: A case report. World J Clin Cases 2020; 8(2): 377-381 [PMID: 32047788 DOI: 10.12998/wjcc.v8.i2.377] [Reference Citation Analysis]
192 Jing X, Zhou Y, Ding J, Wang Y, Qin Z, Wang Y, Zhou H. The Learning Curve for Thermal Ablation of Liver Cancers: 4,363-Session Experience for a Single Central in 18 Years. Front Oncol 2020;10:540239. [PMID: 33194601 DOI: 10.3389/fonc.2020.540239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
193 Muzaffar S, Ahmed N, Rahman U, Al Kandari F, Usmani S. 68Ga-Prostate-Specific Membrane Antigen Uptake as a Surrogate Biomarker of Neovascularity in Hepatocellular Carcinoma. Indian J Nucl Med 2021;36:90-1. [PMID: 34040311 DOI: 10.4103/ijnm.IJNM_38_20] [Reference Citation Analysis]
194 Hwang SH, Hong SB, Park S, Han K, Park YN, Kim SY, Park MS. Subcentimeter hepatocellular carcinoma in treatment-naïve patients: noninvasive diagnostic criteria and tumor staging on gadoxetic acid-enhanced MRI. Eur Radiol 2021;31:2321-31. [PMID: 33044650 DOI: 10.1007/s00330-020-07329-z] [Reference Citation Analysis]
195 Bae H, Lee SA, Choi JW, Hwang SH, Park S, Park MS. Effectiveness of Hepatocellular Carcinoma Surveillance and an Optimal Surveillance Interval: Nationwide Cohort of Korea. Yonsei Med J 2021;62:758-66. [PMID: 34296554 DOI: 10.3349/ymj.2021.62.8.758] [Reference Citation Analysis]
196 Cha DI, Song KD, Kang TW, Lee MW, Rhim H. Small masses (≤3 cm) diagnosed as hepatocellular carcinoma on pre-treatment imaging: comparison of therapeutic outcomes between hepatic resection and radiofrequency ablation. Br J Radiol 2020;93:20190719. [PMID: 31670571 DOI: 10.1259/bjr.20190719] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
197 Mangia A, Bellini D, Cillo U, Laghi A, Pelle G, Valori VM, Caturelli E. Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence. BMC Gastroenterol 2020;20:251. [PMID: 32746786 DOI: 10.1186/s12876-020-01391-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
198 Kim SY, Lim YS. Towards a New Horizon for Individualized Surveillance Tools in Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00498-5. [PMID: 33940226 DOI: 10.1016/j.cgh.2021.04.041] [Reference Citation Analysis]
199 Veldhuijzen van Zanten D, Buganza E, Abraldes JG. The Role of Hepatic Venous Pressure Gradient in the Management of Cirrhosis. Clin Liver Dis 2021;25:327-43. [PMID: 33838853 DOI: 10.1016/j.cld.2021.01.002] [Reference Citation Analysis]
200 Malik A, Thanekar U, Amarachintha S, Mourya R, Nalluri S, Bondoc A, Shivakumar P. "Complimenting the Complement": Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma. Front Oncol 2020;10:627701. [PMID: 33718121 DOI: 10.3389/fonc.2020.627701] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
201 Kobe A, Kindler Y, Klotz E, Puippe G, Messmer F, Alkadhi H, Pfammatter T. Fusion of Preinterventional MR Imaging With Liver Perfusion CT After RFA of Hepatocellular Carcinoma: Early Quantitative Prediction of Local Recurrence. Invest Radiol 2021;56:188-96. [PMID: 32932379 DOI: 10.1097/RLI.0000000000000726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
202 Zhang Z, Ma L, Goswami S, Ma J, Zheng B, Duan M, Liu L, Zhang L, Shi J, Dong L, Sun Y, Tian L, Gao Q, Zhang X. Landscape of infiltrating B cells and their clinical significance in human hepatocellular carcinoma. Oncoimmunology. 2019;8:e1571388. [PMID: 30906667 DOI: 10.1080/2162402x.2019.1571388] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 12.0] [Reference Citation Analysis]
203 Mohkam K, Mabrut JY. Reply to: "Treatment for solitary hepatocellular carcinoma ranging from 2 and 5 cm: Is the curative effect of no-touch multibipolar radiofrequency ablation comparable to that of surgical resection?". J Hepatol 2019;70:576-7. [PMID: 30591264 DOI: 10.1016/j.jhep.2018.11.028] [Reference Citation Analysis]
204 Beudeker BJB, Boonstra A. Circulating biomarkers for early detection of hepatocellular carcinoma. Therap Adv Gastroenterol 2020;13:1756284820931734. [PMID: 32647536 DOI: 10.1177/1756284820931734] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
205 Kanagalingam G, Sostre Santiago V, Vyas V, Manocha D. Gastrointestinal Hemorrhage From Esophageal Dissecans Superficialis After the Initiation of a Tyrosine Kinase Inhibitor. Cureus 2021;13:e16471. [PMID: 34422498 DOI: 10.7759/cureus.16471] [Reference Citation Analysis]
206 Zheng H, Xu C, Wang X, Li J, Zhao X, Qi J, Feng Y, Zhu Q. Microwave ablation shows similar survival outcomes compared with surgical resection for hepatocellular carcinoma between 3 and 5 cm. Int J Hyperthermia 2020;37:1345-53. [PMID: 33289415 DOI: 10.1080/02656736.2020.1849825] [Reference Citation Analysis]
207 Merchante N, Rodríguez-Fernández M, Figueruela B, Rodríguez-Arrondo F, Revollo B, Ibarra S, Téllez F, Merino E, Montero-Alonso M, Galindo MJ, Rivero-Juárez A, Santos IL, Delgado-Fernández M, García-Deltoro M, Vera-Méndez FJ, García MA, Aguirrebengoa K, Portu J, Ríos-Villegas MJ, Villalobos M, Alemán-Valls MR, Mínguez C, Galera C, Macías J, Pineda JA; GEHEP-002 Study Group. Impact of HIV on the survival of hepatocellular carcinoma in hepatitis C virus-infected patients. AIDS 2020;34:1497-507. [PMID: 32675563 DOI: 10.1097/QAD.0000000000002578] [Reference Citation Analysis]
208 Johnston MP, Khakoo SI. Immunotherapy for hepatocellular carcinoma: Current and future. World J Gastroenterol 2019; 25(24): 2977-2989 [PMID: 31293335 DOI: 10.3748/wjg.v25.i24.2977] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 52] [Article Influence: 29.5] [Reference Citation Analysis]
209 Pradat P, Virlogeux V, Trépo E. Epidemiology and Elimination of HCV-Related Liver Disease. Viruses 2018;10:E545. [PMID: 30301201 DOI: 10.3390/v10100545] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 9.7] [Reference Citation Analysis]
210 Giannis D, Morsy S, Geropoulos G, Esagian SM, Sioutas GS, Moris D. The Epidemiology, Staging and Outcomes of Sarcomatoid Hepatocellular Carcinoma: A SEER Population Analysis. In Vivo 2021;35:393-9. [PMID: 33402488 DOI: 10.21873/invivo.12270] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
211 Connolly JC, Lim JK. Non-invasive Fibrosis Assessment of Patients with Hepatitis C: Application of Society Guidelines to Clinical Practice. Curr Hepatology Rep 2019;18:249-58. [DOI: 10.1007/s11901-019-00471-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
212 Guo C, Zou X, Hong Z, Sun J, Xiao W, Sun K, Li X, Shen Y, Liang T, Bai X. Preoperative transarterial chemoembolization for barcelona clinic liver cancer stage A/B hepatocellular carcinoma beyond the milan criteria: a propensity score matching analysis. HPB (Oxford) 2021:S1365-182X(21)00043-5. [PMID: 33715958 DOI: 10.1016/j.hpb.2021.02.006] [Reference Citation Analysis]
213 Lee PC, Chao Y, Chen MH, Lan KH, Lee IC, Hou MC, Huang YH. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer 2020;8:e001072. [PMID: 32863270 DOI: 10.1136/jitc-2020-001072] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
214 D'Angelo A, Sobhani N, Bagby S, Casadei-Gardini A, Roviello G. Cabozantinib as a second-line treatment option in hepatocellular carcinoma. Expert Rev Clin Pharmacol 2020;13:623-9. [PMID: 32394749 DOI: 10.1080/17512433.2020.1767591] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
215 Chen YC, Tseng CW, Tseng KC. Rapid platelet count improvement in chronic hepatitis C patients with thrombocytopenia receiving direct-acting antiviral agents. Medicine (Baltimore) 2020;99:e20156. [PMID: 32384505 DOI: 10.1097/MD.0000000000020156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
216 Okusaka T, Ikeda K, Kudo M, Finn R, Qin S, Han KH, Cheng AL, Piscaglia F, Kobayashi M, Sung M, Chen M, Wyrwicz L, Yoon JH, Ren Z, Mody K, Dutcus C, Tamai T, Ren M, Hayato S, Kumada H. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT. J Gastroenterol 2021;56:570-80. [PMID: 33948712 DOI: 10.1007/s00535-021-01785-0] [Reference Citation Analysis]
217 Zhang XP, Wang K, Gao YZ, Wei XB, Lu CD, Chai ZT, Zhen ZJ, Li J, Yang DH, Zhou D, Fan RF, Yan ML, Xia YJ, Liu B, Huang YQ, Zhang F, Hu YR, Zhong CQ, Lin JH, Fang KP, Cheng ZH, Wu MC, Lau WY, Cheng SQ; Chinese National Research Cooperative Group for Diagnosis and Treatment of Hepatocellular Carcinoma with Tumour Thrombus. Prognostic model for identifying candidates for hepatectomy among patients with hepatocellular carcinoma and hepatic vein invasion. Br J Surg 2020;107:865-77. [PMID: 32246475 DOI: 10.1002/bjs.11524] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
218 Abdel-Rahman O, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2020;1:CD011313. [PMID: 31978267 DOI: 10.1002/14651858.CD011313.pub3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
219 Dong JJ, Ying L, Shi KQ. Expression of the Wnt ligands gene family and its relationship to prognosis in hepatocellular carcinoma. Cancer Cell Int 2019;19:34. [PMID: 30814912 DOI: 10.1186/s12935-019-0743-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
220 Allaire M, Rudler M, Thabut D. Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses…. Liver Int 2021;41:1734-43. [PMID: 34051060 DOI: 10.1111/liv.14977] [Reference Citation Analysis]
221 Drake TM, Bird TG. Editorial: simplifying screening for primary liver cancer - do the LCR1 and LCR2 tests hold the key? Aliment Pharmacol Ther 2019;49:612-3. [PMID: 30746772 DOI: 10.1111/apt.15119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
222 Huang CF, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY, Wei YJ, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Yu ML. Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study. BMJ Open 2019;9:e026703. [PMID: 31061041 DOI: 10.1136/bmjopen-2018-026703] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
223 Parikh ND, Mehta AS, Singal AG, Block T, Marrero JA, Lok AS. Biomarkers for the Early Detection of Hepatocellular Carcinoma.Cancer Epidemiol Biomarkers Prev. 2020;29:2495-2503. [PMID: 32238405 DOI: 10.1158/1055-9965.EPI-20-0005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
224 Personeni N, Rimassa L. Are we ready for patient-reported outcomes in hepatocellular carcinoma? Lancet Gastroenterol Hepatol 2021;6:602-3. [PMID: 34087116 DOI: 10.1016/S2468-1253(21)00139-4] [Reference Citation Analysis]
225 Tang A, Abukasm K, Moura Cunha G, Song B, Wang J, Wagner M, Dietrich CF, Brancatelli G, Ueda K, Choi J, Aguirre D, Sirlin CB. Imaging of hepatocellular carcinoma: a pilot international survey. Abdom Radiol 2021;46:205-15. [DOI: 10.1007/s00261-020-02598-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
226 Jaklitsch M, Sobral M, Carvalho AM, Marques HP. Abernethy malformation and hepatocellular carcinoma: a serious consequence of a rare disease. BMJ Case Rep 2020;13:e231843. [PMID: 31911408 DOI: 10.1136/bcr-2019-231843] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
227 Sposito C, Mazzaferro V. The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future. Hepatobiliary Surg Nutr 2018;7:487-9. [PMID: 30652096 DOI: 10.21037/hbsn.2018.10.06] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 7.7] [Reference Citation Analysis]
228 Yu Z, Song Y, Cai M, Jiang B, Zhang Z, Wang L, Jiang Y, Zou L, Liu X, Yu N, Mao X, Peng C, Liu S. PPM1D is a potential prognostic biomarker and correlates with immune cell infiltration in hepatocellular carcinoma. Aging (Albany NY) 2021;13:21294-308. [PMID: 34470916 DOI: 10.18632/aging.203459] [Reference Citation Analysis]
229 Gomez-Puerto D, Mirallas O, Vidal-González J, Vargas V. Hepatocellular carcinoma with tumor thrombus extends to the right atrium and portal vein: A case report. World J Hepatol 2020; 12(11): 1128-1135 [PMID: 33312435 DOI: 10.4254/wjh.v12.i11.1128] [Reference Citation Analysis]
230 Kanneganti M, Mahmud N, Kaplan DE, Taddei TH, Goldberg DS. Survival Benefit of Liver Transplantation for Hepatocellular Carcinoma. Transplantation 2020;104:104-12. [PMID: 31283688 DOI: 10.1097/TP.0000000000002816] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 9.0] [Reference Citation Analysis]
231 Zheng J, Cai J, Tao L, Kirih MA, Shen Z, Xu J, Liang X. Comparison on the efficacy and prognosis of different strategies for intrahepatic recurrent hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis. International Journal of Surgery 2020;83:196-204. [DOI: 10.1016/j.ijsu.2020.09.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
232 Zheng J, Feng X, Liang Y, Cai J, Shi Z, Kirih MA, Tao L, Liang X. Safety and feasibility of laparoscopic liver resection for hepatocellular carcinoma with clinically significant portal hypertension: a propensity score-matched study. Surg Endosc 2021;35:3267-78. [DOI: 10.1007/s00464-020-07763-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
233 Vasuri F, Renzulli M, Fittipaldi S, Brocchi S, Clemente A, Cappabianca S, Bolondi L, Golfieri R, D'Errico A. Pathobiological and Radiological Approach For Hepatocellular Carcinoma Subclassification. Sci Rep 2019;9:14749. [PMID: 31611584 DOI: 10.1038/s41598-019-51303-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
234 Tsai WL, Wang CF, Cheng JS, Chen WC, Bair MJ, Lo CC. Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience. PLoS One 2020;15:e0227424. [PMID: 31923251 DOI: 10.1371/journal.pone.0227424] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
235 Chew XH, Sultana R, Mathew EN, Ng DCE, Lo RHG, Toh HC, Tai D, Choo SP, Goh BKP, Yan SX, Loke KSH, Thang SP, Gogna A, Venkatanarasimha NK, Tong AKT, Moe FNN, Chua JSS, Ang RWT, Ong AD, Ng AWY, Hoang MTQ, Too CW, Thng CH, Chan WY, Kee W, Chan JHM, Irani F, Leong S, Lim KH, Wang MLC, Chow PKH. Real-World Data on Clinical Outcomes of Patients with Liver Cancer: A Prospective Validation of the National Cancer Centre Singapore Consensus Guidelines for the Management of Hepatocellular Carcinoma. Liver Cancer 2021;10:224-39. [PMID: 34239809 DOI: 10.1159/000514400] [Reference Citation Analysis]
236 Wang LL, Li JF, Lei JQ, Guo SL, Li JK, Xu YS, Dou Y. The value of the signal intensity of peritumoral tissue on Gd-EOB-DTPA dynamic enhanced MRI in assessment of microvascular invasion and pathological grade of hepatocellular carcinoma. Medicine (Baltimore) 2021;100:e25804. [PMID: 34011043 DOI: 10.1097/MD.0000000000025804] [Reference Citation Analysis]
237 Spiliotis AE, Gäbelein G, Holländer S, Scherber PR, Glanemann M, Patel B. Microwave ablation compared with radiofrequency ablation for the treatment of liver cancer: a systematic review and meta-analysis. Radiol Oncol 2021;55:247-58. [PMID: 34167181 DOI: 10.2478/raon-2021-0030] [Reference Citation Analysis]
238 Inchingolo R, Posa A, Mariappan M, Spiliopoulos S. Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions. World J Gastroenterol 2019; 25(32): 4614-4628 [PMID: 31528090 DOI: 10.3748/wjg.v25.i32.4614] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 25] [Article Influence: 16.0] [Reference Citation Analysis]
239 Zhu LJ, Pan Y, Chen XY, Hou PF. BUB1 promotes proliferation of liver cancer cells by activating SMAD2 phosphorylation. Oncol Lett 2020;19:3506-12. [PMID: 32269624 DOI: 10.3892/ol.2020.11445] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
240 Hyde AJ, Nassabein R, AlShareef A, Armstrong D, Babak S, Berry S, Bossé D, Chen E, Colwell B, Essery C, Goel R, Goodwin R, Gray S, Hammad N, Jeyakuymar A, Jonker D, Karanicolas P, Lamond N, Letourneau R, Michael J, Patil N, Powell E, Ramjeesingh R, Saliba W, Singh R, Snow S, Stuckless T, Tadros S, Tehfé M, Thana M, Thirlwell M, Vickers M, Virik K, Welch S, Asmis T. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2018. Curr Oncol 2019;26:e665-81. [PMID: 31708660 DOI: 10.3747/co.26.5193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
241 Liao H, Ahmed M, Markezana A, Zeng G, Stechele M, Galun E, Goldberg SN. Thermal Ablation Induces Transitory Metastatic Growth by Means of the STAT3/c-Met Molecular Pathway in an Intrahepatic Colorectal Cancer Mouse Model. Radiology 2020;294:464-72. [PMID: 31845846 DOI: 10.1148/radiol.2019191023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
242 Komuta M. Histological Heterogeneity of Primary Liver Cancers: Clinical Relevance, Diagnostic Pitfalls and the Pathologist's Role. Cancers (Basel) 2021;13:2871. [PMID: 34201284 DOI: 10.3390/cancers13122871] [Reference Citation Analysis]
243 Auer TA, Fischer T, Garcia SRM, Penzkofer T, Jung EM, Hamm B, Lerchbaumer MH. Value of contrast-enhanced ultrasound (CEUS) in Focal Liver Lesions (FLL) with inconclusive findings on cross-sectional imaging. Clin Hemorheol Microcirc 2020;74:327-39. [PMID: 31658052 DOI: 10.3233/CH-190718] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
244 Liu W, Zou R, Wang C, Qiu J, Shen J, Liao Y, Yang Z, Zhang Y, Wang Y, Yuan Y, Li K, Zuo D, He W, Zheng Y, Li B, Yuan Y. Microwave ablation versus resection for hepatocellular carcinoma within the Milan criteria: a propensity-score analysis. Ther Adv Med Oncol 2019;11:1758835919874652. [PMID: 31588210 DOI: 10.1177/1758835919874652] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
245 Liang B, Zhao D, Liu Y, Guo X, Zhang H, Zhang L, Zheng C. Chemoembolization of liver cancer with doxorubicin-loaded CalliSpheres microspheres: plasma pharmacokinetics, intratumoral drug concentration, and tumor necrosis in a rabbit model. Drug Deliv Transl Res 2020;10:185-91. [PMID: 31482517 DOI: 10.1007/s13346-019-00672-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
246 Zhang K, Tao C, Siqin T, Wu J, Rong W. Establishment, validation and evaluation of predictive model for early relapse after R0 resection in hepatocellular carcinoma patients with microvascular invasion. J Transl Med 2021;19:293. [PMID: 34229698 DOI: 10.1186/s12967-021-02940-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
247 Liao YY, Teng CL, Peng NF, Jia RR, Cui J, Chen K, Ma L, Xiang BD, Zhong JH, Li LQ. Serum Prealbumin is Negatively Associated with Survival in Hepatocellular Carcinoma Patients after Hepatic Resection. J Cancer. 2019;10:3006-3011. [PMID: 31281477 DOI: 10.7150/jca.30903] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
248 Giannitrapani L, Zerbo M, Amodeo S, Pipitone E, Galia M, Li Cavoli TV, Minissale MG, Licata A, Schiavone C, Brancatelli G, Montalto G, Soresi M. The Changing Epidemiology of Hepatocellular Carcinoma :  Experience of a Single Center. Biomed Res Int 2020;2020:5309307. [PMID: 32185209 DOI: 10.1155/2020/5309307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
249 Martins AMA, Garcia JHP, Eberlin MN. Mass Spectrometry as a Clinical Integrative Tool to Evaluate Hepatocellular Carcinoma: Moving to the Mainstream. Expert Rev Gastroenterol Hepatol 2019;13:821-5. [PMID: 31382786 DOI: 10.1080/17474124.2019.1651643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
250 Lambrecht J, Porsch-Özçürümez M, Best J, Jost-Brinkmann F, Roderburg C, Demir M, Tacke F, Mohr R. The APAC Score: A Novel and Highly Performant Serological Tool for Early Diagnosis of Hepatocellular Carcinoma in Patients with Liver Cirrhosis. J Clin Med 2021;10:3392. [PMID: 34362181 DOI: 10.3390/jcm10153392] [Reference Citation Analysis]
251 Golse N, Joly F, Combari P, Lewin M, Nicolas Q, Audebert C, Samuel D, Allard MA, Sa Cunha A, Castaing D, Cherqui D, Adam R, Vibert E, Vignon-Clementel IE. Predicting the risk of post-hepatectomy portal hypertension using a digital twin: A clinical proof of concept. J Hepatol 2021;74:661-9. [PMID: 33212089 DOI: 10.1016/j.jhep.2020.10.036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
252 Muraoka M, Maekawa S, Katoh R, Komiyama Y, Nakakuki N, Takada H, Matsuda S, Suzuki Y, Sato M, Tatsumi A, Miura M, Amemiya F, Shindo H, Takano S, Fukasawa M, Yamauchi K, Yamaguchi T, Nakayama Y, Inoue T, Enomoto N. Usefulness of Cell-Free Human Telomerase Reverse Transcriptase Mutant DNA Quantification in Blood for Predicting Hepatocellular Carcinoma Treatment Efficacy. Hepatol Commun 2021;5:1927-38. [PMID: 34558819 DOI: 10.1002/hep4.1762] [Reference Citation Analysis]
253 Mohan CD, Kim C, Siveen KS, Manu KA, Rangappa S, Chinnathambi A, Alharbi SA, Rangappa KS, Kumar AP, Ahn KS. Crocetin imparts antiproliferative activity via inhibiting STAT3 signaling in hepatocellular carcinoma. IUBMB Life 2021;73:1348-62. [PMID: 34514729 DOI: 10.1002/iub.2555] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
254 Liu J, Sun G, Pan S, Qin M, Ouyang R, Li Z, Huang J. The Cancer Genome Atlas (TCGA) based m6A methylation-related genes predict prognosis in hepatocellular carcinoma. Bioengineered 2020;11:759-68. [PMID: 32631107 DOI: 10.1080/21655979.2020.1787764] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
255 Kan X, Liang B, Zhou G, Xiong B, Pan F, Ren Y, Cao Y, Wang J, Yang F, Zheng C. Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Front Oncol 2020;10:970. [PMID: 32733791 DOI: 10.3389/fonc.2020.00970] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
256 Qiu L, Zhan K, Malale K, Wu X, Mei Z. Transcriptomic profiling of peroxisome-related genes reveals a novel prognostic signature in hepatocellular carcinoma. Genes & Diseases 2020. [DOI: 10.1016/j.gendis.2020.04.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
257 Ye Q, Ling S, Jiang G, Shan Q, Xu S, Zhan Q, Wu Y, Liu Y, Zheng S, Xu X. Sirolimus-based immunosuppression improves the prognosis of liver Transplantation Recipients with low TSC1/2 expression in hepatocellular carcinoma beyond the Milan Criteria. Eur J Surg Oncol 2021:S0748-7983(21)00407-8. [PMID: 33902956 DOI: 10.1016/j.ejso.2021.04.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
258 Shen ZF, Liang X. Current status of radical laparoscopy for treating hepatocellular carcinoma with portal hypertension. World J Clin Cases 2021; 9(11): 2419-2432 [PMID: 33889608 DOI: 10.12998/wjcc.v9.i11.2419] [Reference Citation Analysis]
259 Rimassa L, Personeni N, Czauderna C, Foerster F, Galle P. Systemic treatment of HCC in special populations. J Hepatol 2021;74:931-43. [PMID: 33248171 DOI: 10.1016/j.jhep.2020.11.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
260 Bourlière M, Pénaranda G, Adhoute X, Bronowicki J. The “six-and-twelve score” for TACE treatment: Does it really help us? Journal of Hepatology 2019;71:1051-2. [DOI: 10.1016/j.jhep.2019.06.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
261 Kim DW, Choi SH, Kim SY, Byun JH, Lee SS, Park SH, Kim KW. Diagnostic performance of MRI for HCC according to contrast agent type: a systematic review and meta-analysis. Hepatol Int 2020;14:1009-22. [DOI: 10.1007/s12072-020-10100-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
262 Mai R, Zeng J, Lu H, Liang R, Lin Y, Piao X, Gao X, Wu G, Wu F, Ma L, Xiang B, Li L, Ye J. Combining Aspartate Aminotransferase-to-Platelet Ratio Index with Future Liver Remnant to Assess Preoperative Hepatic Functional Reserve in Patients with Hepatocellular Carcinoma. J Gastrointest Surg 2021;25:688-97. [DOI: 10.1007/s11605-020-04575-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
263 Sarno G, Montalti R, Giglio MC, Rompianesi G, Tomassini F, Scarpellini E, De Simone G, De Palma GD, Troisi RI. Hepatocellular carcinoma in patients with chronic renal disease: Challenges of interventional treatment. Surg Oncol. 2021;36:42-50. [PMID: 33307490 DOI: 10.1016/j.suronc.2020.11.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
264 Yun BY, Lee HW, Min IK, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation. Cancers (Basel). 2020;12. [PMID: 32899584 DOI: 10.3390/cancers12092527] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
265 Onyirioha K, Mittal S, G Singal A. Is hepatocellular carcinoma surveillance in high-risk populations effective? Hepat Oncol 2020;7:HEP25. [PMID: 32774835 DOI: 10.2217/hep-2020-0012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
266 Cao JS, Lu ZY, Chen MY, Zhang B, Juengpanich S, Hu JH, Li SJ, Topatana W, Zhou XY, Feng X, Shen JL, Liu Y, Cai XJ. Artificial intelligence in gastroenterology and hepatology: Status and challenges. World J Gastroenterol 2021; 27(16): 1664-1690 [PMID: 33967550 DOI: 10.3748/wjg.v27.i16.1664] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
267 Uchino K, Tateishi R, Wake T, Kinoshita MN, Nakagomi R, Nakatsuka T, Minami T, Sato M, Enooku K, Nakagawa H, Shiina S, Koike K. Radiofrequency Ablation of Liver Tumors in Patients on Antithrombotic Therapy: A Case-Control Analysis of over 10,000 Treatments. J Vasc Interv Radiol 2021;32:869-77. [PMID: 33689831 DOI: 10.1016/j.jvir.2021.02.021] [Reference Citation Analysis]
268 Liu J, Zhang RX, Dong B, Guo K, Gao ZM, Wang LM. Hepatocellular carcinoma with inferior vena cava and right atrium thrombus: A case report. World J Clin Cases 2021; 9(26): 7893-7900 [PMID: 34621843 DOI: 10.12998/wjcc.v9.i26.7893] [Reference Citation Analysis]
269 Peng Y, Wei Q, He Y, Xie Q, Liang Y, Zhang L, Xia Y, Li Y, Chen W, Zhao J, Chai J. ALBI versus child-pugh in predicting outcome of patients with HCC: A systematic review. Expert Rev Gastroenterol Hepatol 2020;14:383-400. [PMID: 32240595 DOI: 10.1080/17474124.2020.1748010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
270 Amoros R, King R, Toyoda H, Kumada T, Johnson PJ, Bird TG. A continuous-time hidden Markov model for cancer surveillance using serum biomarkers with application to hepatocellular carcinoma. Metron 2019;77:67-86. [PMID: 31708595 DOI: 10.1007/s40300-019-00151-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
271 Guerrero M, Ferrín G, Rodríguez-Perálvarez M, González-Rubio S, Sánchez-Frías M, Amado V, Pozo JC, Poyato A, Ciria R, Ayllón MD, Barrera P, Montero JL, de la Mata M. mTOR Expression in Liver Transplant Candidates with Hepatocellular Carcinoma: Impact on Histological Features and Tumour Recurrence.Int J Mol Sci. 2019;20. [PMID: 30650598 DOI: 10.3390/ijms20020336] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
272 Kanogawa N, Ogasawara S, Ooka Y, Inoue M, Wakamatsu T, Yokoyama M, Maruta S, Unozawa H, Iwanaga T, Sakuma T, Fujita N, Koroki K, Kanzaki H, Maeda T, Kobayashi K, Kiyono S, Nakamura M, Kondo T, Saito T, Motoyama T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato J, Takemura R, Nozaki-Taguchi N, Shiroh I, Yokosuka O, Kato N. Propofol versus midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinoma. JGH Open 2021;5:273-9. [PMID: 33553667 DOI: 10.1002/jgh3.12483] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
273 Chen YC, Li CH, Ko PH, Lee CC, Syu RJ, Tseng CW, Tseng KC. Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals. PLoS One 2021;16:e0256505. [PMID: 34437608 DOI: 10.1371/journal.pone.0256505] [Reference Citation Analysis]
274 Riaño I, Martín L, Varela M, Serrano T, Núñez O, Mínguez B, Rodrigues PM, Perugorria MJ, Banales JM, Arenas JI. Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial). Cancers (Basel) 2020;12:E1900. [PMID: 32674461 DOI: 10.3390/cancers12071900] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
275 Yoon SM, Kim SY, Lim YS, Kim KM, Shim JH, Lee D, An J, Jung J, Kim JH, Lee HC. Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial. Clin Mol Hepatol 2020;26:506-15. [PMID: 32646200 DOI: 10.3350/cmh.2020.0038] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
276 Shimose S, Iwamoto H, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Suga H, Kuromatsu R, Yamaguchi T, Kawaguchi T, Tanaka M, Noguchi K, Koga H, Torimura T. Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. Cancers (Basel) 2020;12:E1867. [PMID: 32664489 DOI: 10.3390/cancers12071867] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 18.0] [Reference Citation Analysis]
277 Yeo YH, Hwang J, Jeong D, Dang N, Kam LY, Henry L, Park H, Cheung R, Nguyen MH. Surveillance of patients with cirrhosis remains suboptimal in the United States. J Hepatol 2021:S0168-8278(21)00307-X. [PMID: 33965477 DOI: 10.1016/j.jhep.2021.04.042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
278 Nunes G, Fonseca C, Patita M, Aleixo MJ, Ramalho M, Fonseca J. Diffuse advanced hepatocellular carcinoma after HCV eradication in an HIV-infected patient: A unique complete response to sorafenib. Turk J Gastroenterol 2020;31:184-6. [PMID: 32141829 DOI: 10.5152/tjg.2020.181044] [Reference Citation Analysis]
279 Son J, Hwang SH, Park S, Han K, Chung YE, Choi J, Kim M, Park M. Imaging Features of Hepatocellular Carcinoma: Quantitative and Qualitative Comparison Between MRI-Enhanced With Gd-EOB-DTPA and Gd-DTPA. Investigative Radiology 2019;54:494-9. [DOI: 10.1097/rli.0000000000000562] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 5.5] [Reference Citation Analysis]
280 Christou CD, Tsoulfas G. Challenges and opportunities in the application of artificial intelligence in gastroenterology and hepatology. World J Gastroenterol 2021; 27(37): 6191-6223 [PMID: 34712027 DOI: 10.3748/wjg.v27.i37.6191] [Reference Citation Analysis]
281 Ratti F, Cipriani F, Fiorentini G, Catena M, Paganelli M, Aldrighetti L. Reappraisal of the advantages of laparoscopic liver resection for intermediate hepatocellular carcinoma within a stage migration perspective: Propensity score analysis of the differential benefit. J Hepatobiliary Pancreat Sci 2020;27:510-21. [PMID: 32189450 DOI: 10.1002/jhbp.736] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
282 Zhang Y, Liu X, Liu L, Chen J, Hu Q, Shen S, Zhou Y, Chen S, Xue C, Cui G, Yu Z. Upregulation of FEN1 Is Associated with the Tumor Progression and Prognosis of Hepatocellular Carcinoma. Dis Markers 2020;2020:2514090. [PMID: 32399086 DOI: 10.1155/2020/2514090] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
283 Liu L, Liang X, Xu X, Zhang X, Wen J, Chen K, Su X, Teng Z, Lu G, Xu J. Magnetic mesoporous embolic microspheres in transcatheter arterial chemoembolization for liver cancer. Acta Biomater 2021;130:374-84. [PMID: 34082098 DOI: 10.1016/j.actbio.2021.05.031] [Reference Citation Analysis]
284 Anugwom CM, Allaire M, Akbar SMF, Sultan A, Bollipo S, Mattos AZ, Debes JD. Hepatitis B-related hepatocellular carcinoma: surveillance strategy directed by immune-epidemiology. Hepatoma Res 2021;7:23. [PMID: 33884303 DOI: 10.20517/2394-5079.2021.06] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
285 Hilmi M, Vienot A, Rousseau B, Neuzillet C. Immune Therapy for Liver Cancers. Cancers (Basel) 2019;12:E77. [PMID: 31892230 DOI: 10.3390/cancers12010077] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
286 Berardi G, Troisi RI. Reply to: "Nomogram to predict surgical hepatocellular carcinoma with Child-Pugh B: Feasibility and overlooked predictors". J Hepatol 2020;72:1033-4. [PMID: 32122725 DOI: 10.1016/j.jhep.2020.02.002] [Reference Citation Analysis]
287 da Silva PH, Gomes MM, de Matos CAL, de Souza E Silva IS, Gonzalez AM, Torres US, Salazar GMM, D'Ippolito G. HCC Detection on Surveillance US: Comparing Focused Liver Protocol Using US LI-RADS Technical Guidelines to a General Complete Abdominal US Protocol. J Ultrasound Med 2021. [PMID: 33463734 DOI: 10.1002/jum.15637] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
288 Loglio A, Iavarone M, Facchetti F, Di Paolo D, Perbellini R, Lunghi G, Ceriotti F, Galli C, Sandri MT, Viganò M, Sangiovanni A, Colombo M, Lampertico P. The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy. Liver Int 2020;40:1987-96. [PMID: 32301212 DOI: 10.1111/liv.14475] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
289 Soulen MC, García-Mónaco R. Closing the Gap in Curative Ablation of Liver Cancer. Radiology 2021;:211204. [PMID: 34313477 DOI: 10.1148/radiol.2021211204] [Reference Citation Analysis]
290 Rojas-Pintor KP, Arizmendi-Villarreal MA, Aparicio-Salas JE, Moreno-Peña DP, Hernández-Barajas D, Cordero-Pérez P, Muñoz-Espinosa LE. Differences in the presentation and treatment of primary liver tumors at a hepatology center and an oncology center. Rev Gastroenterol Mex (Engl Ed) 2021:S0375-0906(21)00002-1. [PMID: 33676785 DOI: 10.1016/j.rgmx.2020.08.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
291 Debaillon Vesque A, Decraecker M, Blanc JF. Profile of Cabozantinib for the Treatment of Hepatocellular Carcinoma: Patient Selection and Special Considerations. J Hepatocell Carcinoma 2020;7:91-9. [PMID: 32607316 DOI: 10.2147/JHC.S195570] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
292 Colombo M, Lleo A. Is there a real survival benefit of surveillance for hepatocellular carcinoma in cirrhotic patients? Hepatobiliary Surg Nutr 2019;8:148-50. [PMID: 31098364 DOI: 10.21037/hbsn.2018.11.15] [Reference Citation Analysis]
293 Beleù A, Drudi A, Giaretta A, De Robertis R, Fedrigo I, Martone E, Simone C, Bovo C, D'Onofrio M. Operator Evaluation of Ultrasound Fusion Imaging Usefulness in the Percutaneous Ablation of Hepatic Malignancies: A Prospective Study. Ultrasound Med Biol 2021:S0301-5629(21)00306-9. [PMID: 34392997 DOI: 10.1016/j.ultrasmedbio.2021.07.008] [Reference Citation Analysis]
294 Huang Q, Zeng Q, Long Y, Tan L, Zheng R, Xu E, Li K. Fusion imaging techniques and contrast-enhanced ultrasound for thermal ablation of hepatocellular carcinoma - A prospective randomized controlled trial. Int J Hyperthermia. 2019;36:1207-1215. [PMID: 31813295 DOI: 10.1080/02656736.2019.1687945] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
295 Lee S, Kim KW, Song GW, Kwon JH, Hwang S, Kim KH, Ahn CS, Moon DB, Park GC, Lee SG. The Real Impact of Bridging or Downstaging on Survival Outcomes after Liver Transplantation for Hepatocellular Carcinoma. Liver Cancer 2020;9:721-33. [PMID: 33442541 DOI: 10.1159/000507887] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
296 Famularo S, Donadon M, Cipriani F, Bernasconi DP, LaBarba G, Dominioni T, Iaria M, Molfino S, Conci S, Ferrari C, Garatti M, Delvecchio A, Troci A, Patauner S, Frassani S, Cosimelli M, Zanus G, Giuliante F, Jovine E, Valsecchi MG, Grazi G, Antonucci A, Frena A, Crespi M, Memeo R, Zimmitti G, Griseri G, Ruzzenente A, Baiocchi G, DallaValle R, Maestri M, Ercolani G, Aldrighetti L, Torzilli G, Romano F; HE.RC.O.LE.S. Group. Curative versus palliative treatments for recurrent hepatocellular carcinoma: a multicentric weighted comparison. HPB (Oxford) 2021;23:889-98. [PMID: 33144053 DOI: 10.1016/j.hpb.2020.10.007] [Reference Citation Analysis]
297 Kobayashi K, Uldry E, Kokudo T, Cristaudi A, Kawaguchi Y, Shirata C, Yamaguchi T, Dormond O, Duran R, Hasegawa K, Demartines N, Halkic N. Correlation Between Portal Pressure and Indocyanine Green Retention Rate is Unaffected by the Cause of Cirrhosis: A Prospective Study. World J Surg 2021;45:2546-55. [PMID: 33891139 DOI: 10.1007/s00268-021-06111-6] [Reference Citation Analysis]
298 Da Fonseca LG, Forner A. Carbon-ion radiotherapy for HCC-A potential tool to fulfil an unmet gap in the treatment algorithms? Liver Int 2018;38:2132-3. [PMID: 30480378 DOI: 10.1111/liv.13990] [Reference Citation Analysis]
299 Cai J, Zhang Z, He C, Zhang W, Fan J. Reply to 'Are the 5-hydroxymethylcytosine-based wd-scores really superior over α-fetoprotein for the early diagnosis of hepatocellular carcinoma?'. Gut 2020;69:1903-4. [PMID: 31871104 DOI: 10.1136/gutjnl-2019-320298] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
300 Shi L, Zhang SJ, Chen J, Lu SX, Fan XJ, Tong JH, Chow C, Tin EK, Chan SL, Chong CC, Lai PB, To KF, Wong N, Chan AW. A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma. Mod Pathol 2019;32:1646-56. [PMID: 31231126 DOI: 10.1038/s41379-019-0307-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
301 Chang YJ, Chen LJ, Chang YJ, Chen PD. Population-based matching comparison between radiofrequency ablation and percutaneous ethanol or acetic acid injection for hepatocellular carcinoma. Eur J Surg Oncol 2020;46:1703-10. [PMID: 32475629 DOI: 10.1016/j.ejso.2020.04.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
302 Yuan G, Song Y, Li Q, Hu X, Zang M, Dai W, Cheng X, Huang W, Yu W, Chen M, Guo Y, Zhang Q, Chen J. Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients. Front Immunol 2020;11:613946. [PMID: 33488622 DOI: 10.3389/fimmu.2020.613946] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
303 Delicque J, Hermida M, Piron L, Allimant C, Belgour A, Pageaux GP, Ben Bouallegue F, Assenat E, Mariano-Goulart D, Guiu B, Cassinotto C. Intra arterial treatment of hepatocellular carcinoma: Comparison of MELD score variations between radio-embolization and chemo-embolization. Diagn Interv Imaging 2019;100:689-97. [PMID: 31281074 DOI: 10.1016/j.diii.2019.05.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
304 Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, Han G, Wang M, Liu R, Lu L, Ren Z, Chen M, Zeng Z, Liang P, Liang C, Chen M, Yan F, Wang W, Ji Y, Yun J, Cai D, Chen Y, Cheng W, Cheng S, Dai C, Guo W, Hua B, Huang X, Jia W, Li Y, Li Y, Liang J, Liu T, Lv G, Mao Y, Peng T, Ren W, Shi H, Shi G, Tao K, Wang W, Wang X, Wang Z, Xiang B, Xing B, Xu J, Yang J, Yang J, Yang Y, Yang Y, Ye S, Yin Z, Zhang B, Zhang B, Zhang L, Zhang S, Zhang T, Zhao Y, Zheng H, Zhu J, Zhu K, Liu R, Shi Y, Xiao Y, Dai Z, Teng G, Cai J, Wang W, Cai X, Li Q, Shen F, Qin S, Dong J, Fan J. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer 2020;9:682-720. [PMID: 33442540 DOI: 10.1159/000509424] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 17.0] [Reference Citation Analysis]
305 Zhou KQ, Sun YF, Cheng JW, Du M, Ji Y, Wang PX, Hu B, Guo W, Gao Y, Yin Y, Huang JF, Zhou J, Fan J, Yang XR. Effect of surgical margin on recurrence based on preoperative circulating tumor cell status in hepatocellular carcinoma. EBioMedicine 2020;62:103107. [PMID: 33181461 DOI: 10.1016/j.ebiom.2020.103107] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
306 Lee JH, Mohan CD, Shanmugam MK, Rangappa S, Sethi G, Siveen KS, Chinnathambi A, Alahmadi TA, Alharbi SA, Basappa S, Rangappa KS, Ahn KS. Vitexin abrogates invasion and survival of hepatocellular carcinoma cells through targeting STAT3 signaling pathway. Biochimie 2020;175:58-68. [PMID: 32445654 DOI: 10.1016/j.biochi.2020.05.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]
307 Sevco TJ, Masch WR, Maturen KE, Mendiratta-Lala M, Wasnik AP, Millet JD. Ultrasound (US) LI-RADS: Outcomes of Category US-3 Observations. AJR Am J Roentgenol 2021;217:644-50. [PMID: 34259543 DOI: 10.2214/AJR.20.23447] [Reference Citation Analysis]
308 Müller M, Bird TG, Nault JC. The landscape of gene mutations in cirrhosis and hepatocellular carcinoma. J Hepatol 2020;72:990-1002. [PMID: 32044402 DOI: 10.1016/j.jhep.2020.01.019] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 31.0] [Reference Citation Analysis]
309 Ahn YE, Suh SJ, Yim HJ, Seo YS, Yoon EL, Kim TH, Lee YS, Yim SY, Kim HR, Kang SH, Jung YK, Kim JH, Yeon JE, Um SH, Byun KS. Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Gut Liver. 2021;15:284-294. [PMID: 32307975 DOI: 10.5009/gnl19367] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
310 Rim CH, Kim HJ, Seong J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Radiother Oncol. 2019;131:135-144. [PMID: 30773180 DOI: 10.1016/j.radonc.2018.12.005] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 14.7] [Reference Citation Analysis]
311 Shanker MD, Moodaley P, Soon W, Liu HY, Lee YY, Pryor DI. Stereotactic ablative radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of local control, survival and toxicity outcomes. J Med Imaging Radiat Oncol 2021. [PMID: 34396706 DOI: 10.1111/1754-9485.13309] [Reference Citation Analysis]
312 Osho A, Rich NE, Singal AG. Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response. Hepatoma Res 2020;6:55. [PMID: 32944652 DOI: 10.20517/2394-5079.2020.42] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
313 Caines A, Selim R, Salgia R. The Changing Global Epidemiology of Hepatocellular Carcinoma. Clinics in Liver Disease 2020;24:535-47. [DOI: 10.1016/j.cld.2020.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
314 Wang E, Xia D, Bai W, Yuan J, Li X, Niu J, Yin Z, Xia J, Cai H, Fan D, Han G, Liu L. Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinoma. BMC Cancer 2019;19:409. [PMID: 31039750 DOI: 10.1186/s12885-019-5570-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
315 Kamimura K, Yokoo T, Abe H, Terai S. Gene Therapy for Liver Cancers: Current Status from Basic to Clinics. Cancers (Basel) 2019;11:E1865. [PMID: 31769427 DOI: 10.3390/cancers11121865] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
316 He ZJ, Li W, Chen H, Wen J, Gao YF, Liu YJ. miR-1306-3p targets FBXL5 to promote metastasis of hepatocellular carcinoma through suppressing snail degradation. Biochem Biophys Res Commun 2018;504:820-6. [PMID: 30219228 DOI: 10.1016/j.bbrc.2018.09.059] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
317 Beaton L, Tregidgo HFJ, Znati SA, Forsyth S, Clarkson MJ, Bandula S, Chouhan M, Lowe HL, Zaw Thin M, Hague J, Sharma D, Pollok JM, Davidson BR, Raja J, Munneke G, Stuckey DJ, Bascal ZA, Wilde PE, Cooper S, Ryan S, Czuczman P, Boucher E, Hartley JA, Lewis AL, Jansen M, Meyer T, Sharma RA. VEROnA Protocol: A Pilot, Open-Label, Single-Arm, Phase 0, Window-of-Opportunity Study of Vandetanib-Eluting Radiopaque Embolic Beads (BTG-002814) in Patients With Resectable Liver Malignancies. JMIR Res Protoc 2019;8:e13696. [PMID: 31579027 DOI: 10.2196/13696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
318 Cai M, Li B, Lin L, Huang J, An Y, Huang W, Zhou Z, Wang Y, Shuai X, Zhu K. A reduction and pH dual-sensitive nanodrug for targeted theranostics in hepatocellular carcinoma. Biomater Sci 2020;8:3485-99. [PMID: 32432234 DOI: 10.1039/d0bm00295j] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
319 Zaki IH, Shropshire E, Zhang S, Xiao D, Wildman-Tobriner B, Marin D, Gupta RT, Erkanli A, Nelson RC, Bashir MR. How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver MRI examination with intravenous Gadobenate dimeglumine? Abdom Radiol (NY) 2021;46:969-78. [PMID: 32951065 DOI: 10.1007/s00261-020-02771-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
320 Degroote H, Lefere S, Vandierendonck A, Vanderborght B, Meese T, Van Nieuwerburgh F, Verhelst X, Geerts A, Van Vlierberghe H, Devisscher L. Characterization of the inflammatory microenvironment and hepatic macrophage subsets in experimental hepatocellular carcinoma models. Oncotarget 2021;12:562-77. [PMID: 33796224 DOI: 10.18632/oncotarget.27906] [Reference Citation Analysis]
321 Peng T, Wonganan O, Zhang Z, Yu J, Xi R, Cao Y, Suksamrarn A, Zhang G, Wang F. A 2-Benzylmalonate Derivative as STAT3 Inhibitor Suppresses Tumor Growth in Hepatocellular Carcinoma by Upregulating β-TrCP E3 Ubiquitin Ligase. Int J Mol Sci 2021;22:3354. [PMID: 33805945 DOI: 10.3390/ijms22073354] [Reference Citation Analysis]
322 Wu CJ, Chau GY, Lee IC, Huo TI, Su CW, Hou MC, Huang YH. Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy. J Formos Med Assoc 2021;120:1563-71. [PMID: 33334659 DOI: 10.1016/j.jfma.2020.11.019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
323 Zhou Y, Liu L, Liu Y, Zhou P, Yan Q, Yu H, Chen X, Zhu F. Implication of human endogenous retrovirus W family envelope in hepatocellular carcinoma promotes MEK/ERK-mediated metastatic invasiveness and doxorubicin resistance. Cell Death Discov 2021;7:177. [PMID: 34238921 DOI: 10.1038/s41420-021-00562-5] [Reference Citation Analysis]
324 Wei CY, Chen PC, Chau GY, Lee RC, Chen PH, Huo TI, Huang YH, Su YH, Hou MC, Wu JC, Su CW. Comparison of prognosis between surgical resection and transarterial chemoembolization for patients with solitary huge hepatocellular carcinoma. Ann Transl Med 2020;8:238. [PMID: 32309385 DOI: 10.21037/atm.2019.12.157] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
325 Oversoe SK, Clement MS, Pedersen MH, Weber B, Aagaard NK, Villadsen GE, Grønbæk H, Hamilton-Dutoit SJ, Sorensen BS, Kelsen J. TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma. Scand J Gastroenterol 2020;55:1433-40. [PMID: 33103505 DOI: 10.1080/00365521.2020.1837928] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
326 Öcal O, Kupčinskas J, Morkunas E, Amthauer H, Schütte K, Malfertheiner P, Klümpen HJ, Sengel C, Benckert J, Seidensticker R, Sangro B, Wildgruber M, Pech M, Bartenstein P, Ricke J, Seidensticker M. Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization. EJNMMI Res 2021;11:51. [PMID: 34080071 DOI: 10.1186/s13550-021-00791-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
327 Li C, Chen K, Liu X, Liu HT, Liang XM, Liang GL, Tang ST, Huo RR, Ma L, Xiang BB, Zhong JH, Li LQ. Analysis of Clinicopathological Characteristics and Prognosis of Young Patients with Hepatocellular Carcinoma after Hepatectomy. J Clin Transl Hepatol 2020;8:285-91. [PMID: 33083251 DOI: 10.14218/JCTH.2020.00021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
328 Troisi RI, Berardi G, Morise Z, Cipriani F, Ariizumi S, Sposito C, Panetta V, Simonelli I, Kim S, Goh BKP, Kubo S, Tanaka S, Takeda Y, Ettorre GM, Russolillo N, Wilson GC, Cimino M, Montalti R, Giglio MC, Igarashi K, Chan CY, Torzilli G, Cheung TT, Mazzaferro V, Kaneko H, Ferrero A, Geller DA, Han HS, Kanazawa A, Wakabayashi G, Aldrighetti L, Yamamoto M. Laparoscopic and open liver resection for hepatocellular carcinoma with Child-Pugh B cirrhosis: multicentre propensity score-matched study. Br J Surg 2021;108:196-204. [PMID: 33711132 DOI: 10.1093/bjs/znaa041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
329 Taflin H, Hafström L, Holmberg E, Castedal M, Lindnér P. The impact of increased immigration to Sweden on the incidence and treatment of patients with HCC and underlying liver disease. Scandinavian Journal of Gastroenterology 2019;54:746-52. [DOI: 10.1080/00365521.2019.1627580] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
330 Kaneko S, Tsuchiya K, Yasui Y, Inada K, Kirino S, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Takeguchi T, Takeguchi Y, Nagano T, Nakanishi H, Itakura J, Takahashi Y, Himeno Y, Hoshi A, Kurosaki M, Izumi N. Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis. Hepatol Res 2020;50:1375-85. [DOI: 10.1111/hepr.13567] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
331 Shen Y, Xiong W, Gu Q, Zhang Q, Yue J, Liu C, Wang D. Multi-Omics Integrative Analysis Uncovers Molecular Subtypes and mRNAs as Therapeutic Targets for Liver Cancer. Front Med (Lausanne) 2021;8:654635. [PMID: 34109194 DOI: 10.3389/fmed.2021.654635] [Reference Citation Analysis]
332 Chen LC, Lin HY, Hung SK, Chiou WY, Lee MS. Role of modern radiotherapy in managing patients with hepatocellular carcinoma. World J Gastroenterol 2021; 27(20): 2434-2457 [PMID: 34092968 DOI: 10.3748/wjg.v27.i20.2434] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
333 Lee HA, Rim CH. Efficacy of Local Treatments for Hepatocellular Carcinoma Involving the Inferior Vena Cava and/or Right Atrium. J Hepatocell Carcinoma 2020;7:435-46. [PMID: 33376712 DOI: 10.2147/JHC.S285357] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
334 Cheng S, Chen M, Cai J, Sun J, Guo R, Bi X, Lau WY, Wu M. Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition). Liver Cancer 2020;9:28-40. [PMID: 32071907 DOI: 10.1159/000503685] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
335 Lang H, Heinrich S, Bartsch F, Hüttl F, Baumgart J, Mittler J. [Surgical treatment of hepatic tumors-liver resection and transplantation]. Internist (Berl) 2020;61:147-57. [PMID: 32016491 DOI: 10.1007/s00108-020-00754-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
336 Lee EJ, Chung HW, Jo JH, So Y. Radioembolization for the Treatment of Primary and Metastatic Liver Cancers. Nucl Med Mol Imaging 2019;53:367-73. [PMID: 31867071 DOI: 10.1007/s13139-019-00615-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
337 Zhang W, Hu B, Han J, Wang Z, Ma G, Ye H, Yuan J, Cao J, Zhang Z, Shi J, Chen M, Wang X, Xu Y, Cheng Y, Tian L, Wang H, Lu S. Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients. Front Oncol 2021;11:747950. [PMID: 34737958 DOI: 10.3389/fonc.2021.747950] [Reference Citation Analysis]
338 Gatselis NK, Zachou K, Giannoulis G, Gabeta S, Norman GL, Dalekos GN. Serum Cartilage Oligomeric Matrix Protein and Golgi Protein-73: New Diagnostic and Predictive Tools for Liver Fibrosis and Hepatocellular Cancer? Cancers (Basel) 2021;13:3510. [PMID: 34298722 DOI: 10.3390/cancers13143510] [Reference Citation Analysis]
339 Song JH, Goh MJ, Park Y, Oh JH, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Prognosis of hepatocellular carcinoma patients diagnosed under regular surveillance: potential implications for surveillance goal. Scand J Gastroenterol 2021;56:274-80. [PMID: 33399022 DOI: 10.1080/00365521.2020.1866063] [Reference Citation Analysis]
340 Devictor J, Leclercq A, Hazo JB, Burnet E, Jovic L, Bouattour M, Ganne-Carrié N. Nurse coordinator roles in the management of patients with hepatocellular carcinoma: A French national survey. Clin Res Hepatol Gastroenterol 2021;45:101650. [PMID: 33609787 DOI: 10.1016/j.clinre.2021.101650] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
341 Cheng TY, Lee PC, Chen YT, Chao Y, Hou MC, Huang YH. Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure. Sci Rep 2020;10:18375. [PMID: 33110117 DOI: 10.1038/s41598-020-75198-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
342 Chan MV, Huo YR, Trieu N, Mitchelle A, George J, He E, Lee AU, Chang J, Yang J. Noncontrast MRI for Hepatocellular Carcinoma Detection: A Systematic Review and Meta-analysis - A Potential Surveillance Tool? Clin Gastroenterol Hepatol 2021:S1542-3565(21)00215-9. [PMID: 33662596 DOI: 10.1016/j.cgh.2021.02.036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
343 Huang M, Zhong J, Lu C, Deng F, Li L, Nong Y, Liang L, Qin H, Deng Y. Genotypic Resistance Remains A Concern In Chronic Hepatitis B Patients With High Viral Load After Lamivudine And Adefovir Combination Therapy. Pharmgenomics Pers Med 2019;12:297-303. [PMID: 31695474 DOI: 10.2147/PGPM.S224256] [Reference Citation Analysis]
344 Choi JW, Lee JM, Kim HC, Lee M, Hur S, Jae HJ, Chung JW. Iatrogenic Arterioportal Fistula Caused by Radiofrequency Ablation of Hepatocellular Carcinoma: Clinical Course and Treatment Outcomes. J Vasc Interv Radiol 2020;31:728-36. [PMID: 32229078 DOI: 10.1016/j.jvir.2019.10.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
345 You Y, Zhang M, Li K, Zeng Q, Luo L, Long Y, Tan L, He X, Liang P, Xu E, Zheng R. Feasibility of 3D US/CEUS-US/CEUS fusion imaging-based ablation planning in liver tumors: a retrospective study. Abdom Radiol (NY) 2021;46:2865-74. [PMID: 33484284 DOI: 10.1007/s00261-020-02909-5] [Reference Citation Analysis]
346 Zhou Y, Hu C, Yuan G, Liu J, Ren Y, Tang C, Yang S, Dai L, Li Y, Yang D. [Antiviral and antifibrotic therapies reduce occurrence of hepatocellular carcinoma in patients with chronic hepatitis B and liver fibrosis: a 144-week prospective cohort study]. Nan Fang Yi Ke Da Xue Xue Bao 2019;39:633-40. [PMID: 31270040 DOI: 10.12122/j.issn.1673-4254.2019.06.02] [Reference Citation Analysis]
347 Chen S, Peng Z, Zhang Y, Chen M, Li J, Guo R, Li J, Li B, Mei J, Feng S, Kuang M. Lack of Response to Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Abandon or Repeat? Radiology 2021;298:680-92. [PMID: 33464183 DOI: 10.1148/radiol.2021202289] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
348 Kaewdech A, Sripongpun P, Cheewasereechon N, Jandee S, Chamroonkul N, Piratvisuth T. Validation of the "Six-and-Twelve" Prognostic Score in Transarterial Chemoembolization-Treated Hepatocellular Carcinoma Patients. Clin Transl Gastroenterol 2021;12:e00310. [PMID: 33605612 DOI: 10.14309/ctg.0000000000000310] [Reference Citation Analysis]
349 Biggemann L, Uhlig J, Streit U, Sack H, Guo XC, Jung C, Ahmed S, Lotz J, Müller-Wille R, Seif Amir Hosseini A. Future liver remnant growth after various portal vein embolization regimens: a quantitative comparison. Minim Invasive Ther Allied Technol 2020;29:98-106. [PMID: 30821547 DOI: 10.1080/13645706.2019.1582067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
350 Choi MH, Choi JI, Lee YJ. Manual versus automated image fusion of real-time ultrasonography and MR/CT images for radiofrequency ablation of hepatic tumors: results of a randomized prospective trial (NCT02705118). Ultrasonography 2021;40:237-47. [PMID: 32660211 DOI: 10.14366/usg.20052] [Reference Citation Analysis]
351 Renzulli M, Clemente A, Brocchi S, Milandri M, Lucidi V, Vukotic R, Cappabianca S, Golfieri R. LI-RADS: a great opportunity not to be missed. Eur J Gastroenterol Hepatol 2019;31:283-8. [PMID: 30234643 DOI: 10.1097/MEG.0000000000001269] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
352 Streubel G, Schrepfer S, Kallus H, Parnitzke U, Wulff T, Hermann F, Borgmann M, Hamm S. Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma. Sci Rep 2021;11:9587. [PMID: 33953226 DOI: 10.1038/s41598-021-88983-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
353 Reiter FP, Hadjamu NJ, Nagdyman N, Zachoval R, Mayerle J, De Toni EN, Kaemmerer H, Denk G. Congenital heart disease-associated liver disease: a narrative review. Cardiovasc Diagn Ther 2021;11:577-90. [PMID: 33968635 DOI: 10.21037/cdt-20-595] [Reference Citation Analysis]
354 Westin J, Aleman S, Castedal M, Duberg A, Eilard A, Fischler B, Kampmann C, Lindahl K, Lindh M, Norkrans G, Stenmark S, Weiland O, Wejstål R. Management of hepatitis B virus infection, updated Swedish guidelines. Infectious Diseases 2020;52:1-22. [DOI: 10.1080/23744235.2019.1675903] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
355 Jin ZC, Zhong BY. Application of radiomics in hepatocellular carcinoma: A review. Artif Intell Med Imaging 2021; 2(3): 64-72 [DOI: 10.35711/aimi.v2.i3.64] [Reference Citation Analysis]
356 Bévant K, Desoteux M, Abdel Wahab AHA, Abdel Wahab SA, Metwally AM, Coulouarn C. DNA Methylation of TGFβ Target Genes: Epigenetic Control of TGFβ Functional Duality in Liver Cancer. Cells 2021;10:2207. [PMID: 34571856 DOI: 10.3390/cells10092207] [Reference Citation Analysis]
357 Duan Y, Xie X, Li Q, Mercaldo N, Samir AE, Kuang M, Lin M. Differentiation of regenerative nodule, dysplastic nodule, and small hepatocellular carcinoma in cirrhotic patients: a contrast-enhanced ultrasound-based multivariable model analysis. Eur Radiol 2020;30:4741-51. [PMID: 32307563 DOI: 10.1007/s00330-020-06834-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
358 Llovet JM, Lencioni R. mRECIST for HCC: Performance and novel refinements. J Hepatol. 2020;72:288-306. [PMID: 31954493 DOI: 10.1016/j.jhep.2019.09.026] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 48.0] [Reference Citation Analysis]
359 Park SJ, Yoon JH, Lee DH, Lim WH, Lee JM. Tumor Stiffness Measurements on MR Elastography for Single Nodular Hepatocellular Carcinomas Can Predict Tumor Recurrence After Hepatic Resection. J Magn Reson Imaging 2021;53:587-96. [PMID: 32914909 DOI: 10.1002/jmri.27359] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
360 Laube R, Sabih AH, Strasser SI, Lim L, Cigolini M, Liu K. Palliative care in hepatocellular carcinoma.J Gastroenterol Hepatol. 2021;36:618-628. [PMID: 32627853 DOI: 10.1111/jgh.15169] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
361 Lim TS, Rhee H, Kim GM, Kim SU, Kim BK, Park JY, Ahn SH, Han K, Choi J, Kim DY. Alpha-Fetoprotein, Des-Gamma-Carboxy Prothrombin, and Modified RECIST Response as Predictors of Survival after Transarterial Radioembolization for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2019;30:1194-1200.e1. [DOI: 10.1016/j.jvir.2019.03.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
362 He M, Hu L, Bai P, Guo T, Liu N, Feng F, Zhang J. LncRNA PCNAP1 Promotes Hepatoma Cell Proliferation through Targeting miR-340-5p and is Associated with Patient Survival. J Oncol 2021;2021:6627173. [PMID: 34007276 DOI: 10.1155/2021/6627173] [Reference Citation Analysis]
363 Choi J, Lee D, Shim JH, Kim KM, Lim YS, Lee YS, Lee HC. Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma.PLoS One. 2020;15:e0229696. [PMID: 32130270 DOI: 10.1371/journal.pone.0229696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
364 Huang J, Tian W, Zhang L, Huang Q, Lin S, Ding Y, Liang W, Zheng S. Preoperative Prediction Power of Imaging Methods for Microvascular Invasion in Hepatocellular Carcinoma: A Systemic Review and Meta-Analysis. Front Oncol 2020;10:887. [PMID: 32676450 DOI: 10.3389/fonc.2020.00887] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
365 Hotta A, Ishikawa M, Tachikake T, Matsuura N, Toyota N, Awai K. Comparison of the effectiveness of celiac versus common hepatic artery injection for the detection of hepatocellular carcinoma and of the feeding artery on cone-beam computed tomographs obtained during hepatic angiography. Acta Radiol Open 2021;10:2058460121994735. [PMID: 34104477 DOI: 10.1177/2058460121994735] [Reference Citation Analysis]
366 Voulgaris T, Papatheodoridi M, Lampertico P, Papatheodoridis GV. Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B. Liver Int 2020;40:484-95. [PMID: 31884726 DOI: 10.1111/liv.14334] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 19.0] [Reference Citation Analysis]
367 Rungsakulkij N, Suragul W, Mingphruedhi S, Tangtawee P, Muangkaew P, Aeesoa S. Prognostic role of alpha-fetoprotein response after hepatocellular carcinoma resection. World J Clin Cases 2018; 6(6): 110-120 [PMID: 29988930 DOI: 10.12998/wjcc.v6.i6.110] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
368 Sadeghi S, Bejjani A, Finn RS. Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma. Surg Oncol Clin N Am 2019;28:695-715. [PMID: 31472914 DOI: 10.1016/j.soc.2019.06.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
369 Banerjee I, Fisher PB, Sarkar D. Astrocyte elevated gene-1 (AEG-1): A key driver of hepatocellular carcinoma (HCC). Adv Cancer Res 2021;152:329-81. [PMID: 34353442 DOI: 10.1016/bs.acr.2021.05.003] [Reference Citation Analysis]
370 Wang Z, Fan Q, Wang M, Wang E, Li H, Liu L. Comparison between Child-Pugh Score and albumin-bilirubin grade in patients treated with the combination therapy of transarterial chemoembolization and sorafenib for hepatocellular carcinoma. Ann Transl Med 2020;8:537. [PMID: 32411760 DOI: 10.21037/atm.2020.02.114] [Reference Citation Analysis]
371 Chen L, Sun T, Kan X, Chen S, Ren Y, Cao Y, Yan L, Liang B, Xiong B, Zheng C. Transarterial chemoembolization combined with iodine-125 seed implantation for patients with hepatocellular carcinoma: a retrospective controlled study. J Int Med Res 2020;48:300060520944309. [PMID: 33050765 DOI: 10.1177/0300060520944309] [Reference Citation Analysis]
372 Alonso López S, Manzano ML, Gea F, Gutiérrez ML, Ahumada AM, Devesa MJ, Olveira A, Polo BA, Márquez L, Fernández I, Cobo JCR, Rayón L, Riado D, Izquierdo S, Usón C, Real Y, Rincón D, Fernández-Rodríguez CM, Bañares R. A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis. Hepatology 2020;72:1924-34. [PMID: 33022803 DOI: 10.1002/hep.31588] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
373 Forner A, Vidili G, Rengo M, Bujanda L, Ponz‐sarvisé M, Lamarca A. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int 2019;39:98-107. [DOI: 10.1111/liv.14086] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 26.0] [Reference Citation Analysis]
374 Bucalau AM, Tancredi I, Pezzullo M, Covas A, Verset G. Complete response of a hepatocellular carcinoma with complex macrovascular invasion after combined treatment with chemoembolization and immunotherapy: a case report. Acta Gastroenterol Belg 2021;84:371-4. [PMID: 34217191 DOI: 10.51821/84.2.371] [Reference Citation Analysis]
375 Zhong BY, Yan ZP, Sun JH, Zhang L, Hou ZH, Yang MJ, Zhou GH, Wang WS, Li Z, Huang P, Zhang S, Zhu XL, Ni CF. Prognostic Performance of Albumin-Bilirubin Grade With Artificial Intelligence for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib. Front Oncol 2020;10:525461. [PMID: 33392064 DOI: 10.3389/fonc.2020.525461] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
376 Lee SM, Lee JM, Ahn SJ, Kang HJ, Yang HK, Yoon JH. Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018. Korean J Radiol 2021;22:1066-76. [PMID: 33739633 DOI: 10.3348/kjr.2020.0846] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
377 Nagaoki Y, Hyogo H, Ando Y, Kosaka Y, Uchikawa S, Nishida Y, Teraoka Y, Morio K, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Okamoto W, Kawaoka T, Tsuge M, Hiramatsu A, Miki D, Imamura M, Takahashi S, Chayama K, Aikata H. Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study. BMC Gastroenterol 2021;21:306. [PMID: 34332532 DOI: 10.1186/s12876-021-01884-5] [Reference Citation Analysis]
378 Meringer H, Shibolet O, Deutsch L. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm? World J Gastroenterol 2019; 25(29): 3929-3940 [PMID: 31413528 DOI: 10.3748/wjg.v25.i29.3929] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
379 Zhang L, Sun JH, Ji JS, Zhong BY, Zhou GH, Song JJ, Hou ZH, Huang P, Zhang S, Li Z, Zhu XL, Ni CF. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study. AJR Am J Roentgenol 2021;217:933-43. [PMID: 33245680 DOI: 10.2214/AJR.20.24708] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
380 Pelizzaro F, Sammarco A, Dadduzio V, Pastorelli D, Giovanis P, Soldà C, Rizzato MD, Lombardi G, Lonardi S, Peserico G, Imondi A, Sartori A, Maddalo G, Farinati F. Capecitabine in advanced hepatocellular carcinoma: A multicenter experience. Digestive and Liver Disease 2019;51:1713-9. [DOI: 10.1016/j.dld.2019.06.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
381 Yushchuk ND, Sleptsova SS, Malov SI, Bilukina IF, Semenov SI, Stepanenko LA, Ogarkov OB, Savilov ED, Malov IV. [Assessment of external risk factors of hepatocellular cancer development and markers of genetic predisposition to its development in the ethnic group of yakut - men]. Ter Arkh 2020;92:56-61. [PMID: 32598664 DOI: 10.26442/00403660.2020.01.000505] [Reference Citation Analysis]
382 Dong Y, Zhou L, Xia W, Zhao XY, Zhang Q, Jian JM, Gao X, Wang WP. Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma: Initial Application of a Radiomic Algorithm Based on Grayscale Ultrasound Images. Front Oncol. 2020;10:353. [PMID: 32266138 DOI: 10.3389/fonc.2020.00353] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
383 Singal AG, Tiro JA, Murphy CC, Blackwell JM, Kramer JR, Khan A, Liu Y, Zhang S, Phillips JL, Hernaez R. Patient-Reported Barriers Are Associated With Receipt of Hepatocellular Carcinoma Surveillance in a Multicenter Cohort of Patients With Cirrhosis. Clin Gastroenterol Hepatol 2021;19:987-995.e1. [PMID: 32629122 DOI: 10.1016/j.cgh.2020.06.049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
384 Scheiner B, Ulbrich G, Mandorfer M, Reiberger T, Müller C, Waneck F, Trauner M, Kölblinger C, Ferlitsch A, Sieghart W, Peck-Radosavljevic M, Pinter M. Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. United European Gastroenterol J 2019;7:850-8. [PMID: 31316789 DOI: 10.1177/2050640619840199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
385 Piñero F, Silva M, Iavarone M. Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors. World J Gastroenterol 2020; 26(16): 1888-1900 [PMID: 32390700 DOI: 10.3748/wjg.v26.i16.1888] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
386 Kim DW, Lee G, Kim SY, Ahn G, Lee JG, Lee SS, Kim KW, Park SH, Lee YJ, Kim N. Deep learning-based algorithm to detect primary hepatic malignancy in multiphase CT of patients at high risk for HCC. Eur Radiol 2021;31:7047-57. [PMID: 33738600 DOI: 10.1007/s00330-021-07803-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
387 Hin Tang JJ, Hao Thng DK, Lim JJ, Toh TB. JAK/STAT signaling in hepatocellular carcinoma. Hepat Oncol 2020;7:HEP18. [PMID: 32273976 DOI: 10.2217/hep-2020-0001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
388 Elfadaly AN, Tsilimigras DI, Hyer JM, Paro A, Bagante F, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Impact of Tumor Burden Score on Conditional Survival after Curative-Intent Resection for Hepatocellular Carcinoma: A Multi-Institutional Analysis. World J Surg 2021. [PMID: 34341844 DOI: 10.1007/s00268-021-06265-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
389 Habibollahi P, Sheth RA, Cressman ENK. Histological Correlation for Radiofrequency and Microwave Ablation in the Local Control of Hepatocellular Carcinoma (HCC) before Liver Transplantation: A Comprehensive Review.Cancers (Basel). 2020;13. [PMID: 33396289 DOI: 10.3390/cancers13010104] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
390 Dioguardi Burgio M, Sartoris R, Libotean C, Zappa M, Sibert A, Vilgrain V, Ronot M. Lipiodol retention pattern after TACE for HCC is a predictor for local progression in lesions with complete response. Cancer Imaging 2019;19:75. [PMID: 31730491 DOI: 10.1186/s40644-019-0260-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
391 Romano F, Chiarelli M, Garancini M, Scotti M, Zago M, Cioffi G, De Simone M, Cioffi U. Rethinking the Barcelona clinic liver cancer guidelines: Intermediate stage and Child-Pugh B patients are suitable for surgery? World J Gastroenterol 2021; 27(21): 2784-2794 [PMID: 34135554 DOI: 10.3748/wjg.v27.i21.2784] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
392 Tsilimigras DI, Bagante F, Moris D, Merath K, Paredes AZ, Sahara K, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Defining the chance of cure after resection for hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guidelines: A multi-institutional analysis of 1,010 patients. Surgery 2019;166:967-74. [DOI: 10.1016/j.surg.2019.08.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
393 Hermann A, Dieudonné A, Ronot M, Sanchez M, Pereira H, Chatellier G, Garin E, Castera L, Lebtahi R, Vilgrain V; For the SARAH Trial Group. Relationship of Tumor Radiation–absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with 90 Y in the SARAH Study. Radiology 2020;296:673-84. [DOI: 10.1148/radiol.2020191606] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 24.0] [Reference Citation Analysis]
394 van Rosmalen BV, Furumaya A, Klompenhouwer AJ, Tushuizen ME, Braat AE, Reinten RJ, Ligthart MAP, Haring MPD, de Meijer VE, van Voorthuizen T, Takkenberg RB, Dejong CHC, de Man RA, IJzermans JNM, Doukas M, van Gulik TM, Verheij J; Dutch Benign Liver Tumor Group and the PALGA group. Hepatocellular adenoma in men: A nationwide assessment of pathology and correlation with clinical course. Liver Int 2021. [PMID: 34155783 DOI: 10.1111/liv.14989] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
395 Renne SL, Sarcognato S, Sacchi D, Guido M, Roncalli M, Terracciano L, Di Tommaso L. Hepatocellular carcinoma: a clinical and pathological overview. Pathologica 2021;113:203-17. [PMID: 34294938 DOI: 10.32074/1591-951X-295] [Reference Citation Analysis]
396 Huang T, Chen QF, Chang BY, Shen LJ, Li W, Wu PH, Fan WJ. TFAP4 Promotes Hepatocellular Carcinoma Invasion and Metastasis via Activating the PI3K/AKT Signaling Pathway. Dis Markers 2019;2019:7129214. [PMID: 31281549 DOI: 10.1155/2019/7129214] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
397 Younes R, Govaere O, Petta S, Miele L, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, McLeod D, Pareja MJ, Fracanzani AL, Aller R, Rosso C, Ampuero J, Gallego-Durán R, Armandi A, Caviglia GP, Zaki MYW, Liguori A, Francione P, Pennisi G, Grieco A, Birolo G, Fariselli P, Eslam M, Valenti L, George J, Romero-Gómez M, Anstee QM, Bugianesi E. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? Gut 2021:gutjnl-2020-322564. [PMID: 33541866 DOI: 10.1136/gutjnl-2020-322564] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
398 Lee DH, Lee MW, Kim PN, Lee YJ, Park HS, Lee JM. Outcome of No-Touch Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Multicenter Clinical Trial. Radiology 2021;:210309. [PMID: 34313474 DOI: 10.1148/radiol.2021210309] [Reference Citation Analysis]
399 Cunha GM, Fowler KJ, Abushamat F, Sirlin CB, Kono Y. Imaging Diagnosis of Hepatocellular Carcinoma: The Liver Imaging Reporting and Data System, Why and How? Clin Liver Dis 2020;24:623-36. [PMID: 33012449 DOI: 10.1016/j.cld.2020.07.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
400 Zhang N, Jiang W, Zhang Y, Song TQ, Lv J, Gu J, Wu Y, Qian J, Tian D, Guo Q, Zhang L, Sun J, Xie Y, Wang Z, Sun X, Yan Z, Zhou Y, Liu J, Qiu Y, Yang B, Shen Z, Lu W. Individualised tailored assessment of therapeutic alternatives for HCC patients within the Milan criteria. Gut 2020;69:1893-5. [PMID: 31748202 DOI: 10.1136/gutjnl-2019-320073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
401 Shek D, Chen D, Read SA, Ahlenstiel G. Examining the gut-liver axis in liver cancer using organoid models. Cancer Lett 2021;510:48-58. [PMID: 33891996 DOI: 10.1016/j.canlet.2021.04.008] [Reference Citation Analysis]
402 Kim TH, Koh YH, Kim BH, Kim MJ, Lee JH, Park B, Park J. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial. Journal of Hepatology 2021;74:603-12. [DOI: 10.1016/j.jhep.2020.09.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
403 Huang J, Huang W, Guo Y, Cai M, Zhou J, Lin L, Zhu K. Risk Factors, Patterns, and Long-Term Survival of Recurrence After Radiofrequency Ablation With or Without Transarterial Chemoembolization for Hepatocellular Carcinoma. Front Oncol 2021;11:638428. [PMID: 34123790 DOI: 10.3389/fonc.2021.638428] [Reference Citation Analysis]
404 Glantzounis GK, Karampa A, Peristeri DV, Pappas-Gogos G, Tepelenis K, Tzimas P, Cyrochristos DJ. Recent advances in the surgical management of hepatocellular carcinoma. Ann Gastroenterol 2021;34:453-65. [PMID: 34276183 DOI: 10.20524/aog.2021.0632] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
405 Garrido I, Liberal R, Macedo G. Review article: COVID-19 and liver disease-what we know on 1st May 2020. Aliment Pharmacol Ther. 2020;52:267-275. [PMID: 32402090 DOI: 10.1111/apt.15813] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 62.0] [Reference Citation Analysis]
406 Nahon P, Vo Quang E, Ganne-Carrié N. Stratification of Hepatocellular Carcinoma Risk Following HCV Eradication or HBV Control. J Clin Med 2021;10:353. [PMID: 33477752 DOI: 10.3390/jcm10020353] [Reference Citation Analysis]
407 Amorim J, França M, Perez-girbes A, Torregrosa A, Martí-bonmatí L. Critical review of HCC imaging in the multidisciplinary setting: treatment allocation and evaluation of response. Abdom Radiol 2020;45:3119-28. [DOI: 10.1007/s00261-020-02470-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
408 Pinato DJ, Kaseb A, Wang Y, Saeed A, Szafron D, Jun T, Dharmapuri S, Naqash AR, Muzaffar M, Navaid M, Khan U, Lee C, Bulumulle A, Yu B, Paul S, Fessas P, Nimkar N, Bettinger D, Hildebrand H, Pressiani T, Abugabal YI, Personeni N, Huang YH, Lozano-Kuehne J, Rimassa L, Ang C, Marron TU. Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. J Immunother Cancer 2020;8:e000726. [PMID: 33028690 DOI: 10.1136/jitc-2020-000726] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
409 Degrauwe N, Hocquelet A, Digklia A, Schaefer N, Denys A, Duran R. Theranostics in Interventional Oncology: Versatile Carriers for Diagnosis and Targeted Image-Guided Minimally Invasive Procedures. Front Pharmacol 2019;10:450. [PMID: 31143114 DOI: 10.3389/fphar.2019.00450] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
410 Liang LY, Wong GL. Unmet need in chronic hepatitis B management. Clin Mol Hepatol 2019;25:172-80. [PMID: 30754963 DOI: 10.3350/cmh.2018.0106] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 15.0] [Reference Citation Analysis]
411 Roth GS, Benhamou M, Teyssier Y, Seigneurin A, Abousalihac M, Sengel C, Seror O, Ghelfi J, Ganne-Carrié N, Blaise L, Sutter O, Decaens T, Nault JC. Comparison of Trans-Arterial Chemoembolization and Bland Embolization for the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis. Cancers (Basel) 2021;13:812. [PMID: 33672012 DOI: 10.3390/cancers13040812] [Reference Citation Analysis]
412 Yang T, Hu LY, Li ZL, Liu K, Wu H, Xing H, Lau WY, Pawlik TM, Zeng YY, Zhou YH, Gu WM, Wang H, Chen TH, Han J, Li C, Wang MD, Wu MC, Shen F. Liver Resection for Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: a Multicenter Propensity Matching Analysis with HBV-HCC. J Gastrointest Surg 2020;24:320-9. [PMID: 30617773 DOI: 10.1007/s11605-018-04071-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
413 Geh D, Rana FA, Reeves HL. Weighing the benefits of hepatocellular carcinoma surveillance against potential harms. J Hepatocell Carcinoma 2019;6:23-30. [PMID: 30666302 DOI: 10.2147/JHC.S159581] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
414 Meyers BM, Vogel A, Marotta P, Kavan P, Kamboj L, Pan J, Geadah M, Trueman D, Sabapathy S. The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian Perspective. Can J Gastroenterol Hepatol 2021;2021:8811018. [PMID: 33681090 DOI: 10.1155/2021/8811018] [Reference Citation Analysis]
415 Shi F, Wang C, Kong Y, Yang L, Li J, Zhu G, Guo J, Zheng Q, Zhang B, Wang S. Assessing the Survival Benefit of Surgery and Various Types of Radiation Therapy for Treatment of Hepatocellular Carcinoma: Evidence from the Surveillance, Epidemiology, and End Results Registries. J Hepatocell Carcinoma 2020;7:201-18. [PMID: 33117754 DOI: 10.2147/JHC.S272813] [Reference Citation Analysis]
416 Rhee H, Kim H, Park YN. Clinico-Radio-Pathological and Molecular Features of Hepatocellular Carcinomas with Keratin 19 Expression. Liver Cancer 2020;9:663-81. [PMID: 33442539 DOI: 10.1159/000510522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
417 Kaneko S, Kurosaki M, Inada K, Kirino S, Hayakawa Y, Yamashita K, Osawa L, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Itakura J, Takahashi Y, Tsuchiya K, Nakanishi H, Izumi N. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroenterol Hepatol 2021. [PMID: 34057248 DOI: 10.1111/jgh.15563] [Reference Citation Analysis]
418 Lee S, Kim SH, Hwang JA, Lee JE, Ha SY. Pre-operative ADC predicts early recurrence of HCC after curative resection. Eur Radiol 2019;29:1003-12. [DOI: 10.1007/s00330-018-5642-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
419 Chu HH, Chun SY, Kim JH, Kim PH, Il Gwon D, Ko HK, Kim N. A prediction model for overall survival after transarterial chemoembolization for hepatocellular carcinoma invading the hepatic vein or inferior vena cava. Eur Radiol 2021;31:4232-42. [PMID: 33241523 DOI: 10.1007/s00330-020-07536-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
420 Christian-Miller N, Frenette C. Hepatocellular cancer pain: impact and management challenges. J Hepatocell Carcinoma 2018;5:75-80. [PMID: 30050880 DOI: 10.2147/JHC.S145450] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
421 Ferrer-Fàbrega J, Forner A. Is downstaging a reliable strategy for expanding criteria for liver transplantation in hepatocellular carcinoma? Lancet Oncol 2020;21:867-9. [PMID: 32615100 DOI: 10.1016/S1470-2045(20)30333-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
422 Saad H, Zahran MA, Hendy O, Abdel-Samiee M, Bedair HM, Abdelsameea E. Matrix Metalloproteinase-11 Gene Polymorphisms as a Risk for Hepatocellular Carcinoma Development in Egyptian Patients. Asian Pac J Cancer Prev 2020;21:3725-34. [PMID: 33369474 DOI: 10.31557/APJCP.2020.21.12.3725] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
423 Huo YR, Chan MV, Chan C. Resection Plus Post-operative Adjuvant Transcatheter Arterial Chemoembolization (TACE) Compared with Resection Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Cardiovasc Intervent Radiol 2020;43:572-86. [PMID: 31897617 DOI: 10.1007/s00270-019-02392-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
424 Bai Y, Lian Y, Chen X, Wu J, Lai J, Qiu F, Zhou S, Zhu Z, Tian Y, Wang Y, Yang Y, Yan M. Immunohistochemical Signature Add Prognostic Value in Patients With Early and Intermediate Hepatocellular Carcinoma Underwent Curative Liver Resection. Front Oncol 2020;10:616263. [PMID: 33585243 DOI: 10.3389/fonc.2020.616263] [Reference Citation Analysis]
425 Nahon P, Aubé C, Moga L, Chalaye J, Guiu B, Luciani A, Rode A, Ronot M, Seror O, Soussan M, Sutter O, Bourlière M, Bureau C, de Lédinghen V, Ganne-Carrié N. NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF PRIMARY MALIGNANT LIVER TUMOURS. Clin Res Hepatol Gastroenterol 2021;:101766. [PMID: 34332137 DOI: 10.1016/j.clinre.2021.101766] [Reference Citation Analysis]
426 Kamimura K, Yokoo T, Abe H, Sakai N, Nagoya T, Kobayashi Y, Ohtsuka M, Miura H, Sakamaki A, Kamimura H, Miyamura N, Nishina H, Terai S. Effect of Diphtheria Toxin-Based Gene Therapy for Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E472. [PMID: 32085552 DOI: 10.3390/cancers12020472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
427 Kietzmann T. Liver Zonation in Health and Disease: Hypoxia and Hypoxia-Inducible Transcription Factors as Concert Masters. Int J Mol Sci 2019;20:E2347. [PMID: 31083568 DOI: 10.3390/ijms20092347] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
428 Liu L, Zhang Q, Geng J, Li S, Zhao S, Zhang X, Hu J, Feng D. Comparison of radiofrequency ablation combined with sorafenib or sorafenib alone in patients with ECOG performance score 1: identifying optimal candidates. Ann Transl Med 2020;8:583. [PMID: 32566610 DOI: 10.21037/atm.2020.03.71] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
429 Celsa C, Cabibbo G, Enea M, Battaglia S, Rizzo GEM, Busacca A, Giuffrida P, Stornello C, Brancatelli G, Cannella R, Gruttadauria S, Cammà C. Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization? Liver Int 2021;41:1105-16. [PMID: 33587814 DOI: 10.1111/liv.14822] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
430 Huang F, Gao J. Modified Child-Pugh grade vs albumin-bilirubin grade for predicting prognosis of hepatocellular carcinoma patients after hepatectomy. World J Gastroenterol 2020; 26(7): 749-758 [PMID: 32116422 DOI: 10.3748/wjg.v26.i7.749] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
431 Choi JW, Lee JM, Lee DH, Yoon JH, Kim YJ, Lee JH, Yu SJ, Cho EJ. Radiofrequency ablation using internally cooled wet electrodes in bipolar mode for the treatment of recurrent hepatocellular carcinoma after locoregional treatment: A randomized prospective comparative study. PLoS One 2020;15:e0239733. [PMID: 32986758 DOI: 10.1371/journal.pone.0239733] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
432 Lee HW, Lee HW, Lee JS, Roh YH, Lee H, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B. J Hepatocell Carcinoma 2021;8:467-76. [PMID: 34079776 DOI: 10.2147/JHC.S300382] [Reference Citation Analysis]
433 Jun T, Ozbek U, Dharmapuri S, Hardy-Abeloos C, Zhu H, Lin JY, Personeni N, Pressiani T, Nishida N, Lee PC, Lee CJ, Hildebrand H, Nimkar N, Paul S, Fessas P, Naeem M, Bettinger D, Khan U, Saeed A, Huang YH, Kudo M, Rimassa L, Marron TU, Pinato DJ, Ang C. Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma. Ther Adv Med Oncol 2021;13:17588359211010937. [PMID: 33995594 DOI: 10.1177/17588359211010937] [Reference Citation Analysis]
434 Pomyen Y, Budhu A, Chaisaingmongkol J, Forgues M, Dang H, Ruchirawat M, Mahidol C, Wang XW; TIGER-LC Consortium. Tumor metabolism and associated serum metabolites define prognostic subtypes of Asian hepatocellular carcinoma. Sci Rep 2021;11:12097. [PMID: 34103600 DOI: 10.1038/s41598-021-91560-1] [Reference Citation Analysis]
435 Chen YX, Zhuang Y, Yang P, Fan J, Zhou J, Hu Y, Zhu WC, Sun J, Zeng ZC. Helical IMRT-Based Stereotactic Body Radiation Therapy Using an Abdominal Compression Technique and Modified Fractionation Regimen for Small Hepatocellular Carcinoma. Technol Cancer Res Treat 2020;19:1533033820937002. [PMID: 32613904 DOI: 10.1177/1533033820937002] [Reference Citation Analysis]
436 de la Torre-aláez M, Jordán-iborra C, Casadei-gardini A, Bilbao JI, Rodriguez-fraile M, Sancho L, D’avola D, Herrero JI, Iñarrairaegui M, Sangro B. The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT. Cardiovasc Intervent Radiol 2020;43:1165-72. [DOI: 10.1007/s00270-020-02444-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
437 Yoo J, Lee MW, Lee DH, Lee JH, Han JK. Evaluation of a serum tumour marker-based recurrence prediction model after radiofrequency ablation for hepatocellular carcinoma. Liver Int 2020;40:1189-200. [PMID: 32056353 DOI: 10.1111/liv.14406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
438 Lokau J, Schoeder V, Haybaeck J, Garbers C. Jak-Stat Signaling Induced by Interleukin-6 Family Cytokines in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1704. [PMID: 31683891 DOI: 10.3390/cancers11111704] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
439 Li X, Zhu X, Cai H, Li Y, Zhou J, Fan J, Tang Z, Sun H. Postoperative α-fetoprotein response predicts tumor recurrence and survival after hepatectomy for hepatocellular carcinoma: A propensity score matching analysis. Surgery 2019;165:1161-7. [DOI: 10.1016/j.surg.2019.01.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
440 Kumada T, Toyoda H, Yasuda S, Sone Y, Ogawa S, Takeshima K, Tada T, Ito T, Sumida Y, Tanaka J. Prediction of Hepatocellular Carcinoma by Liver Stiffness Measurements Using Magnetic Resonance Elastography After Eradicating Hepatitis C Virus. Clin Transl Gastroenterol 2021;12:e00337. [PMID: 33888672 DOI: 10.14309/ctg.0000000000000337] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
441 Hu Y, Qin T, Li S, Zhang T, Xue J. Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: Study Protocol of a Randomized Controlled Trial. Front Oncol. 2020;10:1589. [PMID: 32984021 DOI: 10.3389/fonc.2020.01589] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
442 Tietze L, Kessler SM. The Good, the Bad, the Question-H19 in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1261. [PMID: 32429417 DOI: 10.3390/cancers12051261] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
443 Vitale A, Farinati F, Pawlik TM, Frigo AC, Giannini EG, Napoli L, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Colecchia A, Bernardi M, Trevisani F, Cillo U. The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. Liver Int 2019;39:1478-89. [PMID: 31131974 DOI: 10.1111/liv.14154] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
444 Shi Q, Li T, Huang S, Bai Y, Wang Y, Liu J, Zhou C, Chen Y, Xiong B. Transcatheter Arterial Embolization Containing Donafenib Induces Anti-Angiogenesis and Tumoricidal CD8+ T-Cell Infiltration in Rabbit VX2 Liver Tumor. Cancer Manag Res 2021;13:6943-52. [PMID: 34522137 DOI: 10.2147/CMAR.S328294] [Reference Citation Analysis]
445 Karbeyaz F, Kissling S, Jaklin PJ, Bachofner J, Brunner B, Müllhaupt B, Winder T, Mertens JC, Misselwitz B, von Felten S, Siebenhüner AR. Rates of Hepatocellular Carcinoma After Start of Treatment for Chronic Hepatitis C Remain High with Direct Acting Antivirals: Analysis from a Swiss Liver Transplant Center. J Hepatocell Carcinoma 2021;8:565-74. [PMID: 34150679 DOI: 10.2147/JHC.S289955] [Reference Citation Analysis]
446 Bae JS, Lee JM, Jeon SK, Jang S. Comparison of MicroFlow Imaging with color and power Doppler imaging for detecting and characterizing blood flow signals in hepatocellular carcinoma.Ultrasonography. 2020;39:85-93. [PMID: 31759383 DOI: 10.14366/usg.19033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
447 Zhuang L, Mou HB, Yu LF, Zhu HK, Yang Z, Liao Q, Zheng SS. Immune checkpoint inhibitor for hepatocellular carcinoma recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 2020;19:91-3. [PMID: 31706859 DOI: 10.1016/j.hbpd.2019.09.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
448 Wang JH, Li WF, Yong CC, Liu YW, Lu SN, Wang CC. Liver stiffness and insulin resistance in predicting recurrence for early stage hepatoma patients after curative resection. Sci Rep 2021;11:6041. [PMID: 33723365 DOI: 10.1038/s41598-021-85431-y] [Reference Citation Analysis]
449 Zhang Z, Zhang Y, Mo W. The Autophagy Related Gene CHAF1B Is a Relevant Prognostic and Diagnostic Biomarker in Hepatocellular Carcinoma. Front Oncol 2020;10:626175. [PMID: 33575221 DOI: 10.3389/fonc.2020.626175] [Reference Citation Analysis]
450 Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau GY, Mazzaferro V, Roayaie S, Lee HC, Kokudo N, Zhang Z, Torrecilla S, Moeini A, Rodriguez-Carunchio L, Gane E, Verslype C, Croitoru AE, Cillo U, de la Mata M, Lupo L, Strasser S, Park JW, Camps J, Solé M, Thung SN, Villanueva A, Pena C, Meinhardt G, Bruix J, Llovet JM. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut 2019;68:1065-75. [PMID: 30108162 DOI: 10.1136/gutjnl-2018-316408] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 24.7] [Reference Citation Analysis]
451 Su Y, You Y, Zeng Q, Tan L, Ye H, Liu J, Zheng R, Li K. Transcholecystic Contrast-Enhanced Ultrasound-Guided Percutaneous Transhepatic Biliary Drainage for Central Bile Duct Protection During Thermal Tumor Ablation. J Vasc Interv Radiol 2020;31:1587-91. [PMID: 32951970 DOI: 10.1016/j.jvir.2020.05.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
452 Han S, Lee HW, Park JY, Kim SU, Kim DY, Ahn SH, Han KH, Seong J, Won JY, Han DH, Kim BK. Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion. J Hepatocell Carcinoma 2020;7:403-12. [PMID: 33365287 DOI: 10.2147/JHC.S276528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
453 Bannaga AS, Alvarez R, Zhou L, Petchey M, Noufaily A, Hitchins MP, Arasaradnam RP. Role of methylated septin 9 as an adjunct diagnostic and prognostic biomarker in hepatocellular carcinoma. HPB (Oxford) 2021:S1365-182X(21)00097-6. [PMID: 33931320 DOI: 10.1016/j.hpb.2021.03.015] [Reference Citation Analysis]
454 Duda DG, Dima SO, Cucu D, Sorop A, Klein S, Ancukiewicz M, Kitahara S, Iacob S, Bacalbasa N, Tomescu D, Herlea V, Tanase C, Croitoru A, Popescu I. Potential Circulating Biomarkers of Recurrence after Hepatic Resection or Liver Transplantation in Hepatocellular Carcinoma Patients. Cancers (Basel) 2020;12:E1275. [PMID: 32443546 DOI: 10.3390/cancers12051275] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
455 Byun J, Choi SH, Byun JH, Lee SJ, Kim SY, Won HJ, Shin YM, Kim PN. Comparison of the diagnostic performance of imaging criteria for HCCs ≤ 3.0 cm on gadoxetate disodium-enhanced MRI. Hepatol Int 2020;14:534-43. [PMID: 32314171 DOI: 10.1007/s12072-020-10040-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
456 Bouda D, Barrau V, Raynaud L, Dioguardi Burgio M, Paulatto L, Roche V, Sibert A, Moussa N, Vilgrain V, Ronot M. Factors Associated with Tumor Progression After Percutaneous Ablation of Hepatocellular Carcinoma: Comparison Between Monopolar Radiofrequency and Microwaves. Results of a Propensity Score Matching Analysis. Cardiovasc Intervent Radiol 2020;43:1608-18. [PMID: 32533309 DOI: 10.1007/s00270-020-02549-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
457 Peisen F, Maurer M, Grosse U, Nikolaou K, Syha R, Ketelsen D, Artzner C, Bitzer M, Horger M, Grözinger G. Predictive performance of the mHAP-II score in a real-life western cohort with hepatocellular carcinoma following trans-arterial chemoembolisation with drug-eluting beads (DEB-TACE). Eur Radiol 2020;30:3782-92. [PMID: 32125515 DOI: 10.1007/s00330-020-06734-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
458 Farid K, Elalfy H, Abo El-Khair SM, Elgamal H, Besheer T, Elmokadem A, Shabana W, Abed S, Elegezy M, El-Khalek AA, El-Morsy A, Negm A, Elsamanoudy AZ, El Deek B, Amer T, El-Bendary M. Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients. Expert Rev Gastroenterol Hepatol 2020;14:1203-14. [PMID: 32933325 DOI: 10.1080/17474124.2020.1823215] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
459 Grumme J, Werncke T, Meine TC, Becker LS, Kloeckner R, Maschke SK, Kirstein MM, Vogel A, Wacker FK, Meyer BC, Hinrichs JB, Rodt T. Transarterial chemoembolization for hepatocellular carcinoma: quality of life, tumour response, safety and survival comparing two types of drug-eluting beads. Abdom Radiol (NY). 2019;. [PMID: 31781900 DOI: 10.1007/s00261-019-02349-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
460 Zhen Z, Shen Z, Hu Y, Sun P. Screening and identification of angiogenesis-related genes as potential novel prognostic biomarkers of hepatocellular carcinoma through bioinformatics analysis. Aging (Albany NY) 2021;13:17707-33. [PMID: 34252885 DOI: 10.18632/aging.203260] [Reference Citation Analysis]
461 von Felden J, Craig AJ, Villanueva A. The Impact of Translational Research in Hepatology. Clin Liver Dis (Hoboken) 2019;13:29-33. [PMID: 31168363 DOI: 10.1002/cld.805] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
462 Kim TH, Kim SY, Tang A, Lee JM. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin Mol Hepatol 2019;25:245-63. [PMID: 30759967 DOI: 10.3350/cmh.2018.0090] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 41.0] [Reference Citation Analysis]
463 Johnson PJ, Dhanaraj S, Berhane S, Bonnett L, Ma YT. The prognostic and diagnostic significance of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: a prospective controlled study. Br J Cancer 2021;125:714-6. [PMID: 34127809 DOI: 10.1038/s41416-021-01445-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
464 Ettorre GM, Laurenzi A. Other “Bridge” Therapies for Liver Transplantation: RFA, TACE, and TARE. In: Cillo U, De Carlis L, editors. Liver Transplantation and Hepatobiliary Surgery. Cham: Springer International Publishing; 2020. pp. 183-91. [DOI: 10.1007/978-3-030-19762-9_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
465 Rekik S, Allaire M, Mumana A, Guyot E, Nkontchou G, Grando V, Blaise L, Ziol M, Nahon P, Ganne‐carrié N, Sutter O, Seror O, Nault J. Transient elastography predicts survival after radiofrequency ablation of hepatocellular carcinoma developing on cirrhosis. Journal of Gastroenterology and Hepatology 2019;35:142-50. [DOI: 10.1111/jgh.14763] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
466 Luo L, He X, Li K, Long Y, Zeng Q, Tan L, Zheng R, Xu E. Thermal ablation of medium-sized hepatocellular carcinomas using intraoperative ultrasound fusion imaging: A propensity score-matched analysis. Clin Res Hepatol Gastroenterol 2021;45:101581. [PMID: 33761441 DOI: 10.1016/j.clinre.2020.11.011] [Reference Citation Analysis]
467 Mak LY, Seto WK, Hui RW, Fung J, Wong DK, Lai CL, Yuen MF. Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval. J Viral Hepat 2019;26:818-27. [PMID: 30895682 DOI: 10.1111/jvh.13095] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
468 Nault JC, Cheng AL, Sangro B, Llovet JM. Milestones in the pathogenesis and management of primary liver cancer. J Hepatol 2020;72:209-14. [PMID: 31954486 DOI: 10.1016/j.jhep.2019.11.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
469 Wang SM, Yang PW, Feng XJ, Zhu YW, Qiu FJ, Hu XD, Zhang SH. Apigenin Inhibits the Growth of Hepatocellular Carcinoma Cells by Affecting the Expression of microRNA Transcriptome. Front Oncol 2021;11:657665. [PMID: 33959508 DOI: 10.3389/fonc.2021.657665] [Reference Citation Analysis]
470 Filgueira NA. Hepatocellular carcinoma recurrence after liver transplantation: Risk factors, screening and clinical presentation. World J Hepatol 2019; 11(3): 261-272 [PMID: 30967904 DOI: 10.4254/wjh.v11.i3.261] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 12.5] [Reference Citation Analysis]
471 Kim TH, Park JW, Kim BH, Oh ES, Youn SH, Moon SH, Kim SS, Woo SM, Koh YH, Lee WJ, Kim DY. Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma. Front Oncol 2020;10:542. [PMID: 32411594 DOI: 10.3389/fonc.2020.00542] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
472 Mandorfer M, Hernández-Gea V, García-Pagán JC, Reiberger T. Noninvasive Diagnostics for Portal Hypertension: A Comprehensive Review. Semin Liver Dis 2020;40:240-55. [PMID: 32557480 DOI: 10.1055/s-0040-1708806] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
473 Cucchetti A, Gramenzi A, Johnson P, Giannini EG, Tovoli F, Rapaccini GL, Marra F, Cabibbo G, Caturelli E, Gasbarrini A, Svegliati-Baroni G, Sacco R, Zoli M, Morisco F, Di Marco M, Mega A, Foschi FG, Biasini E, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Farinati F, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group. Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. Eur J Cancer 2021;158:133-43. [PMID: 34666215 DOI: 10.1016/j.ejca.2021.09.018] [Reference Citation Analysis]
474 Rim CH, Lee HY, Kim JS, Kim H. Radiofrequency ablation and stereotactic body radiotherapy for hepatocellular carcinoma: should they clash or reconcile? Int J Radiat Biol 2021;97:111-9. [PMID: 33253598 DOI: 10.1080/09553002.2021.1857453] [Reference Citation Analysis]
475 Lee HA, Lee YR, Lee YS, Jung YK, Kim JH, An H, Yim HJ, Jeen YT, Yeon JE, Byun KS, Seo YS. Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein improves diagnostic accuracy for hepatocellular carcinoma. World J Gastroenterol 2021; 27(28): 4687-4696 [PMID: 34366629 DOI: 10.3748/wjg.v27.i28.4687] [Reference Citation Analysis]
476 Li S, Liu Y, Bai Y, Chen M, Cheng D, Wu M, Xia J. Ras Homolog Family Member F, Filopodia Associated Promotes Hepatocellular Carcinoma Metastasis by Altering the Metabolic Status of Cancer Cells Through RAB3D. Hepatology 2021;73:2361-79. [PMID: 33205519 DOI: 10.1002/hep.31641] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
477 Venerito M, Pech M, Canbay A, Donghia R, Guerra V, Chatellier G, Pereira H, Gandhi M, Malfertheiner P, Chow PKH, Vilgrain V, Ricke J, Leandro G. NEMESIS: Noninferiority, Individual-Patient Metaanalysis of Selective Internal Radiation Therapy with 90Y Resin Microspheres Versus Sorafenib in Advanced Hepatocellular Carcinoma. J Nucl Med 2020;61:1736-42. [PMID: 32358087 DOI: 10.2967/jnumed.120.242933] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
478 Chagas AL, Fonseca LGD, Coelho FF, Saud LRDC, Abdala E, Andraus W, Fiore L, Moreira AM, Menezes MR, Carnevale FC, Tani CM, Alencar RSSM, D'Albuquerque LAC, Herman P, Carrilho FJ. Management of Hepatocellular Carcinoma during the COVID-19 Pandemic - São Paulo Clínicas Liver Cancer Group Multidisciplinary Consensus Statement. Clinics (Sao Paulo) 2020;75:e2192. [PMID: 33146360 DOI: 10.6061/clinics/2020/e2192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
479 Yao S, Ye Z, Wei Y, Jiang HY, Song B. Radiomics in hepatocellular carcinoma: A state-of-the-art review. World J Gastrointest Oncol 2021; 13(11): 1599-1615 [DOI: 10.4251/wjgo.v13.i11.1599] [Reference Citation Analysis]
480 Wade R, Sharif-Hurst S, Harden M, Walton M, Claxton L, Hodgson R, Eastwood A. Methods for selecting the best evidence to inform a NICE technology appraisal on selective internal radiation therapies for hepatocellular carcinoma. Syst Rev 2020;9:184. [PMID: 32799923 DOI: 10.1186/s13643-020-01447-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
481 Ando Y, Kawaoka T, Kosaka M, Shirane Y, Johira Y, Miura R, Murakami S, Yano S, Amioka K, Naruto K, Kosaka Y, Uchikawa S, Kodama K, Fujino H, Nakahara T, Ono A, Murakami E, Yamauchi M, Okamoto W, Takahashi S, Imamura M, Chayama K, Aikata H. Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice. Cancers (Basel) 2021;13:3958. [PMID: 34439111 DOI: 10.3390/cancers13163958] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
482 Singal AG, Chen Y, Sridhar S, Mittal V, Fullington H, Shaik M, Waljee AK, Tiro J. Novel Application of Predictive Modeling: A Tailored Approach to Promoting HCC Surveillance in Patients With Cirrhosis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00217-2. [PMID: 33662594 DOI: 10.1016/j.cgh.2021.02.038] [Reference Citation Analysis]
483 Mattos ÂZ, Debes JD, Boonstra A, Vogel A, Mattos AA. Immune aspects of hepatocellular carcinoma: From immune markers for early detection to immunotherapy. World J Gastrointest Oncol 2021; 13(9): 1132-1143 [PMID: 34616518 DOI: 10.4251/wjgo.v13.i9.1132] [Reference Citation Analysis]
484 Invenizzi F, Iavarone M, Donato MF, Mazzucco A, Torre M, Conforti S, Rimessi A, Zavaglia C, Schiavon M, Comacchio G, Rea F, Boetto R, Cillo U, Dondossola D, De Carlis L, Lampertico P, Nosotti M, Mendogni P. Pulmonary Resection for Metastasis of Hepatocellular Carcinoma Recurring After Liver Transplant: An Italian Multicenter Experience. Front Oncol. 2020;10:381. [PMID: 32351877 DOI: 10.3389/fonc.2020.00381] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
485 Chan TT, Chan WK, Wong GL, Chan AW, Nik Mustapha NR, Chan SL, Chong CC, Mahadeva S, Shu SS, Lai PB, Chan HL, Wong VW. Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2020;115:867-875. [PMID: 32149781 DOI: 10.14309/ajg.0000000000000588] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
486 Hassan I, Gane E. Improving survival in patients with hepatocellular carcinoma related to chronic hepatitis C and B but not in those related to non-alcoholic steatohepatitis or alcoholic liver disease: a 20-year experience from a national programme. Intern Med J 2019;49:1405-11. [PMID: 30908822 DOI: 10.1111/imj.14304] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
487 Mamdouh F, Abdel Alem S, Abdo M, Abdelaal A, Salem A, Rabiee A, Elsisi O. Serum Serotonin as a Potential Diagnostic Marker for Hepatocellular Carcinoma. J Interferon Cytokine Res 2019;39:780-5. [PMID: 31478787 DOI: 10.1089/jir.2019.0088] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
488 Li M, Liang M, Lan T, Wu X, Xie W, Wang T, Chen Z, Shen S, Peng B. Four Immune-Related Long Non-coding RNAs for Prognosis Prediction in Patients With Hepatocellular Carcinoma. Front Mol Biosci 2020;7:566491. [PMID: 33364253 DOI: 10.3389/fmolb.2020.566491] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
489 Ruiz-Margáin A, Román-Calleja BM, Moreno-Guillén P, González-Regueiro JA, Kúsulas-Delint D, Campos-Murguía A, Flores-García NC, Macías-Rodríguez RU. Nutritional therapy for hepatocellular carcinoma. World J Gastrointest Oncol 2021; 13(10): 1440-1452 [PMID: 34721776 DOI: 10.4251/wjgo.v13.i10.1440] [Reference Citation Analysis]
490 Craig AJ, Garcia-Lezana T, Ruiz de Galarreta M, Villacorta-Martin C, Kozlova EG, Martins-Filho SN, von Felden J, Ahsen ME, Bresnahan E, Hernandez-Meza G, Labgaa I, D'Avola D, Schwartz M, Llovet JM, Sia D, Thung S, Losic B, Lujambio A, Villanueva A. Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma. PLoS Genet 2021;17:e1009589. [PMID: 34166362 DOI: 10.1371/journal.pgen.1009589] [Reference Citation Analysis]
491 Abdallah MA, Wongjarupong N, Hassan MA, Taha W, Abdalla A, Bampoh S, Onyirioha K, Nelson M, Glubranson LA, Wiseman GA, Fleming CJ, Andrews JC, Mahipal A, Roberts LR. The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study. Expert Rev Gastroenterol Hepatol 2020;14:619-29. [PMID: 32490691 DOI: 10.1080/17474124.2020.1777856] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
492 Nürnberg M, Arastéh K, Stocker H. [Early detection of gastrointestinal cancer in people living with HIV]. MMW Fortschr Med 2020;162:37-9. [PMID: 32583250 DOI: 10.1007/s15006-020-0644-z] [Reference Citation Analysis]
493 Hagström H, Kechagias S, Ekstedt M. Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease. J Intern Med 2021. [PMID: 34118091 DOI: 10.1111/joim.13343] [Reference Citation Analysis]
494 Sposito C, Spreafico C, Mazzaferro V. Reply to: "Validation of response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion". J Hepatol 2018;69:260-1. [PMID: 29705239 DOI: 10.1016/j.jhep.2018.04.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
495 Liu HY, Lee YD, Sridharan S, Choong ES, Le H, Wang W, Khor R, Chu J, Oar A, Mott R, Smart J, Jenkins T, Anderson N, Cross S, Loo KF, Wigg A, Stuart K, Pryor D. Stereotactic body radiotherapy in the management of hepatocellular carcinoma: An Australian multi-institutional patterns of practice review. J Med Imaging Radiat Oncol 2021;65:365-73. [PMID: 33890425 DOI: 10.1111/1754-9485.13184] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
496 Labgaa I, Demartines N, Melloul E. Surgical Resection Versus Transarterial Chemoembolization for Intermediate Stage Hepatocellular Carcinoma (BCLC-B): An Unsolved Question. Hepatology 2019;69:923. [PMID: 30382593 DOI: 10.1002/hep.30338] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
497 Roderburg C, Özdirik B, Wree A, Demir M, Tacke F. Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies. Hepat Oncol 2020;7:HEP20. [PMID: 32647565 DOI: 10.2217/hep-2020-0004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
498 Kaibori M, Matsushima H, Ishizaki M, Kosaka H, Matsui K, Kariya S, Yoshii K, Sekimoto M. The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2021;22:1217-24. [PMID: 33906315 DOI: 10.31557/APJCP.2021.22.4.1217] [Reference Citation Analysis]
499 Zhang F, Dvornek N, Yang J, Chapiro J, Duncan J. Layer Embedding Analysis in Convolutional Neural Networks for Improved Probability Calibration and Classification. IEEE Trans Med Imaging 2020;39:3331-42. [PMID: 32356739 DOI: 10.1109/TMI.2020.2990625] [Reference Citation Analysis]
500 Moeckli B, Ivanics T, Claasen M, Toso C, Sapisochin G. Recent developments and ongoing trials in transplant oncology. Liver Int 2020;40:2326-44. [PMID: 33021344 DOI: 10.1111/liv.14621] [Reference Citation Analysis]
501 Cardarelli-Leite L, Hadjivassiliou A, Klass D, Chung J, Ho SGF, Lim HJ, Kim PTW, Mujoomdar A, Liu DM. Current locoregional therapies and treatment strategies in hepatocellular carcinoma. Curr Oncol 2020;27:S144-51. [PMID: 33343208 DOI: 10.3747/co.27.7171] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
502 Kesler M, Levine C, Hershkovitz D, Mishani E, Menachem Y, Lerman H, Zohar Y, Shibolet O, Even-Sapir E. 68Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: A prospective pilot study. J Nucl Med. 2019;60:185-191. [PMID: 30002112 DOI: 10.2967/jnumed.118.214833] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 11.7] [Reference Citation Analysis]
503 Deeks ED. Cabozantinib: A Review in Advanced Hepatocellular Carcinoma. Target Oncol 2019;14:107-13. [PMID: 30767164 DOI: 10.1007/s11523-019-00622-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
504 Moris D, Shaw BI, Ong C, Connor A, Samoylova ML, Kesseli SJ, Abraham N, Gloria J, Schmitz R, Fitch ZW, Clary BM, Barbas AS. A simple scoring system to estimate perioperative mortality following liver resection for primary liver malignancy-the Hepatectomy Risk Score (HeRS). Hepatobiliary Surg Nutr 2021;10:315-24. [PMID: 34159159 DOI: 10.21037/hbsn.2020.03.12] [Reference Citation Analysis]
505 Kuroda H, Nagasawa T, Fujiwara Y, Sato H, Abe T, Kooka Y, Endo K, Oikawa T, Sawara K, Takikawa Y. Comparing the Safety and Efficacy of Microwave Ablation Using ThermosphereTM Technology versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. Cancers (Basel) 2021;13:1295. [PMID: 33803926 DOI: 10.3390/cancers13061295] [Reference Citation Analysis]
506 Mai RY, Wang YY, Bai T, Chen J, Xiang BD, Wu GB, Wu FX, Li LQ, Ye JZ. Combination Of ALBI And APRI To Predict Post-Hepatectomy Liver Failure After Liver Resection For HBV-Related HCC Patients. Cancer Manag Res. 2019;11:8799-8806. [PMID: 31632139 DOI: 10.2147/cmar.s213432] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
507 Ioannou GN, Beste LA, Green PK, Singal AG, Tapper EB, Waljee AK, Sterling RK, Feld JJ, Kaplan DE, Taddei TH, Berry K. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. Gastroenterology. 2019;157:1264-1278.e4. [PMID: 31356807 DOI: 10.1053/j.gastro.2019.07.033] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 47.5] [Reference Citation Analysis]
508 De Re V, Tornesello ML, De Zorzi M, Caggiari L, Pezzuto F, Leone P, Racanelli V, Lauletta G, Zanussi S, Repetto O, Gragnani L, Rossi FM, Dolcetti R, Zignego AL, Buonaguro FM, Steffan A. PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases. Liver Int 2021;41:133-49. [PMID: 32937024 DOI: 10.1111/liv.14667] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
509 Ahmed F, Onwumeh-Okwundu J, Yukselen Z, Endaya Coronel MK, Zaidi M, Guntipalli P, Garimella V, Gudapati S, Mezidor MD, Andrews K, Mouchli M, Shahini E. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review. World J Gastrointest Oncol 2021; 13(11): 1813-1832 [DOI: 10.4251/wjgo.v13.i11.1813] [Reference Citation Analysis]
510 Liu T, Shao Y, Lu L, Shen Y, Hsu C, Lin Z, Hsu C, Cheng A. Considerations of heterogeneity in clinical trials for hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2019;13:615-21. [DOI: 10.1080/17474124.2019.1621165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
511 Lu SD, Li L, Liang XM, Chen W, Chen FL, Fan LL, Ahir BK, Zhang WG, Zhong JH. Updates and advancements in the management of hepatocellular carcinoma patients after hepatectomy. Expert Rev Gastroenterol Hepatol 2019;13:1077-88. [PMID: 31648568 DOI: 10.1080/17474124.2019.1684898] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
512 Costentin CE, Nahon P. HCC risk prediction using biomarkers in non-cirrhotic patients following HCV eradication: Reassuring the patient or the doctor? JHEP Rep 2021;3:100320. [PMID: 34308325 DOI: 10.1016/j.jhepr.2021.100320] [Reference Citation Analysis]
513 Papatheodoridis GV, Dalekos GN, Idilman R, Sypsa V, Van Boemmel F, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Loglio A, Papatheodoridi M, Gatselis N, Veelken R, Lopez-Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Yurdaydin C, Esteban R, Janssen HLA, Berg T, Lampertico P. Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. JHEP Rep 2021;3:100290. [PMID: 34041470 DOI: 10.1016/j.jhepr.2021.100290] [Reference Citation Analysis]
514 Schwarze V, Marschner C, Völckers W, Grosu S, Negrão de Figueiredo G, Rübenthaler J, Clevert DA. Diagnostic value of contrast-enhanced ultrasound versus computed tomography for hepatocellular carcinoma: a retrospective, single-center evaluation of 234 patients. J Int Med Res 2020;48:300060520930151. [PMID: 32529869 DOI: 10.1177/0300060520930151] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
515 Troisi RI, Pegoraro F, Giglio MC, Rompianesi G, Berardi G, Tomassini F, De Simone G, Aprea G, Montalti R, De Palma GD. Robotic approach to the liver: Open surgery in a closed abdomen or laparoscopic surgery with technical constraints? Surg Oncol. 2020;33:239-248. [PMID: 31759794 DOI: 10.1016/j.suronc.2019.10.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
516 Lubel JS, Roberts SK, Strasser SI, Thompson AJ, Philip J, Goodwin M, Clarke S, Crawford DH, Levy MT, Shackel N. Australian recommendations for the management of hepatocellular carcinoma: a consensus statement. Med J Aust 2021;214:475-83. [PMID: 33314233 DOI: 10.5694/mja2.50885] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
517 Chen Y, Zeng J, Guo P, Zeng J, Liu J. Prognostic Significance of Platelet-to-Lymphocyte Ratio (PLR) in Extrahepatic Metastasis of Hepatocellular Carcinoma After Curative Resection. Cancer Manag Res 2021;13:1395-405. [PMID: 33603483 DOI: 10.2147/CMAR.S290738] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
518 Cooper GS. Should We Abandon Current Hepatocellular Carcinoma Screening Practices? Gastroenterology 2018;155:972-4. [DOI: 10.1053/j.gastro.2018.09.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
519 Ji GW, Zhu FP, Xu Q, Wang K, Wu MY, Tang WW, Li XC, Wang XH. Machine-learning analysis of contrast-enhanced CT radiomics predicts recurrence of hepatocellular carcinoma after resection: A multi-institutional study. EBioMedicine 2019;50:156-65. [PMID: 31735556 DOI: 10.1016/j.ebiom.2019.10.057] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
520 Ringe KI, Gut A, Grenacher L, Juchems M, Kukuk G, Wessling J, Schreyer AG. LI-RADS in the year 2020 - Are you already using it or still considering? Rofo 2021;193:186-93. [PMID: 32688423 DOI: 10.1055/a-1212-5915] [Reference Citation Analysis]
521 Oh S, Park Y, Lee HJ, Lee J, Lee SH, Baek YS, Chun SK, Lee SM, Kim M, Chon YE, Ha Y, Cho Y, Kim GJ, Hwang SG, Kwack K. A Disintegrin and Metalloproteinase 9 (ADAM9) in Advanced Hepatocellular Carcinoma and Their Role as a Biomarker During Hepatocellular Carcinoma Immunotherapy. Cancers (Basel) 2020;12:E745. [PMID: 32245188 DOI: 10.3390/cancers12030745] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
522 Wang Y, Sun K, Shen J, Li B, Kuang M, Cao Q, Peng S. Novel Prognostic Nomograms Based on Inflammation-Related Markers for Patients with Hepatocellular Carcinoma Underwent Hepatectomy. Cancer Res Treat 2019;51:1464-78. [PMID: 30913869 DOI: 10.4143/crt.2018.657] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
523 Coty JB, Paisant A, Esvan M, Lonjon J, Seror O, Rode A, Ronot M, Lebigot J, Vilgrain V, Aubé C. A proposal for a useful algorithm to diagnose small hepatocellular carcinoma on MRI. Eur J Gastroenterol Hepatol 2020;32:74-9. [PMID: 31211723 DOI: 10.1097/MEG.0000000000001476] [Reference Citation Analysis]
524 Tran NH, Kisiel J, Roberts LR. Using cell-free DNA for HCC surveillance and prognosis. JHEP Rep 2021;3:100304. [PMID: 34136776 DOI: 10.1016/j.jhepr.2021.100304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
525 Sun Y, Wu L, Zhong Y, Zhou K, Hou Y, Wang Z, Zhang Z, Xie J, Wang C, Chen D, Huang Y, Wei X, Shi Y, Zhao Z, Li Y, Guo Z, Yu Q, Xu L, Volpe G, Qiu S, Zhou J, Ward C, Sun H, Yin Y, Xu X, Wang X, Esteban MA, Yang H, Wang J, Dean M, Zhang Y, Liu S, Yang X, Fan J. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell 2021;184:404-421.e16. [PMID: 33357445 DOI: 10.1016/j.cell.2020.11.041] [Cited by in Crossref: 20] [Cited by in F6Publishing: 34] [Article Influence: 20.0] [Reference Citation Analysis]
526 Dahlgren D, Lennernäs H. Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective. Molecules 2020;25:E2861. [PMID: 32575828 DOI: 10.3390/molecules25122861] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
527 Tsilimigras DI, Mehta R, Paredes AZ, Moris D, Sahara K, Bagante F, Ratti F, Marques HP, Silva S, Soubrane O, Lam V, Poultsides GA, Popescu I, Grigorie R, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Spolverato G, Umberto C, Pawlik TM. Overall Tumor Burden Dictates Outcomes for Patients Undergoing Resection of Multinodular Hepatocellular Carcinoma Beyond the Milan Criteria. Ann Surg 2020;272:574-81. [PMID: 32932309 DOI: 10.1097/SLA.0000000000004346] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 10.0] [Reference Citation Analysis]
528 Tsilimigras DI, Moris D, Hyer JM, Bagante F, Sahara K, Moro A, Paredes AZ, Mehta R, Ratti F, Marques HP, Silva S, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Sasaki K, Rodarte AI, Aucejo FN, Pawlik TM. Hepatocellular carcinoma tumour burden score to stratify prognosis after resection. Br J Surg 2020;107:854-64. [PMID: 32057105 DOI: 10.1002/bjs.11464] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 18.0] [Reference Citation Analysis]
529 Liu J, Xie S, Duan X, Chen J, Zhou X, Li Y, Li Z, Han X. Assessment of efficacy and safety of the transcatheter arterial chemoembolization with or without apatinib in the treatment of large hepatocellular carcinoma. Cancer Chemother Pharmacol 2020;85:69-76. [PMID: 31813003 DOI: 10.1007/s00280-019-04004-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
530 Dubbelboer IR, Pavlovic N, Heindryckx F, Sjögren E, Lennernäs H. Liver Cancer Cell Lines Treated with Doxorubicin under Normoxia and Hypoxia: Cell Viability and Oncologic Protein Profile. Cancers (Basel) 2019;11:E1024. [PMID: 31330834 DOI: 10.3390/cancers11071024] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
531 Donadon M, Lopci E, Galvanin J, Giudici S, Del Fabbro D, Lanza E, Pedicini V, Chiti A, Torzilli G. Prognostic Value of Metabolic Imaging Data of 11C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:472. [PMID: 33530520 DOI: 10.3390/cancers13030472] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
532 Shi Q, Chen D, Zhou C, Liu J, Huang S, Yang C, Xiong B. Drug-Eluting Beads versus Lipiodol Transarterial Chemoembolization for the Treatment of Hypovascular Hepatocellular Carcinoma: A Single-Center Retrospective Study. Cancer Manag Res 2020;12:5461-8. [PMID: 32753963 DOI: 10.2147/CMAR.S255960] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
533 Macek-Jilkova Z, Malov SI, Kurma K, Charrat C, Decaens T, Peretolchina NP, Marche PN, Malov IV, Yushchuk ND. Clinical and Experimental Evaluation of Diagnostic Significance of Alpha-Fetoprotein and Osteopontin at the Early Stage of Hepatocellular Cancer. Bull Exp Biol Med 2021;170:340-4. [PMID: 33452981 DOI: 10.1007/s10517-021-05063-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
534 Schellhaas B, Bernatik T, Bohle W, Borowitzka F, Chang J, Dietrich CF, Dirks K, Donoval R, Drube K, Friedrich-Rust M, Gall C, Gittinger F, Gutermann M, Haenle MM, von Herbay A, Ho CH, Hochdoerffer R, Hoffmann T, Hüttig M, Janson C, Jung EM, Jung N, Karlas T, Klinger C, Kornmehl A, Kratzer W, Krug S, Kunze G, Leitlein J, Link A, Lottspeich C, Marano A, Mauch M, Moleda L, Neesse A, Petzold G, Potthoff A, Praktiknjo M, Rösner KD, Schanz S, Schultheiß M, Sivanathan V, Stock J, Thomsen T, Vogelpohl J, Vogt C, Wagner S, Wiegard C, Wiesinger I, Will U, Ziesch M, Zimmermann P, Strobel D. Contrast-Enhanced Ultrasound Algorithms (CEUS-LIRADS/ESCULAP) for the Noninvasive Diagnosis of Hepatocellular Carcinoma - A Prospective Multicenter DEGUM Study. Ultraschall Med 2021;42:178-86. [PMID: 32663881 DOI: 10.1055/a-1198-4874] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
535 Lee SW, Lee TY, Cheng YC, Yen CL, Yang SS. The correlation with tumor radiological characteristics and prognosis of patients with early-stage hepatocellular carcinoma receiving transcatheter arterial chemoembolization. Medicine (Baltimore) 2021;100:e26414. [PMID: 34190159 DOI: 10.1097/MD.0000000000026414] [Reference Citation Analysis]
536 Lupsor-Platon M, Serban T, Silion AI, Tirpe GR, Tirpe A, Florea M. Performance of Ultrasound Techniques and the Potential of Artificial Intelligence in the Evaluation of Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease. Cancers (Basel) 2021;13:790. [PMID: 33672827 DOI: 10.3390/cancers13040790] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
537 Iezzi R, Bilhim T, Crocetti L, Peynircioglu B, Goldberg S, Bilbao JI, Sami A, Akhan O, Scalise P, Giuliante F, Pompili M, Valentini V, Gasbarrini A, Colosimo C, Manfredi R. "Primum Non Nocere" in Interventional Oncology for Liver Cancer: How to Reduce the Risk for Complications? Life (Basel) 2020;10:E180. [PMID: 32899925 DOI: 10.3390/life10090180] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
538 Meloni MF, Francica G, Chiang J, Coltorti A, Danzi R, Laeseke PF. Use of Contrast-Enhanced Ultrasound in Ablation Therapy of HCC: Planning, Guiding, and Assessing Treatment Response. J Ultrasound Med 2021;40:879-94. [PMID: 32936485 DOI: 10.1002/jum.15471] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
539 Sposito C, Monteleone M, Aldrighetti L, Cillo U, Dalla Valle R, Guglielmi A, Ettorre GM, Ferrero A, Di Benedetto F, Rossi GE, De Carlis L, Giuliante F, Mazzaferro V. Preoperative predictors of liver decompensation after mini-invasive liver resection. Surg Endosc 2021;35:718-27. [PMID: 32124061 DOI: 10.1007/s00464-020-07438-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
540 Minici R, Ammendola M, Manti F, Siciliano MA, Minici M, Komaei I, Currò G, Laganà D. Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9. Front Pharmacol 2021;12:634087. [PMID: 33897422 DOI: 10.3389/fphar.2021.634087] [Reference Citation Analysis]
541 Lin CW, Chen YS, Lo GH, Hsu YC, Hsu CC, Wu TC, Yeh JH, Hsiao P, Hsieh PM, Lin HY, Shu CW, Hung CM. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis. BMC Gastroenterol 2020;20:99. [PMID: 32272898 DOI: 10.1186/s12876-020-01235-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
542 Wang H, Lee JC, Cao K, Tang HW, Wang S, Zhang ZY, Wu W, Yan K, Yang W. What is the difference in ablation zone of multi-bipolar radiofrequency ablation between liver cirrhosis and normal liver background? - a prospective clinical study. Int J Hyperthermia 2020;37:1248-59. [PMID: 33164634 DOI: 10.1080/02656736.2020.1838627] [Reference Citation Analysis]
543 Yuan H, Mao J, Liu C, Fu H, Guo W, Ding G. Risk of adverse events in advanced hepatocellular carcinoma with immune checkpoint therapy: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2020;44:845-54. [PMID: 32307332 DOI: 10.1016/j.clinre.2020.02.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
544 Mohan CD, Rangappa S, Nayak SC, Sethi G, Rangappa KS. Paradoxical functions of long noncoding RNAs in modulating STAT3 signaling pathway in hepatocellular carcinoma. Biochim Biophys Acta Rev Cancer 2021;1876:188574. [PMID: 34062154 DOI: 10.1016/j.bbcan.2021.188574] [Reference Citation Analysis]
545 Tan Z, Lu J, Zhu G, Chen L, Wang Y, Zhang Q, Pan T, Wang J, Guo J, Teng G. Portal Vein Irradiation Stent Plus Chemoembolization versus External Radiotherapy Plus Chemoembolization in Hepatocellular Carcinoma with Portal Vein Tumour Thrombus: A Retrospective Study. Cardiovasc Intervent Radiol 2021;44:1414-22. [PMID: 34131776 DOI: 10.1007/s00270-021-02889-z] [Reference Citation Analysis]
546 Nam JY, Choe AR, Sinn DH, Lee JH, Kim HY, Yu SJ, Kim YJ, Yoon JH, Lee JM, Chung JW, Choi SY, Lee JK, Baek SY, Lee HA, Kim TH, Yoo K. A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function. BMC Cancer 2020;20:504. [PMID: 32487089 DOI: 10.1186/s12885-020-06975-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
547 Kang JH, Choi SH, Kim SY, Lee SJ, Shin YM, Won HJ, Kim PN. US LI-RADS visualization score: diagnostic outcome of ultrasound-guided focal hepatic lesion biopsy in patients at risk for hepatocellular carcinoma. Ultrasonography 2021;40:167-75. [PMID: 32623854 DOI: 10.14366/usg.19066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
548 Kim DH, Choi SH, Park SH, Kim KW, Byun JH, Kim SY, Lee SS, Shin YM, Won HJ, Kim P. Meta-analysis of the accuracy of Liver Imaging Reporting and Data System category 4 or 5 for diagnosing hepatocellular carcinoma. Gut 2019;68:1719-21. [DOI: 10.1136/gutjnl-2019-318555] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
549 Roderburg C, Wree A, Demir M, Schmelzle M, Tacke F. The role of the innate immune system in the development and treatment of hepatocellular carcinoma. Hepat Oncol 2020;7:HEP17. [PMID: 32273975 DOI: 10.2217/hep-2019-0007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
550 Dietrich CF, Teufel A, Sirlin CB, Dong Y. Surveillance of hepatocellular carcinoma by medical imaging. Quant Imaging Med Surg 2019;9:1904-10. [PMID: 31867241 DOI: 10.21037/qims.2019.10.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
551 Tsilimigras DI, Mehta R, Merath K, Bagante F, Paredes AZ, Farooq A, Ratti F, Marques HP, Silva S, Soubrane O, Lam V, Poultsides GA, Popescu I, Grigorie R, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Hospital variation in Textbook Outcomes following curative-intent resection of hepatocellular carcinoma: an international multi-institutional analysis. HPB (Oxford). 2020;22:1305-1313. [PMID: 31889626 DOI: 10.1016/j.hpb.2019.12.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
552 Maan R, van der Meer AJ. Hepatocellular carcinoma (HCC) risk stratification after virological cure for hepatitis C virus (HCV)-induced cirrhosis: time to refine predictive models. Hepatobiliary Surg Nutr 2021;10:385-7. [PMID: 34159170 DOI: 10.21037/hbsn-21-95] [Reference Citation Analysis]
553 Yao FY, Fidelman N, Mehta N. The Key Role of Staging Definitions for Assessment of Downstaging for Hepatocellular Carcinoma. Semin Liver Dis 2021;41:117-27. [PMID: 33788207 DOI: 10.1055/s-0040-1716565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
554 Hu K, Yuan J, Tang B, Zhang F, Lu S, Chen R, Zhang L, Ren Z, Yin X. Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment. Ann Transl Med 2021;9:237. [PMID: 33708864 DOI: 10.21037/atm-20-3118] [Reference Citation Analysis]
555 Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW, Yoon JH. Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. Cancer Immunol Immunother. 2019;68:23-32. [PMID: 30232520 DOI: 10.1007/s00262-018-2247-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 10.7] [Reference Citation Analysis]
556 Li Z, Hu Y, Wang H, Wang M, Gu X, Ping Y, Zeng Q, Li H, Yan J, Yu Z. Predictors for the progression of hepatic cirrhosis to hepatocellular carcinoma under long-term antiviral therapy. Eur J Gastroenterol Hepatol 2020;32:447-53. [PMID: 32012142 DOI: 10.1097/MEG.0000000000001631] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
557 Craciun L, de Wind R, Demetter P, Lucidi V, Bohlok A, Michiels S, Bouazza F, Vouche M, Tancredi I, Verset G, Garaud S, Naveaux C, Galdon MG, Gallo KW, Hendlisz A, Derijckere ID, Flamen P, Larsimont D, Donckier V. Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy. BMC Cancer 2020;20:135. [PMID: 32075608 DOI: 10.1186/s12885-020-6613-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
558 Cannella R, Cunha GM, Catania R, Chupetlovska K, Borhani AA, Fowler KJ, Furlan A. Magnetic Resonance Imaging of Nonhepatocellular Malignancies in Chronic Liver Disease. Magn Reson Imaging Clin N Am 2021;29:404-18. [PMID: 34243926 DOI: 10.1016/j.mric.2021.05.009] [Reference Citation Analysis]
559 Lim Y, Ku NO. Revealing the Roles of Keratin 8/18-Associated Signaling Proteins Involved in the Development of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:6401. [PMID: 34203895 DOI: 10.3390/ijms22126401] [Reference Citation Analysis]
560 Purcell Y, Sartoris R, Paradis V, Vilgrain V, Ronot M. Influence of pretreatment tumor growth rate on objective response of hepatocellular carcinoma treated with transarterial chemoembolization. J Gastroenterol Hepatol 2020;35:305-13. [PMID: 31369166 DOI: 10.1111/jgh.14816] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
561 Peschel G, Grimm J, Buechler C, Gunckel M, Pollinger K, Aschenbrenner E, Kammerer S, Jung EM, Haimerl M, Werner J, Müller M, Weigand K. Liver stiffness assessed by shear-wave elastography declines in parallel with immunoregulatory proteins in patients with chronic HCV infection during DAA therapy. Clin Hemorheol Microcirc 2021. [PMID: 34120896 DOI: 10.3233/CH-211193] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
562 Tomita K, Shimazu M, Takano K, Gunji T, Ozawa Y, Sano T, Chiba N, Abe Y, Kawachi S. Resection of recurrent hepatocellular carcinoma with thrombi in the inferior vena cava, right atrium, and phrenic vein: a report of three cases. World J Surg Oncol 2020;18:138. [PMID: 32571339 DOI: 10.1186/s12957-020-01914-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
563 Nodari G, Popoff R, Riedinger JM, Lopez O, Pellegrinelli J, Dygai-Cochet I, Tabouret-Viaud C, Presles B, Chevallier O, Gehin S, Gallet M, Latournerie M, Manfredi S, Loffroy R, Vrigneaud JM, Cochet A. Impact of contouring methods on pre-treatment and post-treatment dosimetry for the prediction of tumor control and survival in HCC patients treated with selective internal radiation therapy. EJNMMI Res 2021;11:24. [PMID: 33687596 DOI: 10.1186/s13550-021-00766-x] [Reference Citation Analysis]
564 Kamal H, Fornes R, Simin J, Stål P, Duberg AS, Brusselaers N, Aleman S. Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: A systematic review and meta-analysis of longitudinal studies. J Viral Hepat 2021. [PMID: 34291520 DOI: 10.1111/jvh.13577] [Reference Citation Analysis]
565 Rimola J, Da Fonseca LG, Sapena V, Perelló C, Guerrero A, Simó MT, Pons M, De La Torre-Aláez M, Márquez L, Calleja JL, Lledó JL, Varela M, Mínguez B, Sangro B, Matilla A, Torres F, Ayuso C, Bruix J, Reig M. Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. Eur J Radiol 2021;135:109484. [PMID: 33383399 DOI: 10.1016/j.ejrad.2020.109484] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
566 Helmberger T, Arnold D, Bilbao JI, de Jong N, Maleux G, Nordlund A, Peynircioglu B, Sangro B, Sharma RA, Walk A. Clinical Application of Radioembolization in Hepatic Malignancies: Protocol for a Prospective Multicenter Observational Study. JMIR Res Protoc 2020;9:e16296. [PMID: 32319960 DOI: 10.2196/16296] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
567 Balaceanu LA. Biomarkers vs imaging in the early detection of hepatocellular carcinoma and prognosis. World J Clin Cases 2019; 7(12): 1367-1382 [PMID: 31363465 DOI: 10.12998/wjcc.v7.i12.1367] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
568 Granito A, Muratori L, Lalanne C, Quarneti C, Ferri S, Guidi M, Lenzi M, Muratori P. Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World J Gastroenterol 2021; 27(22): 2994-3009 [PMID: 34168403 DOI: 10.3748/wjg.v27.i22.2994] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 8] [Article Influence: 15.0] [Reference Citation Analysis]
569 Shi XB, Feng JK, Wang JH, Jiang XQ. Does splenectomy significantly improve the prognosis of hepatocellular carcinoma patients with hypersplenism? A systematic review and meta-analysis. Ann Transl Med 2021;9:641. [PMID: 33987339 DOI: 10.21037/atm-20-6748] [Reference Citation Analysis]
570 Gatti M, Calandri M, Bergamasco L, Darvizeh F, Grazioli L, Inchingolo R, Ippolito D, Rousset S, Veltri A, Fonio P, Faletti R. Characterization of the arterial enhancement pattern of focal liver lesions by multiple arterial phase magnetic resonance imaging: comparison between hepatocellular carcinoma and focal nodular hyperplasia. Radiol Med 2020;125:348-55. [PMID: 31916102 DOI: 10.1007/s11547-019-01127-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
571 Kubota N, Fujiwara N, Hoshida Y. Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk. J Clin Med 2020;9:E3843. [PMID: 33256232 DOI: 10.3390/jcm9123843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
572 Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Ohgi K, Ohtsuka S, Aramaki T, Uesaka K. Changes in patient background and prognosis after hepatectomy for hepatocellular carcinoma by hepatitis virus infection status: New trends in Japan. Ann Gastroenterol Surg 2021;5:553-66. [PMID: 34337304 DOI: 10.1002/ags3.12451] [Reference Citation Analysis]
573 Saborowski A, Vogel A. [Immuno-oncology : No longer a need for interventional radiology?]. Radiologe 2020;60:687-92. [PMID: 32671491 DOI: 10.1007/s00117-020-00722-1] [Reference Citation Analysis]
574 Yu SCH, Hui JWY, Chong CCN, Chu CM, Cheung S, Wong J, Lee KF. Transarterial Ethanol Ablation for Small Hepatocellular Carcinoma (≤ 3 cm): A Comparative Study Versus Radiofrequency Ablation. Cardiovasc Intervent Radiol 2020;43:732-9. [PMID: 32152720 DOI: 10.1007/s00270-020-02426-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
575 Schwarze V, Rübenthaler J, Marschner C, Fabritius MP, Rueckel J, Fink N, Puhr-Westerheide D, Gresser E, Froelich MF, Schnitzer ML, Große Hokamp N, Afat S, Staehler M, Geyer T, Clevert DA. Advanced Fusion Imaging and Contrast-Enhanced Imaging (CT/MRI-CEUS) in Oncology. Cancers (Basel) 2020;12:E2821. [PMID: 33007933 DOI: 10.3390/cancers12102821] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
576 Pascual S, Miralles C, Bernabé JM, Irurzun J, Planells M. Surveillance and diagnosis of hepatocellular carcinoma: A systematic review. World J Clin Cases 2019; 7(16): 2269-2286 [PMID: 31531321 DOI: 10.12998/wjcc.v7.i16.2269] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
577 Zeisel MB, Guerrieri F, Levrero M. Host Epigenetic Alterations and Hepatitis B Virus-Associated Hepatocellular Carcinoma. J Clin Med 2021;10:1715. [PMID: 33923385 DOI: 10.3390/jcm10081715] [Reference Citation Analysis]
578 Kim JS, Lee JK, Baek SY, Yun HI. Diagnostic performance of a minimized protocol of non-contrast MRI for hepatocellular carcinoma surveillance. Abdom Radiol 2020;45:211-9. [DOI: 10.1007/s00261-019-02277-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
579 Li Q, Li JF, Mao XR. Application of artificial intelligence in liver diseases: From diagnosis to treatment. Artif Intell Gastroenterol 2021; 2(5): 133-140 [DOI: 10.35712/aig.v2.i5.133] [Reference Citation Analysis]
580 Shin SW, Ahn KS, Kim SW, Kim TS, Kim YH, Kang KJ. Liver Resection Versus Local Ablation Therapies for Hepatocellular Carcinoma Within the Milan Criteria: A Systemic Review and Meta-analysis. Ann Surg. 2020;. [PMID: 33074898 DOI: 10.1097/sla.0000000000004350] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
581 Urbano J, Echevarria-uraga JJ, Ciampi-dopazo JJ, Sánchez-corral JA, Cobos Alonso J, Anton-ladislao A, Peña-baranda B, Nacarino-mejias V, González-costero R, Muñoz Ruiz-canela JJ, Pérez-cuesta J, Lanciego C, de Gregorio MA. Multicentre prospective study of drug-eluting bead chemoembolisation safety using tightly calibrated small microspheres in non-resectable hepatocellular carcinoma. European Journal of Radiology 2020;126:108966. [DOI: 10.1016/j.ejrad.2020.108966] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
582 Gomaa SH, Abaza MM, Elattar HA, Amin GA, Elshahawy DM. Soluble cluster of differentiation 26/soluble dipeptidyl peptidase-4 and glypican-3 are promising serum biomarkers for the early detection of Hepatitis C virus related hepatocellular carcinoma in Egyptians. Arab J Gastroenterol 2020;21:224-32. [PMID: 32891543 DOI: 10.1016/j.ajg.2020.04.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
583 Farid AA, Afify NA, Alsharnoby AA, Abdelsameea E, Bedair HM. Predictive Role of AURKA rs 1047972 Gene Polymorphism and the Risk of Development of Hepatocellular Carcinoma. Immunol Invest 2021;:1-11. [PMID: 34018460 DOI: 10.1080/08820139.2021.1920609] [Reference Citation Analysis]
584 Chu HH, Kim JH, Shim JH, Gwon DI, Ko HK, Shin JH, Ko GY, Yoon HK, Kim N. Neutrophil-to-Lymphocyte Ratio as a Biomarker Predicting Overall Survival after Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma. Cancers (Basel) 2021;13:2830. [PMID: 34204125 DOI: 10.3390/cancers13112830] [Reference Citation Analysis]
585 Sun X, Li L, Lyu N, Mu L, Lai J, Zhao M. Follow-up schedule for initial recurrent hepatocellular carcinoma after ablation based on risk classification. Cancer Imaging 2020;20:42. [PMID: 32611383 DOI: 10.1186/s40644-020-00319-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
586 Flood HM, Bolte C, Dasgupta N, Sharma A, Zhang Y, Gandhi CR, Kalin TV, Kalinichenko VV. The Forkhead box F1 transcription factor inhibits collagen deposition and accumulation of myofibroblasts during liver fibrosis. Biol Open 2019;8:bio039800. [PMID: 30670377 DOI: 10.1242/bio.039800] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
587 Ji JH, Park SY, Son WJ, Shin HJ, Lee H, Lee HW, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. External validation of CAGE-B and SAGE-B scores for Asian chronic hepatitis B patients with well-controlled viremia by antivirals. J Viral Hepat 2021;28:951-8. [PMID: 33763928 DOI: 10.1111/jvh.13506] [Reference Citation Analysis]
588 Nam JY, Lee YB, Lee JH, Yu SJ, Kim HC, Chung JW, Yoon JH, Kim YJ. A Prognostic Prediction Model of Transarterial Radioembolization in Hepatocellular Carcinoma: SNAP-HCC. Dig Dis Sci 2021. [PMID: 33538921 DOI: 10.1007/s10620-021-06843-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
589 Luo L, Li Q, Su Z, Li L, Cai B, Peng Y, Bai Y, Liu F. Genetic Polymorphisms in CD35 Gene Contribute to the Susceptibility and Prognosis of Hepatocellular Carcinoma. Front Oncol 2021;11:700711. [PMID: 34422654 DOI: 10.3389/fonc.2021.700711] [Reference Citation Analysis]
590 Pang F, Li Y, Zhang W, Xia C, He Q, Li Z, Xiao L, Song S, Dong P, Zhou H, Shao T, Cai H, Li L. Biodegradable 131 Iodine-Labeled Microspheres: Potential Transarterial Radioembolization Biomaterial for Primary Hepatocellular Carcinoma Treatment. Adv Healthc Mater 2020;9:e2000028. [PMID: 32431090 DOI: 10.1002/adhm.202000028] [Reference Citation Analysis]
591 Rimassa L, Wörns MA. Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma. Liver Int 2020;40:1800-11. [PMID: 32432830 DOI: 10.1111/liv.14533] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
592 Boraschi P, Tarantini G, Pacciardi F, Donati F. Dynamic and Multi-phase Contrast-Enhanced CT Scan. In: Radu-ionita F, Pyrsopoulos NT, Jinga M, Tintoiu IC, Sun Z, Bontas E, editors. Liver Diseases. Cham: Springer International Publishing; 2020. pp. 479-91. [DOI: 10.1007/978-3-030-24432-3_42] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
593 Adhoute X, Larrey E, Anty R, Chevallier P, Penaranda G, Tran A, Bronowicki JP, Raoul JL, Castellani P, Perrier H, Bayle O, Monnet O, Pol B, Bourliere M. Expected outcomes and patients’ selection before chemoembolization—“Six-and-Twelve or Pre-TACE-Predict” scores may help clinicians: Real-life French cohorts results. World J Clin Cases 2021; 9(18): 4559-4572 [PMID: 34222423 DOI: 10.12998/wjcc.v9.i18.4559] [Reference Citation Analysis]
594 Kim S, Kim KH, Kim BK, Park JY, Ahn SH, Kim DY, Kim SU. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2021;36:1317-25. [PMID: 33217054 DOI: 10.1111/jgh.15355] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
595 Su C, Jin C, Han J, Hu X, Shi D, Meng F. Ultrasonographic assessment of right heart intracardiac mass in patients with hepatitis B virus infection. Eur J Gastroenterol Hepatol 2020;32:838-43. [PMID: 31725029 DOI: 10.1097/MEG.0000000000001589] [Reference Citation Analysis]
596 Bogdanovic A, Bulajic P, Masulovic D, Bidzic N, Zivanovic M, Galun D. Liver resection versus transarterial chemoembolization for huge hepatocellular carcinoma: a propensity score matched analysis. Sci Rep 2021;11:4493. [PMID: 33627697 DOI: 10.1038/s41598-021-83868-9] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
597 Kim YW, Kim HJ, Cho BM, Choi SH. Triolein emulsion infusion into the hepatic artery increases vascular permeability to doxorubicin in rabbit liver. World J Gastroenterol 2021; 27(2): 152-161 [PMID: 33510556 DOI: 10.3748/wjg.v27.i2.152] [Reference Citation Analysis]
598 Zhou Y, Ouyang J, Wang Z, Chen X, Zhu R, Li Q, Zhou J. A novel internal cold circulation radiofrequency-assisted device for liver transection. Int J Hyperthermia 2021;38:308-15. [PMID: 33627010 DOI: 10.1080/02656736.2021.1889046] [Reference Citation Analysis]
599 Delhaye C, Hendlisz A, Vouche M. Update on transarterial approaches to locoregional treatment in hepatocellular carcinoma. Curr Opin Oncol 2019;31:339-45. [PMID: 30896451 DOI: 10.1097/CCO.0000000000000539] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
600 Chen L, Kan X, Sun T, Ren Y, Cao Y, Yan L, Liang B, Xiong B, Zheng C. Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma. BMC Gastroenterol 2020;20:205. [PMID: 32600349 DOI: 10.1186/s12876-020-01355-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
601 Wang L, Ke Q, Lin N, Zeng Y, Liu J. Does postoperative adjuvant transarterial chemoembolization benefit for all patients with hepatocellular carcinoma combined with microvascular invasion: a meta-analysis. Scandinavian Journal of Gastroenterology 2019;54:528-37. [DOI: 10.1080/00365521.2019.1610794] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
602 Chon HY, Lee HA, Suh SJ, Lee JI, Kim BS, Kim IH, Lee CH, Jang BK, Lee HW, Hwang JS, Lee CH, Lee JW, Yu JH, Seo YS, Yim HJ, Kim SU; Korean Transient Elastography Study Group. Addition of liver stiffness enhances the predictive accuracy of the PAGE-B model for hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 2021;53:919-27. [PMID: 33465253 DOI: 10.1111/apt.16267] [Reference Citation Analysis]
603 Kim K, Kim TH, Kim TH, Seong J. Efficacy of Local Therapy for Oligometastatic Hepatocellular Carcinoma: A Propensity Score Matched Analysis. J Hepatocell Carcinoma 2021;8:35-44. [PMID: 33604314 DOI: 10.2147/JHC.S290197] [Reference Citation Analysis]
604 Hamard A, Frandon J, Larbi A, Goupil J, De Forges H, Beregi J, Greffier J. Impact of ultra-low dose CT acquisition on semi-automated RECIST tool in the evaluation of malignant focal liver lesions. Diagnostic and Interventional Imaging 2020;101:473-9. [DOI: 10.1016/j.diii.2020.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
605 Hughes DM, Berhane S, Emily de Groot CA, Toyoda H, Tada T, Kumada T, Satomura S, Nishida N, Kudo M, Kimura T, Osaki Y, Kolamunage-Dona R, Amoros R, Bird T, Garcίa-Fiñana M, Johnson P. Serum Levels of α-Fetoprotein Increased More Than 10 Years Before Detection of Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2021;19:162-170.e4. [PMID: 32389887 DOI: 10.1016/j.cgh.2020.04.084] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
606 Durazzo M, Ponzo E, Bonetto S, Fagoonee S, Pellicano R. Liver diseases in the elderly. Minerva Med 2019;110. [DOI: 10.23736/s0026-4806.18.05858-5] [Cited by in Crossref: 8] [Article Influence: 4.0] [Reference Citation Analysis]
607 Schwarze V, Marschner C, Völckers W, de Figueiredo GN, Rübenthaler J, Clevert DA. The diagnostic performance of contrast-enhanced ultrasound (CEUS) for evaluating hepatocellular carcinoma (HCC) juxtaposed to MRI findings; a retrospective single-center analysis of 292 patients. Clin Hemorheol Microcirc 2020;76:155-60. [PMID: 32925017 DOI: 10.3233/CH-209213] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
608 Balitzer D, Kakar S. Challenges in Diagnosis of Hepatocellular Carcinoma in Cirrhotic Liver: A Pathologist's Perspective. Clin Liver Dis (Hoboken) 2021;17:249-54. [PMID: 33968384 DOI: 10.1002/cld.1091] [Reference Citation Analysis]
609 Gundlach JP, Schmidt S, Bernsmeier A, Günther R, Kataev V, Trentmann J, Schäfer JP, Röcken C, Becker T, Braun F. Indication of Liver Transplantation for Hepatocellular Carcinoma Should Be Reconsidered in Case of Microvascular Invasion and Multilocular Tumor Occurrence. J Clin Med 2021;10:1155. [PMID: 33801887 DOI: 10.3390/jcm10061155] [Reference Citation Analysis]
610 Kobayashi K, Uldry E, Demartines N, Halkic N. Liver resections between 2014 and 2020 in the Lausanne University Hospital, Switzerland. Glob Health Med 2020;2:337-42. [PMID: 33330829 DOI: 10.35772/ghm.2020.01059] [Reference Citation Analysis]
611 Mulé S, Chalaye J, Legou F, Tenenhaus A, Calderaro J, Galletto Pregliasco A, Laurent A, Kharrat R, Amaddeo G, Regnault H, Tacher V, Kobeiter H, Itti E, Luciani A. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT. Eur Radiol 2020;30:5348-57. [PMID: 32405753 DOI: 10.1007/s00330-020-06923-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
612 Yang X, Zhu Y, Zhao X, Li JH, Xu D, Jia HL, Zhang JB. The Prognostic Comparison Between Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and Bile Duct Cancer Thrombus After Liver Resection. Cancer Manag Res 2020;12:12077-86. [PMID: 33262656 DOI: 10.2147/CMAR.S278777] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
613 Yi C, Chen L, Lin Z, Liu L, Shao W, Zhang R, Lin J, Zhang J, Zhu W, Jia H, Qin L, Lu L, Chen J. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC. Hepatology 2021. [PMID: 34036623 DOI: 10.1002/hep.31921] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
614 De Cinque A, Corcioni B, Rossi MS, Franceschelli A, Colombo F, Golfieri R, Renzulli M, Gaudiano C. Case Report: Testicular Sarcoidosis: The Diagnostic Role of Contrast-Enhanced Ultrasound and Review of the Literature. Front Med (Lausanne) 2020;7:610384. [PMID: 33585510 DOI: 10.3389/fmed.2020.610384] [Reference Citation Analysis]
615 Dagorno C, Sommacale D, Laurent A, Attias A, Mongardon N, Levesque E, Langeron O, Rhaiem R, Leroy V, Amaddeo G, Brustia R. Prehabilitation in hepato-pancreato-biliary surgery: A systematic review and meta-analysis. A necessary step forward evidence-based sample size calculation for future trials. J Visc Surg 2021:S1878-7886(21)00111-9. [PMID: 34489200 DOI: 10.1016/j.jviscsurg.2021.07.003] [Reference Citation Analysis]
616 Dobrzycka M, Spychalski P, Rostkowska O, Wilczyński M, Kobiela P, Grąt M, Dell’acqua V, Høyer M, Jereczek-fossa BA. Stereotactic body radiation therapy for early-stage hepatocellular carcinoma – a systematic review on outcome. Acta Oncologica 2019;58:1706-13. [DOI: 10.1080/0284186x.2019.1657942] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
617 Colapietro F, Aghemo A. Do gamma-glutamyltransferase levels identify HCV patients who require lifelong post-SVR follow-up? Liver Int 2020;40:509-10. [PMID: 32124542 DOI: 10.1111/liv.14394] [Reference Citation Analysis]
618 Karalli A, Teiler J, Haji M, Seth E, Brismar TB, Wahlin S, Axelsson R, Stål P. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting. Scand J Gastroenterol 2019;54:905-12. [PMID: 31287338 DOI: 10.1080/00365521.2019.1632925] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
619 Terzi E, Ayuso C, Piscaglia F, Bruix J. Liver Imaging Reporting and Data System: Review of Pros and Cons. Semin Liver Dis 2021. [PMID: 34298576 DOI: 10.1055/s-0041-1732356] [Reference Citation Analysis]
620 Kim HY, Lampertico P, Nam JY, Lee HC, Kim SU, Sinn DH, Seo YS, Lee HA, Park SY, Lim YS, Jang ES, Yoon EL, Kim HS, Kim SE, Ahn SB, Shim JJ, Jeong SW, Jung YJ, Sohn JH, Cho YK, Jun DW, Dalekos GN, Idilman R, Sypsa V, Berg T, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Janssen H, Jang MJ, Lee YB, Kim YJ, Yoon JH, Papatheodoridis GV, Lee JH. An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. J Hepatol 2021:S0168-8278(21)02087-0. [PMID: 34606915 DOI: 10.1016/j.jhep.2021.09.025] [Reference Citation Analysis]
621 Dang H, Chen L, Tang P, Cai X, Zhang W, Zhang R, Huang A, Tang H. LINC01419 promotes cell proliferation and metastasis in hepatocellular carcinoma by enhancing NDRG1 promoter activity. Cell Oncol (Dordr) 2020;43:931-47. [PMID: 32557341 DOI: 10.1007/s13402-020-00540-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
622 Kanwal F, Singal AG. Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction. Gastroenterology 2019;157:54-64. [PMID: 30986389 DOI: 10.1053/j.gastro.2019.02.049] [Cited by in Crossref: 94] [Cited by in F6Publishing: 88] [Article Influence: 47.0] [Reference Citation Analysis]
623 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Kloeckner R. Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score? Front Oncol 2021;11:696183. [PMID: 34178694 DOI: 10.3389/fonc.2021.696183] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
624 Syed YY. Ramucirumab: A Review in Hepatocellular Carcinoma. Drugs 2020;80:315-22. [DOI: 10.1007/s40265-020-01263-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
625 Sturm L, Roth L, Zoldan K, Schultheiss M, Boettler T, Huber JP, Kaeser R, Thimme R, Bettinger D. Blood reelin in the progression of chronic liver disease. Adv Med Sci 2021;66:148-54. [PMID: 33561810 DOI: 10.1016/j.advms.2021.01.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
626 Santos-de-Frutos K, Djouder N. When dormancy fuels tumour relapse. Commun Biol 2021;4:747. [PMID: 34135460 DOI: 10.1038/s42003-021-02257-0] [Reference Citation Analysis]
627 Wu W, Wang Q, Han D, Li J, Nie Y, Guo D, Yang L, Tao K, Zhang X, Dou K. Prognostic value of preoperative inflammatory markers in patients with hepatocellular carcinoma who underwent curative resection. Cancer Cell Int 2021;21:500. [PMID: 34535132 DOI: 10.1186/s12935-021-02204-3] [Reference Citation Analysis]
628 Ardito F, Famularo S, Aldrighetti L, Grazi GL, DallaValle R, Maestri M, Jovine E, Ruzzenente A, Baiocchi GL, Ercolani G, Griseri G, Frena A, Zanus G, Zimmitti G, Antonucci A, Crespi M, Memeo R, Romano F, Giuliante F; HE.RC.O.LE.S. Group. The Impact of Hospital Volume on Failure to Rescue after Liver Resection for Hepatocellular Carcinoma: Analysis from the HE.RC.O.LE.S. Italian Registry. Ann Surg 2020;272:840-6. [PMID: 32889868 DOI: 10.1097/SLA.0000000000004327] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
629 Mähringer-Kunz A, Meyer FI, Hahn F, Müller L, Düber C, Pinto Dos Santos D, Galle PR, Weinmann A, Kloeckner R, Schotten S. Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma: Prevalence and clinical significance. United European Gastroenterol J 2021;9:590-7. [PMID: 34077613 DOI: 10.1002/ueg2.12098] [Reference Citation Analysis]
630 Kim J, Sinn DH, Choi MS, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW. Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment? PLoS One 2019;14:e0213547. [PMID: 30845192 DOI: 10.1371/journal.pone.0213547] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
631 Xu H, Tang Y, Zhao Y, Wang F, Gao X, Deng D, Gu Y. SPECT Imaging of Hepatocellular Carcinoma Detection by the GPC3 Receptor. Mol Pharm 2021;18:2082-90. [PMID: 33797932 DOI: 10.1021/acs.molpharmaceut.1c00060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
632 Erkan B, Meier J, Clark TJ, Kaplan J, Lambert JR, Chang S. Non-invasive diagnostic criteria of hepatocellular carcinoma: Comparison of diagnostic accuracy of updated LI-RADS with clinical practice guidelines of OPTN-UNOS, AASLD, NCCN, EASL-EORTC, and KLSCG-NCC. PLoS One 2019;14:e0226291. [PMID: 31821360 DOI: 10.1371/journal.pone.0226291] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
633 Tan Z, Teoh WC, Wong KM, Wansaicheong GK, Sandrasegaran K. Analysis of comparative performance of CEUS and CECT/MR LI-RADS classification: Can CEUS dichotomize LI-RADS indeterminate lesions on CT or MRI? Clinical Imaging 2020;62:63-8. [DOI: 10.1016/j.clinimag.2020.02.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
634 Ali S, Ali M, Paudyal V, Rasheed F, Ullah S, Haque S, Ur-Rehman T. A Randomized Controlled Trial to Assess the  Impact of Clinical Pharmacy Interventions on Treatment Outcomes, Health Related Quality of Life and Medication Adherence Among Hepatitis C Patients. Patient Prefer Adherence 2019;13:2089-100. [PMID: 31997877 DOI: 10.2147/PPA.S224937] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
635 Pace C, Nardone V, Roma S, Chegai F, Toti L, Manzia TM, Tisone G, Orlacchio A. Evaluation of Contrast-Enhanced Intraoperative Ultrasound in the Detection and Management of Liver Lesions in Patients with Hepatocellular Carcinoma. J Oncol 2019;2019:6089340. [PMID: 31467539 DOI: 10.1155/2019/6089340] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
636 Debes JD, Romagnoli PA, Prieto J, Arrese M, Mattos AZ, Boonstra A, On Behalf Of The Escalon Consortium. Serum Biomarkers for the Prediction of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1681. [PMID: 33918270 DOI: 10.3390/cancers13071681] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
637 Hu J, Zhang ZQ, Zhu W, Wu ZR, You Y, Liu Y, Su DW, Wang YB, Gong JP. Comparison of clinicopathological traits and prognostic factors of hepatocellular carcinoma with and without cirrhotic background. Carcinogenesis 2020;41:1576-82. [PMID: 32188964 DOI: 10.1093/carcin/bgaa024] [Reference Citation Analysis]
638 Deng S, Solinas A, Calvisi DF. Cabozantinib for HCC Treatment, From Clinical Back to Experimental Models. Front Oncol 2021;11:756672. [PMID: 34722310 DOI: 10.3389/fonc.2021.756672] [Reference Citation Analysis]
639 Demirtas CO, D'Alessio A, Rimassa L, Sharma R, Pinato DJ. ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Rep 2021;3:100347. [PMID: 34505035 DOI: 10.1016/j.jhepr.2021.100347] [Reference Citation Analysis]
640 Costa-Santos MP, Gonçalves A, Ferreira AO, Nunes J. Spontaneous regression of hepatocellular carcinoma: myth or reality? BMJ Case Rep 2020;13:e233509. [PMID: 32047089 DOI: 10.1136/bcr-2019-233509] [Reference Citation Analysis]
641 Galun D, Bogdanovic A, Zivanovic M, Zuvela M. Short- and Long-Term Outcomes After Hepatectomy in Elderly Patients with Hepatocellular Carcinoma: An Analysis of 229 Cases from a Developing Country. J Hepatocell Carcinoma 2021;8:155-65. [PMID: 33791251 DOI: 10.2147/JHC.S297296] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
642 Lin SH, Wu KT, Wang CC, Huang KT, Chen KD, Lin CC, Hsu LW, Chiu KW. HCV RNA in serum and liver samples of patients undergoing living donor liver transplantation. J Int Med Res 2021;49:3000605211034945. [PMID: 34344219 DOI: 10.1177/03000605211034945] [Reference Citation Analysis]
643 Lin SH, Eng HL, Liu YW, Lin CC, Yong CC, Wang CC, Chen CL, Kuo FY, Cheng YF, Wang JH, Yen YH, Liu TT, Li WF, Chen CH. Characteristics and prognosis of patients with large well-differentiated hepatocellular carcinoma who have undergone resection. Am J Surg 2021:S0002-9610(21)00226-9. [PMID: 33840448 DOI: 10.1016/j.amjsurg.2021.03.065] [Reference Citation Analysis]
644 Ferrarese A, Sciarrone SS, Pellone M, Shalaby S, Battistella S, Zanetto A, Germani G, Russo FP, Senzolo M, Burra P, Gambato M. Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma. Minerva Gastroenterol 2021;67. [DOI: 10.23736/s2724-5985.20.02775-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
645 Su TH, Hsu SJ, Kao JH. Paradigm shift in the treatment options of hepatocellular carcinoma. Liver Int 2021. [PMID: 34515412 DOI: 10.1111/liv.15052] [Reference Citation Analysis]
646 Zhang Q, Lou Y, Yang J, Wang J, Feng J, Zhao Y, Wang L, Huang X, Fu Q, Ye M, Zhang X, Chen Y, Ma C, Ge H, Wu J, Wei T, Chen Q, Yu C, Xiao Y, Feng X, Guo G, Liang T, Bai X. Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. Gut. 2019;68:2019-2031. [PMID: 31227589 DOI: 10.1136/gutjnl-2019-318912] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 32.5] [Reference Citation Analysis]
647 Ma R, Zhao M, Zou X, Zhou J, Bai Z. MicroRNA polymorphism: A target for diagnosis and prognosis of hepatocellular carcinoma? Oncol Lett 2021;21:324. [PMID: 33692856 DOI: 10.3892/ol.2021.12586] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
648 Di Sandro S, Danieli M, Ferla F, Lauterio A, De Carlis R, Benuzzi L, Buscemi V, Pezzoli I, De Carlis L. The current role of laparoscopic resection for HCC: a systematic review of past ten years. Transl Gastroenterol Hepatol 2018;3:68. [PMID: 30363804 DOI: 10.21037/tgh.2018.08.05] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
649 Kumada T, Toyoda H, Yasuda S, Tada T, Ogawa S, Takeshima K, Tanaka J, Chayama K, Johnson PJ. Impact of the introduction of direct-acting anti-viral drugs on hepatocarcinogenesis: a prospective serial follow-up MRI study. Aliment Pharmacol Ther 2020;52:359-70. [PMID: 32519782 DOI: 10.1111/apt.15825] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
650 Pelizzaro F, Soldà F, Cardin R, Imondi A, Sartori A, Penzo B, Sammarco A, Aliberti C, Vitale A, Cillo U, Farinati F. SCCA-IgM in hepatocellular carcinoma patients treated with transarterial chemoembolization: gender-related differences. Biomark Med 2020;14:855-67. [PMID: 32808827 DOI: 10.2217/bmm-2019-0564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
651 Roberts SK, Majeed A, Kemp W. Controversies in the Management of Hepatitis B: Hepatocellular Carcinoma. Clin Liver Dis 2021;25:785-803. [PMID: 34593153 DOI: 10.1016/j.cld.2021.06.006] [Reference Citation Analysis]
652 Park C, Chu HH, Kim JH, Kim SY, Alrashidi I, Gwon DI, Yoon HK, Kim N. Clinical Significance of the Initial and Best Responses after Chemoembolization in the Treatment of Intermediate-Stage Hepatocellular Carcinoma with Preserved Liver Function. J Vasc Interv Radiol 2020;31:1998-2006.e1. [PMID: 32988715 DOI: 10.1016/j.jvir.2020.04.017] [Cited by in Crossref: 7] [Article Influence: 7.0] [Reference Citation Analysis]
653 Sangiovanni A, Colombo M. Surveillance for hepatocellular carcinoma in patients with advanced liver fibrosis. Saudi J Gastroenterol 2021;27:64-72. [PMID: 33723094 DOI: 10.4103/sjg.sjg_636_20] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
654 Urban SK, Sänger H, Krawczyk M, Julich-Haertel H, Willms A, Ligocka J, Azkargorta M, Mocan T, Kahlert C, Kruk B, Jankowski K, Patkowski W, Krawczyk M, Zieniewicz K, Hołówko W, Krupa Ł, Rzucidło M, Gutkowski K, Wystrychowski W, Król R, Raszeja-Wyszomirska J, Słomka A, Schwab R, Wöhler A, Gonzalez-Carmona MA, Gehlert S, Sparchez Z, Banales JM, Strassburg CP, Lammert F, Milkiewicz P, Kornek M. Synergistic effects of extracellular vesicle phenotyping and AFP in hepatobiliary cancer differentiation. Liver Int 2020;40:3103-16. [PMID: 32614460 DOI: 10.1111/liv.14585] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
655 Blaise L, Pereira H, Vilgrain V, Sutter O, Gigante E, Walter A, Ganne-Carrié N, Nahon P, Bouattour M, Dioguardi Burgio M, Grando V, Nkontchou G, Seror O, Nault JC. Percutaneous ablation for locally advanced hepatocellular carcinoma with tumor portal invasion. Clin Res Hepatol Gastroenterol 2021;45:101731. [PMID: 34139320 DOI: 10.1016/j.clinre.2021.101731] [Reference Citation Analysis]
656 Mahn R, Sadeghlar F, Bartels A, Zhou T, Weismüller T, Kupczyk P, Meyer C, Gaertner FC, Toma M, Vilz T, Knipper P, Glowka T, Manekeller S, Kalff J, Strassburg CP, Gonzalez-Carmona MA. Multimodal and systemic therapy with cabozantinib for treatment of recurrent hepatocellular carcinoma after liver transplantation: A case report with long term follow-up outcomes. Medicine (Baltimore) 2021;100:e27082. [PMID: 34559100 DOI: 10.1097/MD.0000000000027082] [Reference Citation Analysis]
657 Zhu J, Yin T, Xu Y, Lu XJ. Therapeutics for advanced hepatocellular carcinoma: Recent advances, current dilemma, and future directions. J Cell Physiol. 2019;234:12122-12132. [PMID: 30644100 DOI: 10.1002/jcp.28048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
658 El Jabbour T, Lagana SM, Lee H. Update on hepatocellular carcinoma: Pathologists’ review. World J Gastroenterol 2019; 25(14): 1653-1665 [PMID: 31011252 DOI: 10.3748/wjg.v25.i14.1653] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 34] [Article Influence: 18.0] [Reference Citation Analysis]
659 Chen L, Sun T, Chen S, Ren Y, Yang F, Zheng C. The efficacy of surgery in advanced hepatocellular carcinoma: a cohort study. World J Surg Oncol 2020;18:119. [PMID: 32487104 DOI: 10.1186/s12957-020-01887-8] [Reference Citation Analysis]
660 Min JH, Kim JM, Kim YK, Kim H, Cha DI, Kang TW, Choi GS, Choi SY, Ahn S. EASL versus LI-RADS: Intra-individual comparison of MRI with extracellular contrast and gadoxetic acid for diagnosis of small HCC. Liver Int 2021. [PMID: 34242468 DOI: 10.1111/liv.15012] [Reference Citation Analysis]
661 Ferrín G, Guerrero M, Amado V, Rodríguez-Perálvarez M, De la Mata M. Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E1266. [PMID: 32070029 DOI: 10.3390/ijms21041266] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 20.0] [Reference Citation Analysis]
662 Mocan T, Stiufiuc R, Popa C, Nenu I, Pestean C, Nagy AL, Mocan LP, Leucuta DC, Hajjar NA, Sparchez Z. Percutaneous ultrasound guided PEG-coated gold nanoparticles enhanced radiofrequency ablation in liver. Sci Rep 2021;11:1316. [PMID: 33446793 DOI: 10.1038/s41598-020-79917-4] [Reference Citation Analysis]
663 Lai Q, Di Martino M, Lucatelli P, Mennini G. Locoregional therapy response in patients with hepatocellular cancer waiting for liver transplantation: Only selection or biological effect? World J Gastroenterol 2018; 24(31): 3469-3471 [PMID: 30131653 DOI: 10.3748/wjg.v24.i31.3469] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
664 Cappelli A, Sangro P, Mosconi C, Deppe I, Terzi E, Bilbao JI, Rodriguez-Fraile M, De Benedittis C, Ricke J, Golfieri R, Sangro B. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage. Eur J Nucl Med Mol Imaging 2019;46:661-8. [PMID: 30209522 DOI: 10.1007/s00259-018-4152-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
665 Longo M, Paolini E, Meroni M, Dongiovanni P. Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC. Int J Mol Sci 2021;22:4173. [PMID: 33920670 DOI: 10.3390/ijms22084173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
666 Meng L, Xu KX, Zhao MX, Li K, Zhu K, Yuan DW, Wang HN, Dai PG, Yan R. Nucleolar protein 6 promotes cell proliferation and acts as a potential novel prognostic marker for hepatocellular carcinoma. Chin Med J (Engl) 2021;134:2611-8. [PMID: 34561331 DOI: 10.1097/CM9.0000000000001655] [Reference Citation Analysis]
667 Yang Q, Wei J, Hao X, Kong D, Yu X, Jiang T, Xi J, Cai W, Luo Y, Jing X, Yang Y, Cheng Z, Wu J, Zhang H, Liao J, Zhou P, Song Y, Zhang Y, Han Z, Cheng W, Tang L, Liu F, Dou J, Zheng R, Yu J, Tian J, Liang P. Improving B-mode ultrasound diagnostic performance for focal liver lesions using deep learning: A multicentre study. EBioMedicine. 2020;56:102777. [PMID: 32485640 DOI: 10.1016/j.ebiom.2020.102777] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
668 Huang Y, Zeng J, Liu T, Lin X, Guo P, Zeng J, Zhou W, Liu J. Prognostic Significance of Elevated Preoperative Serum CA125 Levels After Curative Hepatectomy for Hepatocellular Carcinoma. Onco Targets Ther 2020;13:4559-67. [PMID: 32547086 DOI: 10.2147/OTT.S236475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
669 Younes R, Govaere O, Petta S, Miele L, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, Fracanzani AL, Rosso C, Blanco MJG, Armandi A, Caviglia GP, Zaki MYW, Liguori A, Francione P, Pennisi G, Grieco A, Valenti L, Anstee QM, Bugianesi E. Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol 2020;115:1289-92. [PMID: 32453041 DOI: 10.14309/ajg.0000000000000676] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
670 Long Y, Zeng Q, He X, Ye H, Su Y, Zheng R, Yu J, Xu E, Li K. One-lung ventilation for percutaneous thermal ablation of liver tumors in the hepatic dome. Int J Hyperthermia 2020;37:49-54. [PMID: 31918592 DOI: 10.1080/02656736.2019.1708483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
671 Paisant A, Gillard M, Oberti F, Roux M, Aubé C. Validation of a Diagnostic Algorithm for Hepatocellular Carcinoma at Gadoxetic Acid-enhanced MRI. Radiology 2021;300:184-6. [PMID: 33904774 DOI: 10.1148/radiol.2021204529] [Reference Citation Analysis]
672 Ni X, Lin Z, Dai S, Chen H, Chen J, Zheng C, Wu B, Ao J, Shi K, Sun H. Screening and verification of microRNA promoter methylation sites in hepatocellular carcinoma. J Cell Biochem 2020;121:3626-41. [PMID: 32065423 DOI: 10.1002/jcb.29656] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
673 Kono Y, Sirlin CB, Fetzer DT, Kim TK, Rodgers SK, Piscaglia F, Lyshchik A, Dietrich CF, Wilson SR. Time to Clarify Common Misconceptions about the Liver Imaging Reporting and Data System for Contrast-enhanced US. Radiology 2020;295:245-7. [DOI: 10.1148/radiol.2020192557] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
674 Zhong C, Li Y, Yang J, Jin S, Chen G, Li D, Fan X, Lin H. Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects. Front Oncol 2021;11:589680. [PMID: 33854960 DOI: 10.3389/fonc.2021.589680] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
675 Personeni N, Rimassa L. Gauging the quality-of-life benefits of immunotherapy in hepatocellular carcinoma. Lancet Oncol 2021;22:896-8. [PMID: 34051881 DOI: 10.1016/S1470-2045(21)00258-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
676 Krishan S, Dhiman RK, Kalra N, Sharma R, Baijal SS, Arora A, Gulati A, Eapan A, Verma A, Keshava S, Mukund A, Deva S, Chaudhary R, Ganesan K, Taneja S, Gorsi U, Gamanagatti S, Madhusudan KS, Puri P, Shalimar, Govil S, Wadhavan M, Saigal S, Kumar A, Thapar S, Duseja A, Saraf N, Khandelwal A, Mukhopadyay S, Gulati A, Shetty N, Verma N. Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System. J Clin Exp Hepatol 2019;9:625-51. [PMID: 31695253 DOI: 10.1016/j.jceh.2019.07.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
677 Chen M, Cao J, Hu J, Topatana W, Li S, Juengpanich S, Lin J, Tong C, Shen J, Zhang B, Wu J, Pocha C, Kudo M, Amedei A, Trevisani F, Sung PS, Zaydfudim VM, Kanda T, Cai X. Clinical-Radiomic Analysis for Pretreatment Prediction of Objective Response to First Transarterial Chemoembolization in Hepatocellular Carcinoma. Liver Cancer 2021;10:38-51. [PMID: 33708638 DOI: 10.1159/000512028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
678 Caviglia GP, Abate ML, Rolle E, Carucci P, Armandi A, Rosso C, Olivero A, Ribaldone DG, Tandoi F, Saracco GM, Ciancio A, Bugianesi E, Gaia S. The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma. Biology (Basel) 2021;10:215. [PMID: 33799723 DOI: 10.3390/biology10030215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
679 Liu C, Shao J, Dong Y, Xu Q, Zou Z, Chen F, Yan J, Liu J, Li S, Liu B, Shen J. Advanced HCC Patient Benefit From Neoantigen Reactive T Cells Based Immunotherapy: A Case Report. Front Immunol 2021;12:685126. [PMID: 34326839 DOI: 10.3389/fimmu.2021.685126] [Reference Citation Analysis]
680 Sessa A, Allaire M, Lebray P, Medmoun M, Tiritilli A, Iaria P, Cadranel JF. From congestive hepatopathy to hepatocellular carcinoma, how can we improve patient management? JHEP Rep 2021;3:100249. [PMID: 33665589 DOI: 10.1016/j.jhepr.2021.100249] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
681 Sung K, Johnston MP, Lee MY, Byrne CD. Non‐invasive liver fibrosis scores are strongly associated with liver cancer mortality in general population without liver disease. Liver Int 2020;40:1303-15. [DOI: 10.1111/liv.14416] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
682 Haq MI, Drake TM, Goh TL, Ahmed A, Forrest E, Barclay S, Gillespie R, Priest M, Evans J, Graham J, Ballantyne S, McMillan DC, Hayes PC, Bird TG, Stanley AJ. Effect of Hepatocellular Carcinoma Surveillance Programmes on Overall Survival in a Mixed Cirrhotic UK Population: A Prospective, Longitudinal Cohort Study. J Clin Med 2021;10:2770. [PMID: 34202593 DOI: 10.3390/jcm10132770] [Reference Citation Analysis]
683 Li P, Wu L, Li Z, Li J, Ye W, Shi Z, Xu Z, Zhu C, Ye H, Liu Z, Liang C. Spleen Radiomics Signature: A Potential Biomarker for Prediction of Early and Late Recurrences of Hepatocellular Carcinoma After Resection. Front Oncol 2021;11:716849. [PMID: 34485152 DOI: 10.3389/fonc.2021.716849] [Reference Citation Analysis]
684 Ridder DA, Schindeldecker M, Weinmann A, Berndt K, Urbansky L, Witzel HR, Heinrich S, Roth W, Straub BK. Key Enzymes in Pyrimidine Synthesis, CAD and CPS1, Predict Prognosis in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:744. [PMID: 33670206 DOI: 10.3390/cancers13040744] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
685 Labgaa I, Taffé P, Martin D, Clerc D, Schwartz M, Kokudo N, Denys A, Halkic N, Demartines N, Melloul E. Comparison of Partial Hepatectomy and Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Liver Cancer 2020;9:138-47. [PMID: 32399428 DOI: 10.1159/000505093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
686 Li Y, Yang J, Zhang X, Liu H, Guo J. KDM6A suppresses hepatocellular carcinoma cell proliferation by negatively regulating the TGF-β/SMAD signaling pathway. Exp Ther Med 2020;20:2774-82. [PMID: 32765772 DOI: 10.3892/etm.2020.9000] [Reference Citation Analysis]
687 Berman ZT, Newton I. Diagnosis, Staging, and Patient Selection for Locoregional Therapy to Treat Hepatocellular Carcinoma. Semin Intervent Radiol 2020;37:441-7. [PMID: 33328699 DOI: 10.1055/s-0040-1719185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
688 Moteleub HNAE, Moety AAAE, Baddour NM, Shendidi AAE. Predictors for hepatocellular carcinoma recurrence after microwave ablation. Clin Exp Hepatol 2020;6:77-84. [PMID: 32728623 DOI: 10.5114/ceh.2019.95115] [Reference Citation Analysis]
689 Park HJ, Jang HY, Kim SY, Lee SJ, Won HJ, Byun JH, Choi SH, Lee SS, An J, Lim YS. Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: Comparison with ultrasound. J Hepatol 2020;72:718-24. [PMID: 31836549 DOI: 10.1016/j.jhep.2019.12.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 14.0] [Reference Citation Analysis]
690 Zhang X, Wu B, Guo Z, Gao Y, Xi W, Yu H, Feng G, Zhang J, Shen W, Chen J. Determination of portal vein tumor thrombus blood supply using in vivo cellular magnetic resonance imaging in a rabbit model. Cancer Manag Res 2019;11:5523-9. [PMID: 31417305 DOI: 10.2147/CMAR.S197231] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
691 Hui TC, Kwan J, Pua U. Advanced Techniques in the Percutaneous Ablation of Liver Tumours. Diagnostics (Basel) 2021;11:585. [PMID: 33805107 DOI: 10.3390/diagnostics11040585] [Reference Citation Analysis]
692 Abi-Jaoudeh N, Dayyani F, Chen PJ, Fernando D, Fidelman N, Javan H, Liang PC, Hwang JI, Imagawa DK. Phase I Trial on Arterial Embolization with Hypoxia Activated Tirapazamine for Unresectable Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:421-34. [PMID: 34041204 DOI: 10.2147/JHC.S304275] [Reference Citation Analysis]
693 Guiu B, Chevallier P, Assenat E, Barbier E, Merle P, Bouvier A, Dumortier J, Nguyen-Khac E, Gugenheim J, Rode A, Oberti F, Valette PJ, Yzet T, Chevallier O, Barbare JC, Latournerie M, Boulin M. Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II Trial. Radiology. 2019;291:801-808. [PMID: 31038408 DOI: 10.1148/radiol.2019182399] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
694 Mocan T, Ilies M, Nenu I, Craciun R, Horhat A, Susa R, Minciuna I, Rusu I, Mocan LP, Seicean A, Iuga CA, Hajjar NA, Sparchez M, Leucuta DC, Sparchez Z. Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma. Int Immunopharmacol 2021;94:107467. [PMID: 33611059 DOI: 10.1016/j.intimp.2021.107467] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
695 Wilson GC, Geller DA. Evolving Surgical Options for Hepatocellular Carcinoma. Surgical Oncology Clinics of North America 2019;28:645-61. [DOI: 10.1016/j.soc.2019.06.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
696 Wu B, Hu X, Jin H, Zhou L, Zhang D, Man Z, Wang Y, Yang S, Pang Q, Liu H, Cui P. Albumin-bilirubin and platelet-albumin-bilirubin grades for hepatitis B-associated hepatocellular carcinoma in Child-Pugh A patients treated with radical surgery: A retrospective observational study. Medicine (Baltimore) 2019;98:e17394. [PMID: 31651841 DOI: 10.1097/MD.0000000000017394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
697 Labeur TA, Runge JH, Klompenhouwer EG, Klümpen H, Takkenberg RB, van Delden OM. Diffusion-weighted imaging of hepatocellular carcinoma before and after transarterial chemoembolization: role in survival prediction and response evaluation. Abdom Radiol 2019;44:2740-50. [DOI: 10.1007/s00261-019-02030-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
698 Viganò L, Lleo A, Muglia R, Gennaro N, Samà L, Colapietro F, Roncalli M, Aghemo A, Chiti A, Di Tommaso L, Solbiati L, Colombo M, Torzilli G. Intrahepatic cholangiocellular carcinoma with radiological enhancement patterns mimicking hepatocellular carcinoma. Updates Surg 2020;72:413-21. [PMID: 32323164 DOI: 10.1007/s13304-020-00750-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
699 Yamamoto S, Onishi H, Oyama A, Takaki A, Okada H. Severe Colitis Caused by Hepatic Arterial Infusion Chemotherapy with Cisplatin for Hepatocellular Carcinoma. Intern Med 2020;59:69-75. [PMID: 31484909 DOI: 10.2169/internalmedicine.3340-19] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
700 Kim SA, Cho EJ, Lee S, Cho YY, Kim B, Yoon JH, Park T. Changes in serum fibronectin levels predict tumor recurrence in patients with early hepatocellular carcinoma after curative treatment. Sci Rep 2020;10:21313. [PMID: 33277619 DOI: 10.1038/s41598-020-78440-w] [Reference Citation Analysis]
701 Zhang Q, Wang J, Liu M, Zhu Q, Li Q, Xie C, Han C, Wang Y, Gao M, Liu J. Weighted correlation gene network analysis reveals a new stemness index-related survival model for prognostic prediction in hepatocellular carcinoma. Aging (Albany NY) 2020;12:13502-17. [PMID: 32644941 DOI: 10.18632/aging.103454] [Reference Citation Analysis]
702 Zech CJ, Ba-Ssalamah A, Berg T, Chandarana H, Chau GY, Grazioli L, Kim MJ, Lee JM, Merkle EM, Murakami T, Ricke J, B Sirlin C, Song B, Taouli B, Yoshimitsu K, Koh DM. Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging. Eur Radiol 2020;30:370-82. [PMID: 31385048 DOI: 10.1007/s00330-019-06369-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
703 Serenari M, Cappelli A, Cucchetti A, Mosconi C, Strigari L, Monari F, Ravaioli M, Rizzini EL, Fanti S, Golfieri R, Cescon M. Deceased Donor Liver Transplantation After Radioembolization for Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis: A Pilot Study. Liver Transpl 2021. [PMID: 34355489 DOI: 10.1002/lt.26257] [Reference Citation Analysis]
704 Wandeler G, Mauron E, Atkinson A, Dufour JF, Kraus D, Reiss P, Peters L, Dabis F, Fehr J, Bernasconi E, van der Valk M, Smit C, Gjærde LK, Rockstroh J, Neau D, Bonnet F, Rauch A; Swiss HIV Cohort Study, Athena Observational Cohort Study, EuroSIDA, ANRS CO3 Aquitaine Cohort. Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies. J Hepatol 2019;71:274-80. [PMID: 30965070 DOI: 10.1016/j.jhep.2019.03.032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
705 Awad AM, Ragab WS, Degheidy N, Ooda SA. Whole Genome 5'-Methylcytosine Level Quantification in Cirrhotic HCV-Infected Egyptian Patients with and without Hepatocellular Carcinoma. Int J Genomics 2020;2020:1769735. [PMID: 33083446 DOI: 10.1155/2020/1769735] [Reference Citation Analysis]
706 Marasco G, Colecchia A, Colli A, Ravaioli F, Casazza G, Bacchi Reggiani ML, Cucchetti A, Cescon M, Festi D. Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection. Journal of Hepatology 2019;70:440-8. [DOI: 10.1016/j.jhep.2018.10.022] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 20.0] [Reference Citation Analysis]
707 Cornberg M, Sandmann L, Protzer U, Niederau C, Tacke F, Berg T, Glebe D, Jilg W, Wedemeyer H, Wirth S, Höner Zu Siederdissen C, Lynen-Jansen P, van Leeuwen P, Petersen J; Collaborators:. S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11). Z Gastroenterol 2021;59:691-776. [PMID: 34255317 DOI: 10.1055/a-1498-2512] [Reference Citation Analysis]
708 Ioannou GN. HCC surveillance after SVR in patients with F3/F4 fibrosis. J Hepatol. 2021;74:458-465. [PMID: 33303216 DOI: 10.1016/j.jhep.2020.10.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
709 Centonze L, Di Sandro S, Lauterio A, De Carlis R, Frassoni S, Rampoldi A, Tuscano B, Bagnardi V, Vanzulli A, De Carlis L. Surgical Resection vs. Percutaneous Ablation for Single Hepatocellular Carcinoma: Exploring the Impact of Li-RADS Classification on Oncological Outcomes. Cancers (Basel) 2021;13:1671. [PMID: 33916311 DOI: 10.3390/cancers13071671] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
710 Lee HA, Park S, Seo YS, Yoon WS, Rim CH, On Behalf Of The Korean Liver Cancer Study Group. Benefits of Local Treatment Including External Radiotherapy for Hepatocellular Carcinoma with Portal Invasion. Biology (Basel) 2021;10:326. [PMID: 33919745 DOI: 10.3390/biology10040326] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
711 Wei Y, Ye Z, Yuan Y, Huang Z, Wei X, Zhang T, Wan S, Tang H, He X, Song B. A New Diagnostic Criterion with Gadoxetic Acid-Enhanced MRI May Improve the Diagnostic Performance for Hepatocellular Carcinoma. Liver Cancer 2020;9:414-25. [PMID: 32999868 DOI: 10.1159/000505696] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
712 Peña-Asensio J, Calvo H, Torralba M, Miquel J, Sanz-de-Villalobos E, Larrubia JR. Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1922. [PMID: 33923463 DOI: 10.3390/cancers13081922] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
713 Charneau J, Suzuki T, Shimomura M, Fujinami N, Nakatsura T. Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances. J Hepatocell Carcinoma 2021;8:1035-54. [PMID: 34513746 DOI: 10.2147/JHC.S291558] [Reference Citation Analysis]
714 Li L, Xie R, Lu G. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma. Biosci Rep 2021;41:BSR20210760. [PMID: 34027555 DOI: 10.1042/BSR20210760] [Reference Citation Analysis]
715 Ma Z, Guo D, Wang Q, Liu P, Xiao Y, Wu P, Wang Y, Chen B, Liu Z, Liu Q. Lgr5-mediated p53 Repression through PDCD5 leads to doxorubicin resistance in Hepatocellular Carcinoma. Theranostics 2019;9:2967-83. [PMID: 31244936 DOI: 10.7150/thno.30562] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
716 de Mattos ÂZ, Debes JD, Boonstra A, Yang JD, Balderramo DC, Sartori GDP, de Mattos AA. Current impact of viral hepatitis on liver cancer development: The challenge remains. World J Gastroenterol 2021; 27(24): 3556-3567 [PMID: 34239269 DOI: 10.3748/wjg.v27.i24.3556] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
717 Weismüller TJ. Role of Intraductal RFA: A Novel Tool in the Palliative Care of Perihilar Cholangiocarcinoma. Visc Med 2021;37:39-47. [PMID: 33718482 DOI: 10.1159/000513970] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
718 Chong H, Gong Y, Pan X, Liu A, Chen L, Yang C, Zeng M. Peritumoral Dilation Radiomics of Gadoxetate Disodium-Enhanced MRI Excellently Predicts Early Recurrence of Hepatocellular Carcinoma without Macrovascular Invasion After Hepatectomy. J Hepatocell Carcinoma 2021;8:545-63. [PMID: 34136422 DOI: 10.2147/JHC.S309570] [Reference Citation Analysis]
719 Li G, Xu W, Zhang L, Liu T, Jin G, Song J, Wu J, Wang Y, Chen W, Zhang C, Chen X, Ding Z, Zhu P, Zhang B. Development and validation of a CIMP-associated prognostic model for hepatocellular carcinoma. EBioMedicine 2019;47:128-41. [PMID: 31492561 DOI: 10.1016/j.ebiom.2019.08.064] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
720 Zhong FJ, Li YM, Xu C, Sun B, Wang JL, Yang LY. EB2 promotes hepatocellular carcinoma proliferation and metastasis via MAPK/ERK pathway by modulating microtubule dynamics. Clin Sci (Lond) 2021;135:847-64. [PMID: 33755094 DOI: 10.1042/CS20201500] [Reference Citation Analysis]
721 Lin B, Wang Q, Liu K, Dong X, Zhu M, Li M. Alpha-Fetoprotein Binding Mucin and Scavenger Receptors: An Available Bio-Target for Treating Cancer. Front Oncol 2021;11:625936. [PMID: 33718192 DOI: 10.3389/fonc.2021.625936] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
722 Shi F, Wu M, Lian SS, Mo ZQ, Gou Q, Xu RD, Li HL, Huang ZM, Wu PH, Chen XM. Radiofrequency Ablation Following Downstaging of Hepatocellular Carcinoma by Using Transarterial Chemoembolization: Long-term Outcomes. Radiology 2019;293:707-15. [PMID: 31638492 DOI: 10.1148/radiol.2019181991] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
723 Fan W, Guo J, Zhu B, Wang S, Yu L, Huang W, Fan H, Li F, Wu Y, Zhao Y, Wang Y, Xue M, Wang H, Li J. Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS. Eur Radiol 2021. [PMID: 33893536 DOI: 10.1007/s00330-021-07834-9] [Reference Citation Analysis]
724 Yan F, Feng M, Wang X, Wang P, Xie Y, Liu X, Li W, Yang Z. Molecular targets of Yangyin Fuzheng Jiedu Prescription in the treatment of hepatocellular carcinoma based on network pharmacology analysis. Cancer Cell Int 2020;20:540. [PMID: 33292207 DOI: 10.1186/s12935-020-01596-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
725 Qian X, Liu S, Long H, Zhang S, Yan X, Yao M, Zhou J, Gong J, Wang J, Wen X, Zhou T, Zhai X, Xu Q, Zhang T, Chen X, Hu G, Wang J, Gao Z, Nan Y, Chen J, Hu B, Zhao J, Lu F. Reappraisal of the diagnostic value of alpha-fetoprotein for surveillance of HBV-related hepatocellular carcinoma in the era of antiviral therapy. J Viral Hepat 2021;28:20-9. [PMID: 32852885 DOI: 10.1111/jvh.13388] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
726 Chang Y, Lee JH. Optimal Modalities for HCC Surveillance in a High-Incidence Region. Clin Liver Dis (Hoboken) 2020;16:236-9. [PMID: 33489094 DOI: 10.1002/cld.923] [Reference Citation Analysis]
727 Kim TH, Yoon JH, Lee JM. Emerging Role of Hepatobiliary Magnetic Resonance Contrast Media and Contrast-Enhanced Ultrasound for Noninvasive Diagnosis of Hepatocellular Carcinoma: Emphasis on Recent Updates in Major Guidelines. Korean J Radiol 2019;20:863-79. [PMID: 31132813 DOI: 10.3348/kjr.2018.0450] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
728 Hermida M, Preel A, Assenat E, Piron L, Cassinotto C, Ursic-Bedoya J, Guillot C, Herrero A, Panaro F, Pageaux GP, Guiu B. Small Steatotic HCC: A Radiological Variant Associated With Improved Outcome After Ablation. Hepatol Commun 2021;5:689-700. [PMID: 33860126 DOI: 10.1002/hep4.1661] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
729 Coletta D, De Padua C, Parrino C, De Peppo V, Oddi A, Frigieri C, Grazi GL. Laparoscopic Liver Surgery: What Are the Advantages in Patients with Cirrhosis and Portal Hypertension? Systematic Review and Meta-Analysis with Personal Experience. J Laparoendosc Adv Surg Tech A 2020;30:1054-65. [PMID: 32707003 DOI: 10.1089/lap.2020.0408] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
730 Xing J, Bhuria V, Bui KC, Nguyen MLT, Hu Z, Hsieh CJ, Wittstein K, Stadler M, Wilkens L, Li J, Kalesse M, Bozko P, Plentz RR. Haprolid Inhibits Tumor Growth of Hepatocellular Carcinoma through Rb/E2F and Akt/mTOR Inhibition. Cancers (Basel) 2020;12:E615. [PMID: 32155915 DOI: 10.3390/cancers12030615] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
731 Lee J, Kim GA, Kim HJ, Cho S, Ko MJ, Lim YS. Tenofovir disoproxil fumarate on the risk of hepatocellular carcinoma in chronic hepatitis B patients with failure to preceding treatments: A nationwide cohort study. J Viral Hepat 2021;28:1150-9. [PMID: 33934466 DOI: 10.1111/jvh.13530] [Reference Citation Analysis]
732 Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ. [DOI: 10.1136/bmj.m3544] [Cited by in Crossref: 13] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
733 Renzulli M, Tovoli F, Clemente A, Ierardi AM, Pettinari I, Peta G, Marasco G, Festi D, Piscaglia F, Cappabianca S, Carrafiello G, Golfieri R. Ablation for hepatocellular carcinoma: beyond the sta